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Hepatotoxicity which is also known as liver damage is mainly caused by intake of medicine. It is 
common among patients who are co-administering Tuberculosis (TB) treatment and the 
antiretroviral therapy (ART) for the Human Immunodeficiency Viruses (HIV). If severe, 
hepatotoxicity sometimes necessitates cessation or interruption of treatment. Therefore, 
understanding, monitoring and managing hepatotoxicity in patients co-infected with TB and HIV is 
crucial for optimal treatment outcomes. Hepatotoxicity has been investigated in patients co-
infected with TB and HIV, however, most studies have analyzed only the first occurrence of 
hepatotoxicity and discarded information relating to the resolution and recurrence of hepatotoxicity. 
Data from the ‘Starting Antiretroviral therapy at three Points in Tuberculosis’ (SAPiT) trial is used 
in this project. This was a trial that was instrumental in finalizing treatment guidelines for patients 
co-infected with HIV and TB in South Africa.  
The clinical objectives of this project are to estimate incidence rates and determine risk factors 
associated with hepatotoxicity. The statistical objectives are to fit a Cox regression model, the 
resolution model of hepatotoxicity, and the extended Cox models for recurring events, including 
the Andersen Gill (AG) model, the Shared frailty model, the Prentice, Williams and Peterson (PWP) 
total time (TT) model, the PWP gap time (GT) model, as well as a Cox based recurrent model, that 
models only the second occurrence of hepatotoxicity. 
There were 593 patients assessed for hepatotoxicity in the study, 30% (179/593) developed the 
first occurrence of hepatotoxicity (grade >=1) and 2% (13/593) developed severe hepatotoxicity 
(grade >=3). Resolved cases (grade = 0) are 76% (136/179) and recurring cases (grade >=1) 24% 
(32/136). In the Cox multivariable analyses: time-varying treatment arm, older patients, alcohol 
consumption, low baseline total bilirubin and a positive baseline Hepatitis B surface antigen status, 
were associated with a higher risk of developing the first occurrence of hepatotoxicity. The 
extended Cox models (AG model, Shared frailty model, PWP TT model and PWP GT model)  in 
combination identified that: time-varying treatment arm, older patients, alcohol consumption, 
baseline CD4 count that is greater than 50 cells per mm3, low baseline total bilirubin, and a positive 
baseline Hepatitis B surface antigen status were associated with an increased risk of developing 
recurrent hepatotoxicity. In the resolution model multivariable analyses; non-consumers of alcohol 




resolving the first occurrence of hepatotoxicity. In the multivariable analyses of the recurrent model: 
younger patients and the time-varying treatment arm were associated with the development of the 
second occurrence hepatotoxicity.  
Since the Cox regression model utilized data up to the first occurrence of hepatotoxicity, in some 
instances, the time-varying treatment effect based on the Cox regression model was closer to unity 
and marginally significant. And the corresponding effect based on the recurrent event models (AG 
model, Shared frailty model, PWP TT model, PWP GT model and the recurrent model), that utilized 
data of the first and second occurrence of hepatotoxicity, generally produced a time-varying 
treatment effect slightly far from unity with a strong statistical significance. This trend was similar 
for other predictors of hepatotoxicity, like CD4 count and alcohol consumption. 
In conclusion, hepatotoxicity is common in this study, however, it is often transient or mild and did 
not necessitate treatment interruption. However, close monitoring of patients especially in the first 
5 months of TB-treatment is recommended. The PWP TT model seemed to be the best model for 
modelling recurring hepatotoxicity, since the identified risk factors that were associated with 
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South Africa carries the highest burden of the Human Immunodeficiency Virus (HIV) pandemic 
in the world (AVERT, 2019). In 2017, there were 7.2 million people in South Africa estimated to 
be living with HIV (AVERT, 2019). Making matters worse is the Tuberculosis (TB) pandemic, 
which is also a leading cause of death in South Africa. It is estimated that people living with HIV 
have a 60% chance of developing TB due to a weakened immune system caused by HIV 
(AVERT, 2019). TB is the most common cause of morbidity and mortality in HIV infected 
patients and people in the African region are most susceptible (World Health Organization, 
2018).  
The two pandemics are described as inextricably intertwined with a bidirectional relationship  
(Naidoo, et al., 2015). HIV increases the risk of primary and reactivation of TB infection and this 
risk increases with advanced HIV (Kwara, et al., 2005). It is pivotal therefore, to identify an 
effective way of treating these two pandemics.  
Up to approximately year 2005, there was very little understanding of clinical management of 
concurrent HIV and TB. Clinical guidelines regarding the concomitant antiretroviral therapy 
(ART) and TB treatment were complicated with a high pill burden, overlapping drug toxicities, 
drug-drug interactions, paradoxical immune reconstitution reaction and hepatotoxicity. These 
were concerns that justified delaying ART therapy in patients treated for TB or the cessation of 
the TB treatment, and lives were lost as a result. At this point, prospective studies that identified 
the optimal timing for initiating ART in patients treated for TB patients were lacking (Kwara, et 
al., 2005). 
In 2010 Abdool Karim, et al. published a paper regarding a prospective study that they 
conducted named ‘Starting Antiretroviral therapy at three Points in Tuberculosis’ (SAPiT) trial. 
Their objective was to identify an optimal timing for initiating ART in patients with TB. The trial 




of TB treatment or during the continuation phase of TB treatment, or after the completion of TB 
treatment. Mortality rates were reduced substantially in patients who initiated ART during TB 
treatment, compared to patients who initiated ART after completion of TB treatment. Other 
studies in line with the survival benefit of initiating ART during TB treatment, include the 
Cambodian Early versus Late Introduction of Antiretrovirals (CAMELIA) trial by Blanc, et al., 
(2011), a clinical trial conducted in Addis Ababa, Ethiopia by Degu, et al., (2012), and a trial that 
included study participants from different geographies to aid the generalizability of the outcome 
to inform policy by Havlir, et al., (2011). Subsequently, these studies and others solidified the 
World Health organization (WHO) guideline for treating the HIV/TB co-infection, which were 
before this point based on observational studies and expert opinion. 
Although the SAPiT trial showed a survival benefit for patients that initiated ART earlier 
compared to those who initiate ART late, there were still concerns relating to the general 
wellbeing of HIV infected individuals. These were investigated as secondary outcomes of this 
trial. For example, the immune reconstitution inflammatory syndrome (IRIS) rates were reported 
to be significantly higher in the group that initiated ART early compared to the group that 
delayed ART initiation. However, this did not outweigh the survival benefit, and there were no 
deaths associated with IRIS, more detail on this is reported elsewhere (Naidoo, et al., 2012). 
Moreover, other reasons for delaying ART included; a high pill burden, overlapping drug 
toxicities and concerns about drug-drug complications arising from cotreatment of ART and TB 
treatment were reported elsewhere (Naidoo, et al., 2014). 
Hepatotoxicity due to concomitant administration of ART and TB treatment has not been 
addressed well to date, given the proposed guidelines of integrating ART therapy earlier rather 
than late during TB treatment. Hepatotoxicity is commonly referred to as the liver damage that is 
caused by medicine, chemical, herbal or dietary supplement (U.S. Department of Health and 
Human Services, 2019). Hepatotoxicity is also commonly known as drug-induced hepatotoxicity, 
or drug-induced liver injury. Patients cotreated for TB and HIV, generally take four drugs for TB 
treatment and 3 drugs for ART therapy (now commonly administered as a single pill), these 
multiple drugs take a toll on the patients’ liver, and this results in liver damage. Hepatotoxicity is 
a serious infection, that if not treated can be fatal (Tostmann, et al., 2008). 
There is an extensive amount of literature reporting anti-tuberculosis drug induced 
hepatotoxicity (Kwara, et al., 2005; Shu, et al., 2013; Tostmann, et al., 2008). Additionally, 




about ART induced hepatotoxicity. Several TB treatment drugs are more likely to induce 
hepatotoxicity than others (Tostmann, et al., 2008) and co-treatment of ART further aggravates 
hepatotoxicity (Kwara, Flanigan, & Carter, 2005). 
There are a few studies in Sub-Saharan Africa that investigate hepatotoxicity in patients that are 
co-treating HIV and TB; one of which is a study by Hoffmann, et al., (2007). However, the 
generalizability of this study may be questionable, since the cohort population is predominantly 
male (94%). Male sex has been identified by Nagu, et al. (2012) as risk factor that increases the 
occurrence of hepatotoxicity. Therefore, Hoffmann’s study may have reported high cases of 
hepatotoxicity due to the sampling bias of including a disproportionate high male cohort relative 
to the female cohort.  
The intention of this project is to investigate hepatotoxicity in the SAPiT trial, to add to the 
knowledge base pertaining to hepatotoxicity in Sub-Saharan Africa. The SAPiT trial patients 
were co-treated for TB and HIV. Therefore investigating hepatotoxicity rates that occured prior 
and post ART initiation will be considered, where prior ART initiation results will be comparable 
to studies reporting anti-tuberculosis drug induced hepatotoxicity, and post ART initiation results 
would be comparable to studies reporting ART induced hepatotoxicity. Furthermore, the SAPiT 
trial is a randomized controlled clinical trial, thus sampling bias will not be a shortfall as it was for 
Hoffmann, et al., (2007). 
Common risk factors associated with development of hepatotoxicity include, sex, alcohol 
consumption, and co-infection of Hepatitus B and C virus (Nagu, et al., 2012; den Brinker M. , et 
al., 2000; de Lima & de Melo, 2012; Yimer, et al., 2014; Tostmann, et al., 2008; Sulkowski, et al., 
2000; Pukenyte, et al., 2007). In addittion, there are also risk factors associated with increased 
hepatotoxicity that are not common, these include, baseline abnormal liver function test and CD4+ 
count cells per mm3 identified by den Brinker, et al. (2000) and by Hoffmann, et al., (2007), 
respectively, these would be considered as potential confounders before investigating them as 
effect modifiers. 
Furthermore, studies have merely stated the number of resolution and reccurence of 
hepatotoxicity cases (Hoffmann, et al., 2007; Nagu, et al., 2012), and do not necessarily analyse 
the risk factors associated with these events. The omission of this analyses may be partly due to 
lack of awareness of the advanced statistical methods available. This project will attempt to 
explore and expose the advanced methods which are an extension of the Cox proportional 




and Peterson (PWP) total time (TT) model, and the PWP gap time (GT) model for recurring 
hepatotoxicity. Additionally, a simpler extension of Cox proportional hazards model will be 
considered to model the resolution of hepatotoxicity and the second occurrence of hepatotoxicity. 
1.2 Objectives of this study 
 
This research will have two main objectives.  
Clinical objectives: 
• Investigate the incidence rates of hepatotoxicity in each of the three treatment arms that 
are defined in the SAPiT trial. 
• Identify factors that influence occurrence hepatotoxicity. 
• Investigate factors associated with resolved and recurrent hepatotoxicity. 
Statistical objectives; 
• To assess/evaluate the application of the Cox PH model with non-proportional hazards 
• To evaluate and compare models for recurrent events. 
• To develop a resolution model for time to resolution of a hepatotoxicity event. 
The dissertation proceeds as follows, in Chapter 2 the study design is outlined, and hepatotoxicity 
is defined. The incidence rates are presented. The survival analysis is introduced, and then the 
Kaplan-Meier method, the cumulative incidence function and the log-rank test are described and 
applied. 
Chapter 3 introduces the Cox proportional hazards model. Descriptive statistics are presented, 
and then, an application of the univariate and multivariable Cox proportional hazards model 
determines the relevant predictor variables that describe the hazard of hepatotoxicity. The model 
validity is assessed, therafter the Cox model is adequately applied in a non-proportional hazard 
setting.  
In Chapter 4 recurrent event models are described and compared to the Cox model with non-
proportional hazards. A resolution model which analyses time to resolving the first hepatotoxicity 
event is introduced and applied. 
Lastly, the Discussion in Chapter 5 refers to the performance of the different models summarizes 




Chapter 2  
 




This chapter will apply basic concepts and tools of epidemiology to describe the distribution and 
factors associated with the occurrence of hepatotoxicity. 
Firstly, the design overview of the SAPiT trial is described and hepatotoxicity is defined. Upon 
defining hepatotoxicity, epidemiological tools such as incidence rates and incidence ratios are 
described and applied to quantify the occurrence of first hepatotoxicity, severe hepatotoxicity, 
resolved hepatotoxicity and recurring hepatotoxicity in the trial. The probability of surviving and 
the probability of developing first or recurring hepatotoxicity is evaluated through the Kaplan-Meier 
Method and the cumulative incidence function respectively. These aforementioned parameters 
are compared between the treatment arms and or between levels of potential confounders. Lastly, 
the baseline characteristics of patients in the SAPiT trial are examined and interpreted.  
2.2 Design overview 
The Starting Antiretroviral Therapy at three Points in Tuberculosis (SAPiT) trial was a randomized, 
open label clinical trial which was conducted from June 2005 to July 2010. The study was 
conducted at the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 
eThekwini clinic for HIV and TB, which adjoins the Prince Cyril Zulu Communicable Disease 
Centre, an outpatient TB facility in Durban. There were 642 ambulatory patients recruited for this 
study. Recruited patients were 18 years and older and co-infected with HIV and pulmonary TB. A 
signed consent form was required from the recruited patients before partaking in the study.  
Diagnosis of pulmonary TB was confirmed by a positive sputum smear for acid fast bacilli. The 
HIV infection was confirmed by two rapid screening tests for HIV. Only patients with CD4+ T cell 
count of less than 500 per cubic millimetre were included in the study. All 642 patients, initiated 




The study was approved by the Biomedical Research Ethics Committee of the University of 
KwaZulu-Natal and the Medicines Control Council of the South African government (BREC Ref 
number: E107/05).  
Patients were randomly assigned into three groups with a ratio of 1:1:1 (with the use of sealed 
envelopes) in permuted blocks of 6 or 9 with no stratification. Patients were assigned to initiate 
ART within four weeks of TB treatment initiation (early arm), within four weeks after completion of 
the intensive phase of TB treatment (late arm), or within completion of TB therapy (sequential 
arm). A graphical view of how the treatment arms were segmented is shown in Figure 2.1 below. 
 
 
Figure 2.1: SAPiT trial study schema (Naidoo, et al., 2012) 
Follow up visits for clinical monitoring were scheduled monthly for the first 24 months, and serum 
tests such as CD4 count, HIV RNA, and the liver serum chemestry tests, such as alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALK) and the 







2.3.1. Event definition  
 
As mentioned previously, hepatotoxicity is liver damage that is caused by medicine, chemical, 
herbal or dietary supplement. Liver damage causes enzymes to be released into the bloodstream 
and the levels of these enzymes are used  to monitor the liver function (U.S. Department of Health 
and Human Services, 2019). Subsequently, the liver function tests are then used to define the 
extent of hepatotoxicity (Kwara, et al., 2005). Serum liver chemistry tests of alanine 
aminotransferase (ALT) (Altman, et al., 1995), aspartate aminotransferase (AST) (Binquet, et al., 
2009), alkaline phosphatase (ALK) and gamma-glutamlytransferase (GGT) are common 
chemistries used to classify hepatotoxicity. 
It should be noted that hepatotoxicity is defined differently in different settings. In addition to liver 
function tests, clinical symptoms can also be used to identify hepatotoxicity. Symptoms such as 
nausea, vomiting, abdominal pain, loss of appetite, diarrhoea, feeling tired or weak, jaundice and 
hepatomegaly may occur due to the presence of hepatotoxicity (U.S. Department of Health and 
Human Services, 2019). 
In this project, hepatotoxicity is classified according to the Division of AIDS Table Grading and 
Severity of adults and Paediatric Adverse effects (“DAIDS AE Grading Table”) Version 1.0  (U.S. 
Department of Health and Human Services, National Institutes of Health, National Institute of 
Allergy and Infectious Diseases, Division of AIDS, 2004). Hepatotoxicity is classified into grades 
based on changes of ALT or AST levels relative to the upper limit of normal (ULN): 
• grade 0: <1.25 × ULN 
• grade 1: 1.25 - 2.5 × ULN 
• grade 2: 2.6   - 5.0 × ULN 
• grade 3: 5.1   - 10.0 × ULN 
• grade 4: > 10 × ULN 
The normal range is adjusted by gender for both ALT and AST. The normal range for ALT is 10 - 
40 and 7 - 35 for males and females respectively, and the normal range for AST is 15 - 40 and 13 




measurement for subjects with elevated baseline liver enzymes (Becker, 2004; Sulkowski, et al., 
2000).  
As can be seen hepatotoxicity manifests as 5 grade types. However, in this project hepatotoxicity 
will be investigated as a binary event, where grade >=1 defines the occurrence of any 
hepatotoxicity, and grade 0 defines the absence of hepatotoxicity. Other ways of grouping the 
hepatotoxicity grades are considered, and investigated further if the quantity of the data permits. 
The distribution of hepatotoxicity will be examined interms of the following dimensions 
Table 2.1: Dimensions of hepatotoxicity 
Dimension Description Rationale 
1) First occurrence of 
hepatotoxicity 
As the name suggests, the 
first occurrence of any 
hepatotoxicity during the 
study follow-up. 
To cover all grades (grade >=1) that indicate 
some elevating of liver enzymes above ULN. 
2) Severe hepatotoxicity Classified as grade >=3, 
otherwise not severe. 
To examine the progression of hepatotoxicity 
in the study. 
3) Resolved hepatotoxicity Defined as the first drop from 
either grade 1, 2, 3 or 4 to a 
grade 0 hepatotoxicity.  
To investigate protective factors of resolving 
hepatotoxicity. 
4) Recurring hepatotoxicity  Considers repeated cases of 
hepatotoxicity. 
The intention is to use all information relating 
to the occurrence of hepatotoxicity, to examine 
if the concluding results change. 
It is important to note that severe hepatotoxicity is a composite of the first occurrence of 
hepatotoxicity. As can be seen, hepatotoxicity will not be investigated on merely the grade levels, 
but rather on grade groupings, that answer specific questions, for ease of interpretation 
2.3.2. Time to event 
Described as per the 4 dimensions of the event presented in Table 2.1. 
First occurrence of hepatotoxicity  
Time at risk of developing hepatotoxicity was calculated as time from randomization to the date 




calculated from randomization to: loss to follow up, withdrawal from the study, study termination 
and or, death which ever occurred first.   
Severe hepatotoxicity  
Time at risk of developing severe hepatotoxicity was calculated as time from randomization to the 
date when grade >=3 is detected. Time at risk for patients who did not experience severe 
hepatotoxicity was calculated from randomization to: loss to follow up, withdrawal from the study, 
study termination and or, death which ever occurred first.   
Resolved hepatotoxicity  
Time at risk of resolving hepatotoxicity was calculated as time from first hepatotoxicity (grade >=1) 
to the date when grade = 0 is detected. Time at risk for patients who did not resolve hepatotoxicity 
was calculated from first hepatotoxicity to: loss to follow up, withdrawal from the study, study 
termination and or, death which ever occurred first.   
Recurring hepatotoxicity  
Time at risk of developing first hepatotoxicity was calculated as time from randomization to the 
date when grade > = 1 is detected. Time at risk of developing second hepatotoxicity was 
calculated as time from when first hepatotoxicity was resolved to the date when grade >= 1 is 
detected again. Time at risk for patients who did not experience hepatotoxicity was calculated 
from randomization to: loss to follow up, withdrawal from the study, study termination and or, 
death which ever occurred first.  For patients who resolved their first event of hepatotoxicity but 
did experience the second event of hepatotoxicity, time at risk for these patients was calculated 
from the resolution of hepatotoxicity of the first hepatotoxicity to: loss to follow of up, withdrawal 
from the study, study termination and or, death which ever occurred first. 
2.3.3. Potential confounders 
Confounders that make the patients biological make up vulnerable to hepatotoxicity, as well as 
increase the likelihood of hepatotoxicity, will consided as follows : 
• A variable that classifies patients who had a baseline liver enzymes that was above ULN 
(i.e. where grade >=1) as abnormal liver function test (LFT) at baseline, otherwise normal 
LFT at baseline. Baseline LFTs so as to, identifying pre-existings abnormalities before any 
treatment is adminisistered, so that any elavation of liver enzymes that occur during the 




• A variable indicating if the patient’s HIV has progressed severely (baseline CD4 count < 
50 cells/mm3), or not (baseline CD4 count >= 50 cells/mm3).  
• A classification of when the patient developed hepatotoxicity, prior antiretrovial therapy 
(ART) initiation, or  post - ART initiation. 
2.4 Data management 
The data used were received in a Microsoft excel format, the information was in multiple 
workbooks. Which was then imported, cleaned and manipulated in SAS Enterprise Guide version 
7.1 (SAS Institute Inc., Cary, NC, USA). 
2.4.1. Data inclusions and exclusions  
All data received was used, except records of patients with missing baseline ALT and AST 
information. It is important to note that patients with a history of hepatotoxicity may have been 
included in data, as there was no data available to indicate if the patient had a history of 
hepatotoxicity or not. 
2.5 Descriptive statistics  
Statistical analyses were done using SAS Enterprise Guide version 7.1 (SAS Institute Inc., Cary, 
NC, USA).  
2.5.1. Incidence rate 
Incidence rates are a core concept of epidemiology. Incidence rates describe the frequency of 
the event of interest relative to the time each subject is at risk of developing the event. The formula 
for incidence rates takes the number of events that have develop during the study divided by the 
sum of the follow up times for all subjects that are at risk of experiencing the event of interest.  
Incidence rate can simply be calculated as: 






,where 𝑅𝑔 is the number of events that developed during the study period in group 𝑔, and 𝑀𝑖𝑔 is 
the length of time subject 𝑖 (𝑖 = 1, … . 𝑁𝑔) is at risk for. Follow up time 𝑀𝑖𝑔 is often called person-




or person-years. In this project the incidence rate will be reported as person-years, for easier 
interpretation, incidence rates will be reported per 100 person-years this is, 𝐼𝑅𝑔 × 100, will be 
interpreted. The Poisson approximation was used to determine the 95% confidence intervals (CIs) 
for incidence rates. 
Generally, incidence rate estimates are based on counts of new events and the sum of follow-up 
times that begin at randomization and ends when the first event occurs or when the subject is lost 
of follow-up. However, incidence rates can be estimated for recurring events as well, the follow-
up time for recurring events begins at the time a subject resolves hepatotoxicity to the time the 
subject develops the second occurrence of hepatotoxicity, and again time at risk for the third event 
of hepatotoxicity commences when the second hepatotoxicity has resolved until the time the 
subject develops third hepatotoxicity, and so on and so forth. 
An appealing feature of incidence rate is that it can be estimated per 100 person years, however, 
you do not need to conduct a study that will last for 100 years to estimate this measurement. A 
shortfall of this estimate is that, it those not indicate how soon or how late during the study follow-
up did the subject develop hepatotoxicity.  
2.5.2. Incidence rate ratio  
Difference in incidence rates is compared using estimated incidence rate ratios, a ratio is a 
measurement that indicates how much larger one quantity is compared to another. Incidence rate 
ratio when comparing group 𝑔 to group 𝑘, is simply 𝐼𝑅𝑅 = 𝐼𝑅𝑔/𝐼𝑅𝑘. The chi-square test is used 
to test the difference in incidence rates between the two groups and the F-distribution is used to 
determine the 95% CIs for incidence rate ratios.  
2.5.3. Introduction to survival analysis  
The type of data that is considering in this project, tracks patients from baseline to the end of the 
study. This project is particulary concerned with the time from baseline of the study to the time 
when patient develops hepatotoxicity (if it is observable). This data is widely known as time to 
event data or the survival time data, thus the outcome of interest is the time to event.  
2.5.4. Nature of data under survival analysis 
The most distinguishing feature of survival time data is that it contains censored observations. An 




during the study period. In other words, the observation is incomplete, since we do not have the 
full information about the individuals’ total survival time. If the observation time ends before the 
event of interest is observed, this type of censoring mechanism is called right censoring. In 
contrast, if the event of interest occurred before the individual commenced with the study follow 
up, then such censoring mechanism is called left censoring. Furthermore, an outcome of interest 
may be known to have occurred within some time interval, meaning that the time in which the 
event of interest occurred is not known exactly. This type of censoring mechanism is called 
interval censoring. 
It is common practice to assume that the censoring time for a patient provides no further 
information about this person’s likelihood of survival at a future time, had the individual continued 
in the study (Klein & Moeschberger, 1997). This assumption is called the non-informative 
censoring. 
In this study, some patients were lost to follow up before developing hepatotoxicity, and some did 
not develop hepatotoxicity until the study ended. This implies that this study was subjected to the 
right censoring mechanism.  
2.5.5. Main characteristics of survival analysis method 
The below notation is introduced to aid the discussion in this section: 
• 𝑇 denotes a random time variable for the subjects in the study. 
• Small letter 𝑡 denotes some specific time of interest, during the study period.  
• The Greek letter 𝛿 (delta) is an event indicator, 𝛿 = 1 indicating event occurrence and 
𝛿 = 0 indicating indicating that no event was observed. 
There are two functions that are frequently considered to characterize the outcome variable under 
survival analysis. Namely, the survival function which gives a probability of a subject surviving 
beyond time  𝑡 ( 𝑆(𝑡) = 𝑃(𝑇 > 𝑡)). This function is a non-increasing function as 𝑡 increases.  
The survival function is estimable on a homogeneous population (ignoring any risk factors that 
may be present) just to see survival experience of the population as whole. Frequently the survival 
function is stratified by categories of a risk factor of interest, and the survival experience per risk 




Klein and Moeschberger (1997) mention that the survival function is a very important function that 
shows us the survival experience of individuals in the study; however, it is difficult to see the failure 
pattern from it. This motivates the consideration of this second function called the hazard function. 
The hazard function gives the probability that an individual will experience the event in the next 
instant (i.e. in next infinitesimal interval of ∆𝑡), given that the subject has survived up to time  𝑡 
(𝑃(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡|𝑇 ≥ 𝑡), per unit time. The ‘per unit time’ translates to the division of the 
conditional probability (𝑃(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡|𝑇 ≥ 𝑡) by the interval of ∆𝑡, to give a rate. The hazard 
function is denoted as 
 









As ∆𝑡  approaches zero, 𝜆(𝑡) is equivalent to the limit, of the probability statement about the 
survival, divided by ∆𝑡 (Kleinbaum & Klein, 2005). This function is always non-negative. The 
function 𝜆(𝑡) is also known as the hazard rate, or the conditional failure rate, or instantaneous 
death rate, or intensity rate, or the force mortality and this list is not exhaustive.  
The survival and the hazard function measure contradicting features of the event process, since 
the former is concerned with the survival and latter concerned with failure. There are general 
formulae that show how to mathematically manipulate either function to get the other. Given the 
hazard function, the survival function can be derived as  
 
                     𝑆(𝑡) = exp [− ∫ 𝜆(𝑢)𝑑𝑢
𝑡
0




The above formula is the exponentiation of the negative integral of the hazard function over the 




known as the cumulative hazard, and it is widely denoted as 𝐻(𝑡). 
The hazard function can be estimated for a homogeneous population; however, the hazard 
function estimated for the heterogeneous population (adjusting for the risk factors) is commonly 
of more interest.  
I will now consider the Kaplan-Meier estimator, which is a method that is commonly used to 




2.5.6. The Kaplan-Meier (KM) estimate of the survival function 
The Kaplan-Meier (KM) method is a non-parametric estimator of the survivor function; non-
parametric meaning that the distribution of the survival times, do not need to be specified. The 
KM method can estimate the survivor function per group, and plotting these group estimates of 
the survivor function on the same axes will facilitate the comparison of the survival distribution, 
for example, by treatment arm. 
To obtain the Kaplan-Meier estimator, the time intervals based on distinct survival times observed 
in the study are constructed. Suppose that there are 𝑛 subjects in a study, who have observed 
survival times of  𝑡1, 𝑡2, … , 𝑡𝑛 respectively. Of the 𝑛 observed survival times, 𝑟 events were 
experienced (𝑟 ≤ 𝑛), and the rest of the observed times are due to right-censoring. If the observed 
survival times of the subjects that experienced the event are arranged in ascending order, the 𝑗𝑡ℎ 
observed survival time is denoted as  𝑡(𝑗) for 𝑗 = 1, 2, … 𝑟, and the ordered 𝑟 observed survival 
times are  𝑡(1) <   𝑡(2) < ⋯ < 𝑡(𝑟). Note that, there might be more than one subject who has 
experienced an event at the same time.  
Let  𝑛𝑗 be the number of subjects who have not experienced the event by 𝑡(𝑗), including those 
who will experience the event at this time. And let  𝑑𝑗 denote the number of subjects who 
experience the event at  𝑡(𝑗). It follows that the conditional probability of a subject experiencing 
the event in a very small interval of  𝑡(𝑗) − ∆𝑡 to  𝑡(𝑗) can be estimated by (𝑑𝑗/ 𝑛𝑗). Then the 
conditional survival probability of a subject surviving beyond time  𝑡(𝑗) can be calculated as (1 −
 𝑑𝑗/ 𝑛𝑗) . Note that if  𝑡(𝑗) corresponds to both a censored and an event survival time, then 
censoring is assumed to have occurred immediately after event in computing  𝑛𝑗. In a limit where 
∆𝑡 tends to zero, (1 −  𝑑𝑗/ 𝑛𝑗)  becomes the estimate of surviving from  𝑡(𝑗) to  𝑡(𝑗+1) (Collett, 
1994). The events that occur per interval are assumed to be independent of each other. Therefore, 
the Kaplan-Meier estimate of the survival function is the product of the conditional estimated 
survival probabilities which can be written as, 
 








The ?̂?(𝑡)𝐾𝑀 estimate is always between 0 and 1, implying that the numerator in ?̂?(𝑡)𝐾𝑀  is always 




numerator and denominator decreases at every successive step. The ?̂?(𝑡)𝐾𝑀 estimate drops in 
the times when the event occurs and remains constant between observed survival times, resulting 
in a non-increasing step function commonly called the survival curve.   
2.5.7. Cumulative incidence function  
A non-parametric probability of failure is estimated by the cumulative incidence function, which is 
not to be confused with the incidence proportion that is a point of estimate rather than a function 
of the probabily of failure, as it sometimes appears in public health literature (Boston University 
School of Public Health, 2016). It is intuitive to assume that the complement of the population 
surviving from the event gives the probability of failure (1 - ?̂?(𝑡)𝐾𝑀). However, it is not that 
straightforward. Gooley et al (1999) in their comprehensive paper illustrate that (1 - ?̂?(𝑡)𝐾𝑀) is not 
an unbiased estimate of the probability of failure, since it accounts for competing events as if there 
were censored events. A competing event is an event that precludes the occurrence of the event 
of interest from occurring.   
When a patient is censored in (1 - ?̂?(𝑡)𝐾𝑀) it is assumed that, that patient will have the same 
probability of experiencing the event of interest like patients who have not been censored, this 
affects the level of (1 - ?̂?(𝑡)𝐾𝑀). However, in essence, if a patient experiences a competing event, 
the probability of failure of the event of interest becomes 0. It is essential therefore that the 
construct of the probability of failure be based on the hazard of experiencing the event of interest 
and the hazard of experiencing the competing event.     
In the SAPiT trial the competing event is death, patients cannot experience hepatotoxicity if they 
are dead. It is difficult to ignore death in the study because there is quite a number of patients 
who die during the trial (Figure 2.2).  The cumulative incidence function is proposed to estimate 
the probability of failure, the formulation is as below: 
 


















The CIF formula is an estimate of the probability of failure, the formulae is a product of the hazard 
of experiencing the event of interest at time 𝑡𝑗 denoted by 
 𝑑𝑗
 𝑛𝑗




survived from the event of interest until this time, is estimated as ?̂?(𝑡)𝐾𝑀1 = (1 −
 𝑑𝑗
 𝑛𝑗
), and that 
this patient has not experienced the competing event ?̂?(𝑡)𝐾𝑀2 = (1 −
 𝑒𝑗
 𝑛𝑗
), this is, 𝑒𝑗 is number 
of subjects who experience a competing event at 𝑡(𝑗). The plot of CIF over the study period results 
in an increasing step function.  
2.5.8. The log-rank test 
The log-rank test is derived from the Mantel-Haenstel 2 x 2 table test of the difference between 2 
groups (Mantel & Haenszel, 1959), Cox adopted this for survival analysis, the test is also referred 
to as the Cox-Mantel test.   
The log-rank test is essentially a chi-square test that compares observed events to expected 
events under the null hypothesis of independence for each time interval (Kleinbaum & Klein, 
2005). This test combines information of the extent of the difference between groups over each 
of the observed survival times into a single statistic.  
Suppose that at time 𝑡(𝑗) the below detail can be tabulated: 
Group (𝑖) Number of events Number subjects who are 
event free 
Number at risk 
1 𝑑1𝑗 𝑛1𝑗 − 𝑑1𝑗 𝑛1𝑗 
2 𝑑2𝑗 𝑛2𝑗 − 𝑑2𝑗 𝑛2𝑗 
Study totals at survival time 𝑡(𝑗) 𝑑𝑗 𝑛𝑗 − 𝑑𝑗 𝑛𝑗 
Furthermore,  
• 𝑖 = 1, 2 is the group index 
• 𝑂𝑖 = ∑ 𝑑𝑖𝑗
𝑟
𝑗  is the sum of observed events in group 𝑖 
• 𝐸𝑖 = ∑ 𝑒𝑖𝑗
𝑟
𝑗 =  
𝑛𝑖𝑗
𝑛𝑗
× 𝑑𝑗, is the number of expected events in group 𝑖, where 𝑛𝑖𝑗 is the number 
subjects at risk in group 𝑖 at survival time 𝑡(𝑗), 𝑛𝑗 = 𝑛1𝑗 + 𝑛2𝑗 and 𝑑𝑗 = 𝑑1𝑗 + 𝑑2𝑗 




)𝑟𝑗  is the variance of the difference of observed events 
versus expected events in group 𝑖.  









  ~ χ(1) . (2.6) 
An alternative simpler formulation of the log-rank test statistc, which does not require the 
calculation of the variance terms, is written as: 
  








~ χ(1) . (2.7) 
Equation (2.7), can be easily generalized to more than two groups by extending the summation 
to cover all groups. The resulting test statistic would have 𝑘 − 1 degrees of freedom, where 𝑘 is 
the number of groups. 
A large log-rank test statistic corresponds to small p-value, indicating evidence against the null 
hypothesis that the survival distribution is the same across the groups. This test is a good test 
when the hazards are expected to be proportional and the sample has relatively few censored 
events. The power of the log-rank test depends on the number of observed failures rather than 
the sample sizes. 
2.6 Results 
2.6.1. Study flow 
A study flow diagram of how the study evolved from study initiation until study termination is shown 
in Figure 2.2: Study flow. Of the 642 randomly assigned patients, 49 patients were missing both 
AST and ALT levels at baseline were subsequently excluded from the analysis, leaving 593 
patients eligible for the study. Of 593 patients, 121 had abnormal liver function at baseline, of the 
121, 42 patients were from the early arm, 40 were from the late arm and 39 were from the 
sequential arm. Of the 593, 126 of these patients did not initiate ART, of the 126, there were 15, 
44 and 67 patients in the early arm, late arm and sequential arm, respectively. Of the 593, 179 
patients developed first occurrence of hepatotoxicity in the study. Of the 179, 2 patients in the 
early arm, 8 patients in the late arm, and 3 patients in the sequential arm developed severe 
hepatotoxicity. 
Of the 179, 136 patients resolved their first hepatotoxicity sometime in the study. In the early arm, 
there were 46 resolved first hepatotoxicity, 46 resolved resolved first hepatotoxicity in the late arm 




any hepatotoxicity, 11 patients in the early arm, 9 patients in the late arm and 12 patients in the 
sequential arm developed recurrent hepatotoxicity. 
In Figure 2.2 it is shown that 18 patients were lost to follow in the early arm, 11 of these patients 
did not initiate ART, 31 patients were lost to follow in the late arm, all 31 patients did not initiate 
ART and 30 patients were lost to follow in the sequential arm, 29 of these patients did not initiate 
ART. Additionally, of the 593 patients, 52 died during the course of the study none of the deaths 
were due to hepatotoxicity. Thirteen patients died in the early arm, 2 of these patients did not 
initiate ART, 15 patients died in the late arm 7 of these patients did not initiate ART, and 24 




























Recruited for screening  
(n=3301) 
Screened (n=1331) 
Excluded (n= 1970) 
 HIV-negative: 794 
 Declined HIV testing: 627 
 Did not return for screening visit: 349 
 Other reasons: 20  
 
  Excluded (n=689) 
 Did not return for enrollment visit: 130 
 Beyond enrollment window: 101 
 Returned for enrollment when enrollment was not open: 100 
 Did not have confirmed positive smear for acid-fast bacilli: 91 
 CD4+ count <0.05 × 109 cell/L: 55 
 Declined participation: 44 
 Medical reasons: 38 
 Planned to relocate: 17 
 Practical reasons: 17 
 Declined ART: 16 
 Receiving ARV: 13 
 No sputum test: 12 
 Died: 10 
 Not receiving TB treatments: 6 
 Pregnancy or planned pregnancy: 3 
 Other reasons: 36 
 
 
Randomly assigned (n= 642) 
 
Early Integrated treatment 
group (n=214) 
42) Early Integrated treatment 
group (n=214) 
Late Integrated treatment group 
(n=215) 
Sequential treatment group 
(n=213) 
Excluded (19): Missing baseline 
ALT and AST measurements 
Excluded (17): Missing baseline 
ALT and AST measurements 
Excluded (13): Missing baseline 
ALT and AST measurements  
Baseline Liver Function Test (195) 
  Abnormal (42) 
  Normal (153) 
Normal baseline Normal baseline 
Baseline Liver Function Test (198) 
  Abnormal (40) 
  Normal (158) 
Normal baseline Normal baseline 
Baseline Liver Function Test (200) 
  Abnormal (39) 
  Normal (161) 
Normal baseline Normal baseline 
Hepatotoxicity development  
 First hepatotoxicity - Grade > 0 (59) 
 Severe hepatotoxicity - Grade >2 (2)  
 
Hepatotoxicity development 
 First hepatotoxicity - Grade > 0 (61) 
 Severe hepatotoxicity - Grade >2 (8)  
 
Hepatotoxicity development 
 First hepatotoxicity - Grade > 0 (59) 
 Severe hepatotoxicity - Grade >2 (3) 
Resolved first hepatotoxicity to Grade 0 (46) 
 
Resolved first hepatotoxicity to Grade 0 (46) 
 
Resolved first hepatotoxicity to Grade 0 (44) 
 
Recurrent hepatotoxicity Grade > 0 (11) 
 
Recurrent hepatotoxicity Grade > 0 (9) 
 
Recurrent hepatotoxicity Grade > 0 (12) 
 
Last seen observation in study of the (195) 
  Normal liver function (107) 
  Resolved hepatotoxicity (37) 
  Unresolved hepatotoxicity (20) 
  Lost to follow up (18)  
• Did not start ART (11) 
• Started ART (7) 
  Died - none due to hepatotoxicity (13) 
• Did not start ART (2) 
• Started ART (11) 
 
Last seen observation in study of the (198) 
  Normal liver function (93) 
  Resolved hepatotoxicity (39) 
  Unresolved hepatotoxicity (20) 
  Lost to follow up (31)  
• Did not start ART (31) 
• Started ART (0) 
  Died - none due to hepatotoxicity (15) 
• Did not start ART (7) 
• Started ART (8) 
 
Last seen observation in study of the (200) 
  Normal liver function (89) 
  Resolved hepatotoxicity (37) 
  Unresolved hepatotoxicity (20) 
  Lost to follow up (30)  
• Did not start ART (29) 
• Started ART (1) 
  Died - none due to hepatotoxicity (24)   
• Did not start ART (13) 
• Started ART (11) 
 
Did not start ART (15) 
Started ART (180) 
Did not start ART (44) 
Started ART (154) 
Did not start ART (67) 
Started ART (133) 




2.6.2. Hepatotoxicity incidence 
Overall incidence 
First occurrence of any hepatotoxicity occurred  in 179 (30.2%) patients during study follow-up. 
In Table 2.2, there were 29.0  incidence cases of hepatotoxicity per 100 person-years(py) that 
developed in the early arm over a median of 5.2 months, 32.6 incidence cases of hepatotoxicity 
per 100 py that developed in the late arm over a median of 4.7 months, and 32.6 incidence cases 
of hepatotoxicity per 100 py that developed in the sequential arm over a median of 5.1 months. 
Incidence rate ratios between the treatment arms were not statistically significant.  
Severe hepatotoxicity 
Severe hepatotoxicity (grade 3+) occurred in 13 (2.2%) patients during follow-up. In Table 2.2, 
there were 0.7 (95% CI 0.1 to 2.7) incidence cases of severe hepatotoxicity per 100 py that 
developed in the early arm over a median of 9.2 months, 3.2 (95% CI 1.4 to 6.3) incidence 
cases of severe hepatotoxicity per 100 py developed in the late arm over median of 4.6 months 
and 1.2 (95% CI 0.3 to 3.5) incidence cases of severe hepatotoxicity per 100 py developed in 
the sequential arm over a median 13.8 months. There were 77% less severe hepatotoxicity 
incidence cases in the early arm compared to the late arm, the IRR = 0.23, 95% CI (0,05; 1.1) is 
marginally significant with p-value = 0.0652.  
Resolved hepatotoxicity 
Of the patients that developed first hepatotoxicity 136 (77%) resolved their first hepatotoxicity 
during the study follow up. In Table 2.2, the early arm had 267.3 (95% CI 195.7 to 356.5)  
incidence cases of resolved hepatotoxicy per 100 py occurred within a median of 2.9 months, 
243.1 (95% CI 178.0 to 324.2)  incidence cases of resolved hepatotoxicity per 100 py occurred 
in the late arm within a median of 2.8 months, and 347.8 (95% CI 252.7 to 466.9)  incidence 
cases of resolved hepatotoxicity per 100 py occurred in the sequential over a median of 2.1 
months. There were 30% less resolved cases of hepatotoxicity in the late arm compared to the 
sequential arm, the IRR = 0.7, 95% CI (0,46; 1.1) is marginally significant with p-value = 0.0892 
(Table 2.2). 
Recurrent hepatotoxicity 
Of the cases that resolved first occurrence of hepatotoxicity 32 (24%) developed a recurring 




recurring hepatotoxicity per 100 py that occurred in the early arm within a median of 2.9 months, 
29.6 incidence cases of recurring hepatotoxicity per 100 py occurred in the late arm within a 
median of 2.8 months, and 42.8 incidence cases of recurring hepatotoxicity per 100 py occurred 
in the sequential arm within a median of 2.1 months. The incidence rate ratios between 
treatment arms for recurring hepatotoxicity indicated no difference in the incidence rates. 
 
Table 2.2: Overall incidence rates and incidence rate ratios by treatment arm 










Events, n 59 2 46 11 
Person Years 203.4 269.6 17.2 22.1 
Incidence rate per 100 
Person-Years (95% CI) 
29             
(22.1; 37.4) 
0.7             
(0.1; 2.7) 
267.3             
(195.7; 356.5) 
49.8             
(24.9; 89.2) 
Late Arm 
Events, n 61 8 46 9 
Person Years 187 251.0 18.93 30.43 
Incidence rate per 100 
Person-Years (95% CI) 
32.6             
(25.0; 41.9) 
3.2             
(1.4; 6.3) 
243.1             
(178; 324.2) 
29.6             
(13.5; 56.2) 
Sequential Arm 
Events, n 59 3 44 12 
Person Years 184.46 247.5 12.7 28.1 
Incidence rate per 100 
Person-Years (95% CI) 
32             
(24.3; 41.3) 
1.2             
(0.3; 3.5) 
347.8             
(252.7; 466.9) 
42.8             
(22.1; 74.7) 
Early Arm vs Late Arm 
Incidence Rate Ratio 
(95% CI); 
p-value 
0.89             
(0.62; 1.27); 
0.5189 
0.23             
(0.05; 1.1); 
0.0652 
1.1             
(0.73; 1.65); 
0.649 
1.68             
(0.7; 4.07); 
0.2459 
Early Arm vs Sequential 
Arm 
0.91             
(0.63; 1.30); 
0.5944 
0.61             
(0.1; 3.66); 
0.5906 
0.77             
(0.51; 1.16); 
0.2115 
1.16             
(0.51; 2.64); 
0.7148 
Late Arm vs Sequential 
Arm 
1.02             
(0.71; 1.46); 
0.9139 
2.63             
(0.7; 9.91); 
0.1534 
0.7             
(0.46; 1.06); 
0.0892 




2.6.3. Hepatotoxicity incidence by potential confounders 
 
Hepatotoxicity incidence occurrence of abnormal LFT versus normal LFT at baseline 
Of the patients with abnormal baseline LFT 27% (33/121) developed first hepatotoxicity. There 
were 14.1 cases of first occurrence of hepatotoxicity per 100 py observed in early arm (95% CI 
5.7 to 29.0), 39.1 cases of first occurrence of hepatotoxicity per 100 py observed in the late arm 




in the sequential arm (95% CI 19.8 to 66.8). Among patients with abnormal baseline LFT 
incidence cases of first hepatotoxicity is 64% less in the early arm compared to the late arm the 
IRR = 0.36, 95% CI (0,15; 0.89), significant with p-value = 0.0276. Similary, incidence cases of 
first occurrence of hepatotoxicity is 63% less in the early arm compared to the sequential arm, 
the IRR = 0.37, 95% CI (0,15; 0.94), significant with p-value = 0.0358 (Table 2.3).   
Incidence rates among the group of patients who had a normal baseline LFT were similar across 
the treatment arms, comparative incidence rate ratios were close to unity.   
Table 2.3: Incidence of hepatotoxicity for patients with abnormal baseline LFT versus normal 
baseline LFT  
Treatment Arm Parameter Abnormal LFT Normal LFT Grand Total 
Early Arm 
Events, n 7 52 59 
Person Years 49.7 153.8 203.5 
Incidence rate per 100 
Person-Years (95% CI) 
14.1             
(5.7; 29) 
33.8             
(25.3; 44.3) 
29             
(22.1; 37.4) 
Late Arm 
Events, n 14 47 61 
Person Years 35.8 151.2 187.00 
Incidence rate per 100 
Person-Years (95% CI) 
39.1             
(21.4; 65.5) 
31.1             
(22.8; 41.3) 
32.6             
(25; 41.9) 
Sequential Arm 
Events, n 12 47 59 
Person Years 31.4 153.1 184.49 
Incidence rate per 100 
Person-Years (95% CI) 
38.2             
(19.8; 66.8) 
30.7             
(22.6; 40.8) 
32.6             
(25; 41.9) 
Early Arm vs Late Arm 
Incidence Rate Ratio (95% 
CI); 
p-value 
0.36             
(0.15; 0.89); 
0.0276 
1.09             
(0.73; 1.61); 
0.6768 
0.89             
(0.62; 1.27); 
0.5189 
Early Arm vs Sequential Arm 
0.37             
(0.15; 0.94); 
0.0358 
1.1             
(0.74; 1.63); 
0.6314 
0.91             
(0.63; 1.3); 
0.5944 
Late Arm vs Sequential Arm 
1.02             
(0.47; 2.21); 
0.9564 
1.01             
(0.68; 1.52); 
0.951 




Hepatotoxicity incidence prior and post ART initiation 
There were notable differing incidence rates of hepatotoxicity, that occurred post ART initiation 
by treatment arm amongst patients with CD4+ cell count that are more than 50 cells/mm3, 28.4 
incidence cases of hepatotoxicity per 100 py developed in early arm (95% CI 20.9 to 37.8). This 




p-value =0.0285. And 2.2 times more than 13.1 cases per 100 person-years that developed in the 
sequential arm (95% CI; 8.0 to 20.2) – p-value =0.0037 (Table 2.4). 
Hepatotoxicity incidence stratified by CD4 count strata 
In the subgroup of patients with CD4+ cell count that is less than 50 cells/mm3, there were 26.6 
incidence cases of hepatotoxicity per 100 person-years that developed in the early arm (95% CI 
12.7 to 48.9) this is almost half of the 53.3 incidence cases of hepatotoxicity per 100 py that 
developed in the sequential arm (95% CI 28.4 to 91.2). The incidence ratio is 0.5 (95% CI; 0.22 
to 1.14), and p-value = 0.0975. Further comparison of the hepatotoxicity incidence rate stratified 
by CD4 count strata and treatment arm were not significant (Table 2.4). 
Table 2.4: Incidence of hepatotoxicity prior and post ART initiation, stratified by CD4 count strata  
Treatment Arm Parameter 
CD4 count < 50 cell/L CD4 count > 50 cell/L 
Grand Total Prior ART Post ART Subtotal 
Prior 
ART Post ART Subtotal 
Early Arm 
Events, n 2 8 10 2 47 49 59 
Person Years 0.00 37.6 37.60 0.3 165.5 165.8 203.4 
Incidence 





21.3             
(9.2; 41.9) 
26.6             
(12.7; 48.9) 
- 
28.4             
(20.9; 37.8) 
29.5             
(21.9; 39.1) 
29             
(22.1; 37.4) 
Late Arm 
Events, n 5 8 13 24 24 48 61 
Person Years 0.8 34.6 35.4 5.1 146.5 151.6 187 
Incidence 





23.1             
(10; 45.5) 
36.7             
(19.5; 62.8) 
- 
16.4             
(10.5; 24.4) 
31.7             
(23.3; 42) 
32.6             
(25; 41.9) 
Sequential Arm 
Events, n 7 6 13 26 20 46 59 
Person Years 2.1 22.3 24.36 7.1 153 160.1 184.46 
Incidence 





27             
(9.9; 58.7) 
53.3             
(28.4; 91.2) 
- 
13.1             
(8; 20.2) 
28.7             
(21; 38.3) 
32.6             
(25; 41.9) 







0.92             
(0.35; 2.45); 
0.869 




1.73             
(1.06; 2.83); 
0.0285 
0.93             
(0.63; 1.39); 
0.7332 
0.89             
(0.62; 1.27); 
0.5189 
Early Arm vs 
Sequential Arm 
- 
0.79             
(0.27; 2.27); 
0.6614 




2.17             
(1.29; 3.66); 
0.0037 
1.03             
(0.69; 1.54); 
0.8915 
0.91             
(0.63; 1.3); 
0.5944 
Late Arm vs 
Sequential Arm 
- 
0.86             
(0.3; 2.47); 
0.7754 




1.25             
(0.69; 2.27); 
0.4558 
1.1             
(0.74; 1.65); 
0.6374 







2.6.4. Application of Kaplan-Meier methodology 
The hepatotoxicity free survival profiles of the three treatment groups were calculated using the 
Kaplan Meier method and compared using the log-rank test. 
In Figure 2.3 the probability of remaining hepatotoxicity free for patients in the late arm dropped 
rapidly from beginning of study to the 6th month after study randomization, compared to the other 
treatment arms. After 6 months, the curves estimating the probability of remaining hepatotoxicity 
free for the treatment arms are overlapping for most of the study follow up period; this suggests 
that the probability of remaining hepatotoxicity free is similar across the three treatment arms at 
this period. The log-rank test statistics that compared the probability of remaining hepatotoxicity 
free in the three treatment arms is estimated to be 0.4247 with p-value =0.8076. The very large 
p-value indicates there is not enough evidence to suggest that survival experience in each of the 
treatment arms is different.  
 
Figure 2.3: Kaplan-Meier estimates first occurrence of any hepatotoxity by treatment arm  
 





2.6.5. Cumulative incidence function estimate 
 
The probability of developing hepatotoxicity in the three treatment groups was calculated using 
the cumulative incidence function and compared using the log-rank test. In Figure 2.4 the 
probability of developing first occurrence of any hepatotoxicity is similar across the treatment 
arms, p-value =0.7395. 
 
Figure 2.4: : Cumulative incidence function first occurrence of any hepatotoxity by treatment arm 
 
2.7 Conclusion  
There were 179 cases of first occurrence of hepatotoxicity in study, the cases were evenly 
distributed within each treatment arm and the corresponding person-time in each arm was similar. 
Severe hepatotoxicity occurred in 13 patients, 8 cases occurred in the late arm, a much higher 
number compared to 2 and 3 cases of severe hepatotoxicity that developed in the early and late 
arm respectively. There was quite a number of patients in study who resolved hepatotoxicity 76% 
(136/179). Suggesting that first hepatotoxicity was a transitory state for most patients. 
Furthermore, there were 24% (32/136) of patients that developed recurring hepatotoxicity after 
resolving their first hepatotoxicity.  Nevertheless, the incidence rate ratio comparing the incidence 





rates between the treatment arm for the occurrence of first hepatotoxicity, severe hepatotoxicity, 
resolved hepatotoxicity and recurring hepatotoxicity were no different to unity.   
The KM estimator for the first occurrence of hepatotoxicity revealed that the probability of 
remaining hepatotoxicity free was similar across the treatment arms. There were also no signicant 
differences in the cumulative incidence functions between the treatment arms for the first 
occurrence of hepatotoxicity. 
Incidence rates of first occurrence of hepatotoxicity were investigated between the treatment arms 
and the levels of potential confounders. And for the confounder that classifies patients as having 
abnormal LFT vs normal LFT at baseline; the analysis revealed that patients in the early arm with 
abnormal LFT had a statistically lower incidence rates of developing first hepatotoixicty compared 
to the other treatment arms. 
Another confounder investigated was whether hepatotoxicity occured prior or post ART initiation, 
within each baseline CD4 count level. There were not enough persons at risk prior ART initiation, 
incidence rates were not estimated in this group and therefore not compared between the 
treatment arms as a result this confounder was not investigated further. Also this confounder may 
have been prone to bias as patients would have to have remained hepatotoxicity free in order to 
have experienced hepatotoxicity post-ART initiation. However, incidence rates in early arm were 
significantly higher in patients with CD4 greater than 50 cells/mm3 and whose hepatotoxicity 




Chapter 3  
 
The Cox Proportional Hazards 
Model 
 
3.1 Introduction  
The objective is to ascertain the association of the incidence of hepatotoxicity with treatment arm 
and other risk factors in the study. This can be done by modeling the hazard function that was 
introduced in Chapter 2. 
The hazard function is typically used to determined event occurrence patterns and describe how 
the chance of experiencing the event changes over time. This function is modelled in one of two 
ways; using the multiplicative hazard model procedure or using the less popular approach, called 
the additive hazard model (Klein & Moeschberger, 1997). The former model, determines 
association between the risk factor and the occurrence of the disease by examining the relative 
hazards between risk factor levels, the latter model determines association between the risk factor 
and the occurrence of the disease by examining the absolute difference in hazards between risk 
factor levels (Madadizadeh, et al., 2017).  
The relative hazard (hazard ratio) quantifies the strength of the association of the risk factor and 
the occurrence of the disease, whereas the absolute difference quantifies the public health impact 
of the risk factor, and focuses on the number of cases that could potentially be prevented by 
eliminating the risk factor (Boston University School of Public Health, 2018). As can be derived 
from descriptions above, the parameters estimated by multipilicative hazard model and the 
additive hazard model are equally important. However, in this dissertation only the multiplicative 
hazards model will be considered. As this model forms the foundation of the extended models 
that are considered in Chapter 4. 
As discussed in Chapter 2, the occurrence of hepatotoxicity can be analysed in one of 4 ways, 




occurrence of hepatotoxicity.  The occurrence of severe hepatotoxicity will not be considered 
further in this project due to the sparse occurrence of this event in the study. Resolved 
hepatotoxicity and recurrent hepatotoxicity are considered in the next chapter. 
3.2 Model form 
The multiplicative hazard models (Therneau & Grambsch, 2000) are expressed as a product of a 
baseline hazard function and a non-negative function of covariates. The general formula for the 
multiplicative hazard models can thus be written as:  
 𝜆(𝑡|𝒙) = 𝜆0(𝑡)𝑐(𝜷
′𝒙), (3.1) 
where 𝜆0(𝑡) is the baseline hazard function that can be specified using a parametric form, or left 
unspecified. Any function can be used for  𝑐(. ). In 1972, Sir David Cox proposed this function to 
be 𝑐 (𝜷′𝒙) = exp (𝜷′𝒙) to ensure positivity. The hazard formula of the Cox model for subject 𝑖 
from 𝑛 subjects can be expressed as: 
 𝜆(𝑡|𝒙𝑖) = 𝜆0(𝑡)exp(𝜷
′𝒙𝑖), (3.2) 
 
where the baseline hazard function 𝜆0(𝑡) is left unspecified.  𝒙𝑖 is the subject specific vector of 𝑝 
covariates, and the 𝜷 is the vector of the corresponding 𝑝 unknown regression coefficients. Note 
that, the baseline hazard function is the hazard function for subject 𝑖 when all the covariates are 
equal to 0 (𝒙𝑖 = 𝟎). Furthermore, the vector of covariates include time-invariant covariates and 
or time-varying covariates, in which case the vector will be denoted as 𝒙𝑖(𝒕).  
The Cox model is a type of a semi-parametric model because it has an unspecified 𝜆0(𝑡) and a 
specified exp(𝜷′𝒙𝑖) element in its model form. A possible advantage of this model over a fully 
specified parametric model is that, specifying the probability distribution of the baseline hazard 
may give rise to the risk of choosing the wrong probability distribution (Kleinbaum & Klein, 2005). 
3.3 Computing the hazard ratio 
Results from the Cox model are often expressed as hazard ratios. Suppose that at time  𝑡, subject 
𝑖 has a covariate 𝑥𝑖 and subject  𝑗 has a covariate 𝑥𝑗. The hazard ratio formula between subject 𝑖 














= exp (𝛽(𝑥𝑖 − 𝑥𝑗))
=  𝜃, 
(3.3) 
where ?̂? denotes the constant difference in the effect of the covariate 𝑥 on the relative hazards 
over time. 
The ‘constant difference in the effect’ between subject 𝑖 and 𝑗 is another way of saying that the 
hazards between subject 𝑖 and 𝑗 are proportional over time, also called the proportional hazards 
assumption. As a result, this model is referred as a proportional hazards model. 
The proportional hazards assumption is pivotal when considering the Cox model, because 
interpreting ratios from a Cox model that are breaching the PH assumption may lead to misleading 
model results. Therefore, it is crucial to check if the proportional hazards assumption holds per 
covariate considered in the Cox model. This will be demonstrated in subsequent sections. 
3.4 Fitting the Cox model 
To fit the Cox model presented in equation (3.2), the baseline hazard function 𝜆0(𝑡) and the 
regression coefficients vector of  𝜷 need to be estimated. However, the interest of this study 
focuses on obtaining the hazard ratio shown in equation (3.3). An attractive feature of the Cox PH 
model is that hazard ratios can be estimated without estimating the unknown baseline hazard 
function (Collett, 1994). 
Like in standard regression models, the vector of the 𝛽-coefficients is estimable by the method of 
maximum of likelihood. This method considers a function of the unknown 𝛽- coefficients that is a 
joint probability of obtaining the data that is observed, this function is called the likelihood function. 
The estimates of the 𝛽’s are the values that are more likely in line with the observed data (Collett, 
1994), these estimates are called the maximum likelihood estimates. 
In the context of the Cox PH model, the likelihood function is defined by the unknown 𝛽-
coefficients and the observed survival times that experienced the event of interest. The 





3.4.1. The Likelihood function  
Following Collett (1994), suppose that there are 𝑛 subjects in the study, 𝑟 of these subjects 
experienced the event (𝑟 ≤ 𝑛), and the remaining observed times (𝑛 − 𝑟) are due to right-
censoring. Suppose further that the 𝑟 subjects had distinct observed survival times, arranged in 
ascending order. The 𝑗𝑡ℎ observed survival time is denoted as  𝑡(𝑗) for 𝑗 = 1, 2, … 𝑟, and the 
ordered 𝑟 observed survival times are 𝑡(1) <   𝑡(2) < ⋯ < 𝑡(𝑟).  
In general, at time  𝑡(𝑗) the likelihood function (𝐿𝑗) is the hazard of experiencing the event for 
subject 𝑗 (this is 𝜆0(𝑡)exp(𝜷
′𝒙𝑗)), over the sum of the hazard of experiencing the event for each 
subject that is still under observation in the study (this is ∑ 𝜆0(𝑡)exp(𝜷
′𝒙𝑖) if each subject 𝑖 has 
not experienced the event of interest). Note that the subjects that are still under observation may 
include subjects that have not been censored by 𝑡(𝑗), but will be censored some time after 
interval  𝑡(𝑗). Since the observed survival times are assumed to be independent, the likelihood 
function of the study becomes the product of likelihoods at each of the observed survival times of 
the study ∏ 𝐿𝐽. Evidently, only the observed survival time times due to an event are used in 
constructing the likelihood function, under such circumstances this function is called the partial 
likelihood function (Collett, 1994). 
The general formula of the partial likelihood suggested by Cox is as follows: 
 
            𝑙𝑝(𝜷, 𝒙) = 𝐿(𝜷)












,      
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where 𝛿𝑗 is a binary indicator of censoring that takes on a value of 1 if the event of interest occurs 
and 0 if the observation was censored, 𝜷 is the vector of unknown regression coefficients, 𝒙𝑗 is 




the event of interest by ordered observed time 𝑡(𝑗). It can easily be seen that the baseline hazard 
function has cancelled out in the likelihood function formula. 
3.4.2.  Likelihood function in the presence of tied data 
The notion of tied data occurs when subjects in the study have the same observed survival time, 
this is when both subject 𝑎 and 𝑏 contribute the same 𝑗𝑡ℎ observed survival time  𝑡(𝑗) (i.e. 𝑡(𝑗) 
= 𝑡𝑎 =  𝑡𝑏). For data in the SAPiT trial the observed survival time were computed as months 
between the date in which a subject was randomized into the study and date in which the subject 
developed hepatotoxicity or date when the subject was last seen, if the subject was censored. 
Since time to a hepatotoxicity event was measured in months, there is a high chance that some 
subjects will have observed survival times that are the same due to the rounding process.  
The likelihood method discussed above requires distinct observed survival times in order to 
correctly calculate the probability (𝐿𝑗) at each time interval  𝑡(𝑗) for 𝑗 = 1, 2, … 𝑟. Collett (1994)  
discussed a likelihood method proposed by Efron (1977), which will be applied in this study. 
Additional notation is required for this method to be discussed. Collett (1994), introduced the 
vector  𝒔𝑗 to denote the vector of sums of each of the 𝑝 covariates for those subjects who 
experience the event at the 𝑗𝑡ℎ time for  𝑗 = 1, 2, … 𝑟. If there are 𝑑𝑗 events at time 𝑡(𝑗), the ℎ
𝑡ℎ 
element of  𝒔𝑗 is 𝑠ℎ𝑗 = ∑ 𝑥ℎ𝑗𝑘
 𝑑𝑗
𝑘=1 , where 𝑥ℎ𝑗𝑘 is the value of the ℎ
𝑡ℎ covariate for  ℎ = 1, 2, … 𝑝, for 
the 𝑘𝑡ℎ of the  𝑑𝑗 subjects, 𝑘 = 1, 2, …  𝑑𝑗, who experience the 𝑗
𝑡ℎ event, 𝑗 = 1, 2, … 𝑟. 
The approximation of the likelihood function proposed by Efron (1977)  is written as: 
 𝑙𝑝(𝐸𝑓𝑟𝑜𝑛)(𝜷, 𝒙)             
= ∏
exp(𝜷′𝒔𝑗)
∏ [∑ exp(𝜷′𝒙𝑖) − (𝑘 − 1)𝑑𝑗
−1 ∑ exp(𝜷′𝒙𝑖)𝑖𝜖𝐷(𝑡𝑗)𝑖𝜖𝑅(𝑡𝑗) ]
 𝑑𝑗
𝑘=1






in which 𝐷(𝑡𝑗) is the set of the subjects who experience the event at time 𝑡(𝑗). When there are no 
ties present in the data, equation (3.5) is equivalent to equation (3.4). There are other methods 
discussed in literature that approximate the likelihood function for the Cox proportional hazards 
model in the presence of tied data. Authors such as Collett (1994) and Allison (1995) amongst 




well, even when number of tied data points increase. The computational time when using this 
method is reduced compared to other methods. 
3.5 Variable selection approach 
The goal of this study is to determine the relationship between the treatment arm and the 
occurrence of hepatotoxicity, implying that treatment arm will be included in the final model 
automatically. Furthermore, studies conducted in the past that investigate hepatotoxicity in 
patients who are co-infected with HIV/TB have given indication of the risk factors that are 
consistently related to hepatotoxicity. Therefore, these risk factors will be included in the final 
model accordingly.  
Additional risk factors will be included in the final model based on the ‘backward elimation’ 
procedure as proposed by (Jewell, 2003). His method follows 6 steps: 
1. Fit univariate models for each potential risk factor and retain risk factors with level of 
significance of p-value < 0.2. In this study however, risk factors that will be retained will be 
those with level of significance of p-value < 0.1. 
2. Secondly, fit a multivariable model with all risk factors that are retained in Step 1. 
3. Thirdly, remove risk factors from this model one by one if they are no longer significant at 
p-value < 0.1. Compare models using the likelihood ratio statistics to ensure that deletion 
of a variable does not cause a significantly poorer fit.  
4. In the fourth step, consider each of the risk factors that were discarded in step 1 on their 
own to determine whether any one of these risk factors should be added to the model. 
5. In the fifth step, consider any relevant interaction terms between pairs of included risk 
factors. 
6. Lastly, assess the final model for goodness of fit. 
3.5.1. The Wald test statistic  
The Wald test statistic is essentially a ratio of the estimated coefficient to its estimated standard 
error. This statistic will be introduced as illustrated by Hosmer Jr, et al., (2008). Suppose that 𝜷 ̂ 
is a 𝑝 × 1 vector regression of coefficients that are maximum likelihood estimates from equation 
(3.5). And let 𝑰(𝜷) be the 𝑝 × 𝑝 observed information matrix evaluated at  𝜷, this is equivalent to 
the second derivative of the log partial likelihood (𝑰(𝜷) = 𝜕2𝐿𝑝(𝜷) 𝜕𝜷
𝟐⁄ ). The estimate of the 




Var̂(?̂?) =  𝑰−1(?̂?).  The estimator of the standard error is the positive square root of the variance 
estimator, denoted as SÊ(?̂?). Note that this is notation for a single covariate, for multiple 
covariates, a variance-covariance matrix is estimated by Var̂ (?̂?). 
The Wald test statistic to test the null hypothesis that 𝜷 ̂ has no effect (𝐻0: 𝜷 = 𝟎) can be written 
as: 
 𝑋𝑊
2 = 𝜷 ̂′𝑰(𝜷 ̂)𝜷 ̂.  
This test statistic is asymptotically equivalent to a chi-square random variable with 𝑝 degrees of 
freedom. It is assumed that asymptotically the 𝑝 estimated coefficients of 𝜷 ̂ are normally 
distributed with mean 𝜷 and variance-covariance matrix  𝑰−1(𝜷 ̂).   
The 100(1 − 𝛼) confidence interval for a single coefficient  𝛽 ̂ can be defined as: 
 
𝛽 ̂ ±  𝓏1−𝛼 2⁄ SÊ(?̂?). 
 
 
This confidence interval for coefficient 𝛽 ̂is also called the Wald statistic based confidence interval. 
Therefore, the endpoints of this interval follow the same assumptions that are specified for the 
Wald test statistic discussed above. These confidence limits can be exponentiated to obtain 
confidence intervals on the hazard ratio scale. 
3.6 Model adequacy assessment 
The multivariable Cox model will include treatment arm, age, gender, CD4 count, baseline LFT 
results and the covariates with strong association identified through Jewell’s backwards 
elimination procedure described above. Model adequacy will be based on quantities called 
residuals. Residuals are estimated for each individual in the study, and their expected behavior 
is known when the model is correctly fitted (Collett, 1994). 
The residual techniques require estimates of the baseline hazard function. This makes intuitive 
sense, because to assess if the estimated model fits the data well, you need to have estimates 




3.6.1. Estimate of the baseline hazard function 
The estimation of the baseline hazard function illustrated here is as proposed by Kalbfleisch & 
Prentice, (1973). Suppose that there are 𝑟 subjects who experienced the event (𝑟 ≤ 𝑛), and the 
remaining observed times (𝑛 − 𝑟) reflect right-censoring. Suppose further that the 𝑟 subjects had 
observed survival times (not necessarily all distinct), arranged in ascending order. The 𝑗𝑡ℎ 
observed survival time is denoted as  𝑡(𝑗) for 𝑗 = 1, 2, … 𝑟, and the ordered 𝑟 observed survival 
times are 𝑡(1) <   𝑡(2) < ⋯ < 𝑡(𝑟).  
The estimate of the baseline hazard function at time  𝑡(𝑗) is written as: 















where 𝐷(𝑡𝑗) is the set of all  𝑑𝑗 subjects who experience the event at 𝑗
𝑡ℎ ordered observed time 
𝑡(𝑗),  and 𝑅(𝑡𝑗) is the risk set of subjects who have not experienced the event of interest, at ordered 
observed time 𝑡(𝑗). ?̂? is a vector of the maximum likelihood estimates that will  be obtained from 
equation (3.5). Collett (1994) pointed out that equation (3.7) requires to be solved by an iterative 
scheme, as it cannot not be solved explicitly.  
Once the baseline hazard has been estimated, then the estimated hazard function for subject 𝑖 is 
given by: 
 ?̂?𝑖(𝑡|𝒙𝑖) = ?̂?0(𝑡)exp(?̂?′𝒙𝑖). (3.8) 
 
And the cumulative hazard function for subject 𝑖 is simply the integral of the hazard function 
denoted as 
 










where ?̂?0(t) is the cumulative baseline hazard function.  
3.6.2. Estimate of the adjusted survival function 
Once the baseline hazard function has been estimated, the estimated adjusted survival function 
of the study can be obtained. Assuming that time 𝑡 is continuous then the estimate of the adjusted 
survival function for subject 𝑖 given by 
 
?̂?𝑖(𝑡|𝒙𝑖) =  [?̂?𝑜(𝑡)]
exp(?̂?′𝒙𝑖)




,in which ?̂?𝒐(𝒕) is the estimated baseline survival function, 
 





for  𝑡(𝑗) <   𝑡 < 𝑡(𝑗+1), 𝑗 = 1, 2, … 𝑟 − 1 where ?̂?𝑗 is the solution of equation (3.7). 
3.6.3. Cox-Snell residuals 
Cox & Snell (1968) proposed the Cox-Snell residuals that allows an assessment of the overall fit 
of the model. The Cox-Snell residuals (𝑟𝐶𝑖) for the 𝑖
𝑡ℎ subject where 𝑖 = 1,2, … 𝑛 is given by: 
 𝑟𝐶𝑖 = ?̂?0(𝑡𝑖)exp(?̂?′𝒙𝑖), 
(3.11) 
where ?̂?0(𝑡) is the estimated cumulative baseline hazard function at observed time 𝑡𝑖. 𝒙𝒊 is the 
vector of explanatory variables for subject 𝑖 and 𝜷 ̂ are the corresponding estimated maximum 
likelihood estimates from equation (3.5). Note that the Cox-Snell residual of  𝑟𝐶𝑖, is the estimated 
point of equation (3.9) when time is 𝑡𝒊. 
If the model is a good fit of the data, this is, if the assumed Cox model holds and ?̂?, ?̂?0 are close 
to the true values 𝜷, 𝛬0, then the Cox-Snell residuals 𝑟𝐶𝑖 should indicate that they come from an 
exponential distribution with a mean and variance of 1. This implies that if ?̂?𝑖(𝑟𝐶𝑖) is the cumulative 
hazard function evaluated at each 𝑟𝐶𝑖 for 𝑖 = 1,2, … 𝑛, the plot of ?̂?𝑖(𝑟𝐶𝑖) =
?̂?0(𝑟𝐶𝑖)exp(?̂?′𝒙𝑖) against the actual Cox-Snell residual  𝑟𝐶𝑖 will have a slope that is equivalent to 




3.6.4. Martingale residuals 
Wilson (2013) discussed that the partial likelihood method estimates regression coefficients of the 
respective covariates on the basis that the covariates operate linearly on the hazard function. If 
the linear relationship is not satisfied than the interpretation of the hazard would be incorrect. The 
assessment of the linearity is often called the assessment of the functional form. The martingale 
residual will be used to assess the functional form of the covariate, as discussed extensively by 
Therneau & Grambsch (2000) amongst other authors.  
The martingale residual is basically the difference between the observed number of events and 
the expected number of events predicted by the fitted model, given the observed survival time 
and the observed covariate. The martingale residual for the 𝑖𝑡ℎ  subject is written as: 




where 𝛿𝑗 takes on a value of 1 if the event of interest occurred and 0 if subject 𝑖 was censored. 
𝑟𝐶𝑖 is the Cox-Snell residual of subject 𝑖 as illustrated in equation (3.11), this element represents 
the number of events expected from subject 𝑖 based on the fitted model.  
The martingale residuals are estimated without the covariate which the functional form is been 
assessed for, and the resulting martingale residual is plotted for this covariate in question for each 
subject. If the covariate is fitted correctly in the model, the fit of a loess regression (Cleveland, 
1979) line will be a horizontal line at 0. The values of martingale residuals range −∞ to 1, implying 
that the resulting plot will be asymmetrical. 
3.6.5. Deviance residuals 
Deviance residuals are conceptually martingale residuals that are transformed to produce values 
that are symmetric about zero when the fitted model is appropriate (Collett, 1994). They are 
defined by 





,where 𝑟𝑀𝑖 is the martingale residual, 𝛿𝑗 the event indicator of 1 if the event has occurred or 0 and 




3.7 Proportional hazard assumption test 
Two methods discussed by Kleinbaum & Klein (2005) will be used to assess whether the 
proportional hazards assumption holds for the covariates included in the multivariable Cox model. 
3.7.1.  Applying the time dependent covariates method 
The time-dependent covariates method specifies a model that is an extension of the Cox Model 
in equation (3.2). This model fits the main effects of the covariates and the interaction effects 
between the covariate and some function of time (𝑔(𝑡)). The form of this model for subject 𝑖 can 
be written as: 
 𝜆(𝑡|𝒙𝑖) = 𝜆0(𝑡)exp(𝜷
′𝒙𝑖 + 𝝋
′𝒙𝑖(𝑡)), (3.14) 
where 𝜆0(𝑡) is the baseline hazard function, 𝒙𝑖 is the vector of 𝑝 covariates, and the 𝜷 is the 
vector of the corresponding 𝑝 unknown regression coefficients, 𝒙𝑖(𝑡) =  [𝒈𝑖(𝒕)]′𝒙𝑖 is a vector of 
interaction terms of the 𝒙𝑖 vector of 𝑝 covariates and 𝒈𝒊(𝒕) vector of 𝑝 functions of time, and lastly 
𝝋 is the vector of the corresponding  𝑝 unknown interaction term coefficients. 
This model in equation (3.14) is fitted by a likelihood function specified in equation (3.5), with a 
modification that, the hazard that a subject contributes into the construction of the likelihood 
function per time interval will vary with time. Once the model is fitted, the effects of the interaction 
terms 𝝋 are tested for significance in the model, using the Wald test statistic with 𝑝 degrees of 
freedom. If there is no evidence that the interaction term has an effect on the hazard of event 
occurrence this would imply that the proportional hazards assumptions is satisfied.   
3.7.2.  Graphical approach assessment  
The graphical approach is based on a double log transformation of the survival curves. This 
method transforms the estimated survival curves by taking the natural log twice. Suppose the 
estimated survival curve for subject 𝑖 given that  𝒙𝑖 is vector of covariates is given by: 
 
?̂?𝑖(𝑡|𝒙𝑖) =  [?̂?𝑜(𝑡)]
exp(?̂?′𝒙𝑖)






Replacing the vector multiplication of ?̂?′𝒙𝑖 by the summation form ∑ ?̂?𝑙
𝑝
𝑙=1 𝑥𝑙 and taking a natural 
log on both sides of the equation; 
 
ln [?̂?𝑖(𝑡|𝒙𝑖)] = exp(∑ ?̂?𝑙
𝑝
𝑙=1 𝑥𝑙) × ln[?̂?𝑜(𝑡)].    
Step 2 
Note that the survival function ?̂?𝑖(𝑡|𝒙𝑖) and the baseline survival function are quantities that range 
between 0 to unity over time. It follows that the natural log of a number between 0 to unity is 
negative. This implies that in order to take the second natural log we need to negate both sides 
of the equation in Step 2 and then take the second log as below: 
 ln[−ln [?̂?𝑖(𝑡|𝒙𝑖)]] =  ∑ ?̂?𝑙
𝑝
𝑙=1 𝑥𝑙 + ln [−ln [?̂?𝑜(𝑡)]]. 
Step 3 
Lastly, both sides of the equation are negated; note that this is usually an optional step, is  
 
−ln[−ln [?̂?𝑖(𝑡|𝒙𝑖)]] = − ∑ ?̂?𝑙
𝑝
𝑙=1
𝑥𝑙 − ln [−ln [?̂?𝑜(𝑡)]].  (3.15) 
It follows that if equation (3.15) is specified for subject 𝑖 and 𝑗, the difference of these two 
specifications is independent of time, since element of ln [−ln [?̂?𝑜(𝑡)]] cancels out. This means 
that the plot of equation (3.15) over time, for subjects from different categories of the covariate 
variable should result in curves which are parallel if the proportional hazards assumption is 
satisfied. This is straight forward for covariates that are categorical in nature. Continuous variables 
need to be categorized to assess proportional hazards using the graphical approach. 
3.8 Treatment of predictors that do not satisfy PH assumption 
3.8.1. Cox model with non-proportional hazards 
One way to adjust the Cox model for non-proportional hazards is to allow the covariates to interact 
with time. The general formula for the Cox model with non-proportional hazards for subject 𝑖 is 
written as: 
 
𝜆(𝑡|𝒙𝑖) = 𝜆0(𝑡)exp (∑ 𝛽𝑗
𝑝−𝑞
𝑗=1 𝑥𝑖𝑗 + ∑ 𝜑𝑙
𝑞
𝑙=1 𝑥𝑖𝑙(𝑡)), (3.16) 
where 𝜆0(𝑡) is the baseline hazard function, 𝑥𝑖𝑗 is the 𝑗
𝑡ℎ covariate that is fixed for the subject 𝑖 
and 𝛽𝑗 is the corresponding unknown regression coefficient, lastly 𝑥𝑖𝑙(𝑡) is the 𝑙




is time-dependent for the subject 𝑖, and 𝜑𝑙 is the corresponding unknown regression coefficient. 
𝑥𝑖𝑙(𝑡) is a covariate which is function of time that can be defined as 𝑥𝑖𝑙(𝑡) = 𝑥𝑖𝑙 × 𝑔𝑙(𝑡) where 𝑥𝑖𝑙 
is the fixed 𝑙𝑡ℎ covariate for subject 𝑖 and 𝑔𝑙(𝑡) is the function of time. Note that equation (3.16) 
can be fitted by the partial likelihood already specified in equation (3.5); however, it will require 
more computational time. 
The choice of 𝑔𝑙(𝑡) is left to the discretion of the modeler. In general, the choice of 𝑔𝑙(𝑡) affects 
how the hazard function is interpreted. If 𝑔𝑙(𝑡) is chosen to be 𝑡 and the resulting estimate of ?̂?𝑙 
is a negative value, this means that the effect of covariate 𝑥𝑖𝑙 increases the hazard of experiencing 
the event as time increases. And if the estimate of ?̂?𝑙 is a positive value, then this suggests that 
the effect of covariate 𝑥𝑖𝑙 decreases the hazard of experiencing the event as time increases.  
There are many choices for the form of 𝑔𝑙(𝑡). For example, choosing 𝑡 as a form of 𝑔𝑙(𝑡) is 
typically justified if the difference in hazard between the risk levels is monotonically increasing or 
decreasing over time. Likewise, log(𝑡) is considered as a form of 𝑔𝑙(𝑡) for the same reason as 
mentioned above, the natural log is applied when the monotonic pattern is not readily seen.  
Kleinbaum and Klein (2005) discussed the heavyside function as a choice for the function time 
𝑔𝑙(𝑡). 
The heavyside function  
The heavyside function is a function that segments the study period into intervals, in order to 
estimate a different coefficient for covariate 𝑥𝑖𝑙 in each defined interval. The estimated 
coefficient is constant within the interval, however varies from interval to interval. The general 
form of heavyside function is expressed as:  
                          𝑔𝑙𝑠(𝑡) = {
 1     if 𝑡 ≤  𝑡𝑙  
0     if 𝑡 >  𝑡𝑙
   (3.17) 
  
where 𝑡𝑙 represents the maximum time for which the hazard ratio will be estimated, otherwise the 
hazard ratio will be equivalent to zero. The heavyside function defined in equation (3.17), is ideal 
when the modeler suspects that the hazard ratio in the interval [0, 𝑡𝑙] will constant and then 
equivalent to zero beyond 𝑡𝑙. Note that the hazard ratio is only obtained for a single interval, since 
only a single heavyside function has been defined here. If the modeler is interested in more 




3.8.2. The stratified Cox procedure 
Another way to control for variables which do not satisfy the PH assumption is by stratification of 
the Cox model. Variables that do not satisfy the PH assumption are used to stratify the Cox model, 
and variables that satisfy the PH assumption are included in the Cox model. The general stratified 
Cox model discussed here will be as illustrated by Kleinbaum & Klein (2005).  
Suppose that there are 𝑝 explanatory variables that are considered in the Cox model and 𝑞 of the 
𝑝 variables do not satisfy the PH assumption. For the 𝑖𝑡ℎ subject, variables that satisfy the PH 
assumption will be denoted as  𝑥𝑖𝑗 where  𝑗 = 1, 2, ⋯ 𝑝 − 𝑞, and variables that do not satisfy the 
PH assumption will be denoted as 𝑧𝑖𝑙 where  𝑙 = 1, 2, ⋯ , 𝑞. 
To perform a stratified cox model, the categories of 𝑧.′𝑠 are considered, if the variable is 
continuous it is categorized. The combination of the categories is formed, and these combinations 
form the stratas. A combination of the categories form a new variable denoted as a 𝑧∗.  The 
stratification variable 𝑧∗ has  𝑘∗ categories, where 𝑘∗ is the total number of possible combinations 
(or strata) formed after categorizing each of the  𝑧.′𝑠. The general stratified Cox model is written 
as  
 





, where  𝑔 = 1, 2, ⋯ , 𝑘∗ indicates a stratum of 𝑧∗ and 𝜆0𝑔(𝑡) is the baseline hazard function for 
the 𝑔th stratum, 𝑥𝑖𝑗 is the 𝑗
𝑡ℎ covariate that is fixed for the subject 𝑖 and 𝛽𝑗 is the corresponding 
unknown regression coefficient. As can be seen the variable 𝑧∗, is not explicitly included in the 
in the model but the 𝑥.
′s which are assumed to satisfy the PH assumption are included.  
The regression coeffiecients 𝛽.’s are estimable by the maximum of likelihood method. The 
likelihood function 𝐿 is the product of partial likelihood functions that are determined for each 
stratum, 𝐿 = ∏ 𝐿𝑔
𝑘∗
𝑔=1 , each 𝐿𝑔 is determined by equation (3.5). The 𝛽.’s estimates are then the 





Note that the baseline hazard function is allowed to vary per stratum. However, the regression 
coefficients are the same for each statum, this feature is what is called a ‘no-interaction 
assumption’. The no-interaction assumption is tested by fitting an alternative model that assumes 
that, there is interaction in the model, this model is written as : 
 




where  𝑔 = 1, 2, ⋯ , 𝑘∗ indicates a stratum of 𝑧∗, and 𝜆0𝑔(𝑡) is the baseline hazard function for 
the 𝑔th stratum, 𝑥𝑖𝑗 is the 𝑗
𝑡ℎ covariate that is fixed for the subject 𝑖 and 𝛽𝑗𝑔 is the corresponding 
unknown regression coefficient for the 𝑔th stratum.  The log-likehood test is then performed  
between the no-intereaction models equation (3.18) and equation (3.19), with 𝑝 − 𝑞(𝑘∗ − 1)  
degrees of freedon, if the outcome of the test is statitistically significant, then it will mean that the 





3.9 Application  
3.9.1. Background 
The primary aim of the SAPiT trial was to identify the optimal timing for initiating ART therapy in 
patients who are HIV/TB co-infected, and are on TB treatment. All patients in the trial initiated TB 
treatment at or before randomization. Patients were then randomized to either initiate ART within 
four weeks of the TB therapy (early arm), or within four weeks after completion of the intensive 
phase of tuberculosis treatment (late arm), or within completion of TB therapy (sequential arm). 
Abdool Karim, et al., (2010) found that the mortality rates in trial were at least doubled in patients 
who were in the sequential arm, compared to patients in the early and the late arm combined. 
They also reported that the HIV RNA was suppressed in higher levels for patients in the early and 
late arm compared to patients in the sequential arm; this is after 12 months of study 
randomization. This study indicated that there was a survival benefit for those patients who were 
in the early and late arm compared to patients in the sequential arm.  
Of interest in this analysis is the relationship of liver injury (hepatotoxicity) within the three 
treatment arms. Patients in the early and late arm co-administered more drugs at the same time, 
compared to the number of drugs co-administered by patients in the sequential arm, leading to a 
clinical hypothesis that patients in the early and late arm will be at a higher risk of hepatotoxicity 
compared to patients in the sequential arm; because of the number drugs taken by each arm.  Of 
secondary interest in this project is to model the impact of the covariates on the occurrence 
hepatotoxicity. Thus, the summary statistics of these covariates by treatment arm is reviewed 
next. Moreover, the assessment of the covariate characteristic that describes a subject with 
baseline abnormal liver function to those with normal liver function is performed to test if this 
variable is confounding or not. If necessary, a description of the covariate and the reasons for 
including these covariates in the analysis is discussed. 
3.9.2. Covariates distribution at baseline 
Continuous variables were summarised using means and standard errors, or medians and 
interquartile ranges. Categorical variables were summarized using frequencies and proportions. 
Wilcoxon rank sum test or unpaired t-test were used for the analysis of continuous data. Fisher’s 
exact test was used for the analyses of categorical variables. Observed p-values were reported 




3.9.3. Baseline characteristics 
The demographic data variables that were considered in the SAPiT trial were age and gender. 
The overall median and mode of the age in the study is 33 and 31 years of age respectively, this 
indicates that the age distribution is positively skewed under this study. The median age of a study 
subject was 34 years old in the early arm, 33 years old in the late arm and 33 years old in the 
sequential arm. The proportion of males was 45% in the early arm, 52% in the late arm and 52% 
in the sequential arm (Table 3.1). 
There were not that many subjects that were underweight across the treatment arms. Only 12% 
of subjects were underweight in the early arm, 13% in the late arm and 14% in sequential arm 
(Table 3.1). There were 37% of the subjects in the early arm, 32% of the subjects in the late arm, 
and 31% of the subjects in sequential arm, reporting a history of TB. Furthermore, patients with 
abnormal liver function at baseline were less likely to have a history of TB than patients with a 
normal liver function at baseline (22% versus 36%, p-value = 0.0024). 
Patients, who reported suffering from extra pulmonary TB were not that common in the study, 
with only 5% of the study subjects in the early arm, 4% of the study subjects in the late arm, and 
4% of the study subjects in the sequential arm. In subjects with extra pulmonary TB, none had TB 
of the liver. The World Health Organization (WHO) clinical stage 4 (severely symptomatic stage, 
designation includes all of the AIDS-defining illnesses) is not frequent in the study, with a 
proportion 7% of subjects in the early arm, 5% of subjects in the late arm and 6% of subjects in 
the sequential arm presenting with WHO stage 4.  
Alcohol use has been investigated in literature primarily because alcohol use may cause liver 
disease. There were 12%, 11% and 14% patients in the early, late and sequential arm respectively 
who reported to be occasional consumers of alcohol. In patients with abnormal liver function 13% 
of the patients reported to be occasional consumers of alcohol, this is comparable to 12% of 
patients, who have a normal liver function and reported to be an occasional consumer of alcohol.  
CD4+ count <0.05 × 109 cell/L is commonly a threshold that indicates severe HIV progression, 
17% of subjects in the early arm, 16% of subjects in the late arm and 19% of subjects in the 
sequential arm were at a severe HIV progression stage. Furthermore, patients with abnormal liver 
function at baseline were more likely to have CD4+ count < 0.05 ×  109 compared to patients with 




The CD8+ count median was 0.7 × 109 cell/L across the treatment arms, which is within the range 
[0.2 – 1.0] × 109 cell/L that is considered normal. However, patients with abnormal liver function 
at baseline had a median of 0.5× 10𝟗 CD8+ count, this is significantly lower than the median of 
0.7× 10𝟗 CD8+ count observed in patients with normal liver function at baseline (p-value = 0.005).  
The medians for log10 HIV RNA were the same across all treatment arms. 
Alkaline phosphatase (ALK), total bilirubin (BIL) and lactate dehydrogenase (LDH) are liver 
function tests that are performed along with ALT and AST liver function tests. It is of interest to 
also explore the relationship of these serum chemistries to hepatotoxicity, given that they come 
from the same source as that of ALT and AST. The median levels for ALK, BIL and LDH were 
similar across the treatment arms. While, patients with abnormal liver function at baseline had 
higher ALK, BIL and LDH medians compared to patients with normal liver function at baseline.  
The proportion of patients who had Hepatitis B surface antigen (HBsAg) positive status compared 
to patients with a negative HBsAg status at baseline, was the same across the treatment arms. 
Additionally, there was no significant difference between patients with abnormal liver function 
compared to patients with normal baseline function with respect to HBsAg status (p-value = 0.17). 
However, 17% of observations were missing a HBsAg status  at baseline and this result may not 
be precise, since the missing number of observations are above the threshold of  5 %  (Marshall, 





Table 3.1: Baseline characteristics of participants in the SAPiT trial 














normal liver function 
tests 
(n=472) 
p- Value a 
Median age (IQR) 34 (28 - 39) 
 
33 (28 - 40) 
 
33 (28 - 38) 
 
34 (28 - 39) 32 (28 - 39) 0.6096 
Male, n (%) 97 (45.3) 112 (52.1) 110 (51.6) 63 (52.1) 230 (48.7) 0.5417 
BMI<18.5 kg/m2, n (%) b 25 (11.7) 28 (13.0) 29 (13.6) 12 (10.0) 63 (13.6) 0.3592 
History of tuberculosis n (%) 80 (37.4) 68 (31.6) 66 (31.0) 26 (21.5) 169 (35.8) 0.0024 
Extra pulmonary Tuberculosis, n (%) c 10 (4.7) 9 (4.2) 9 (4.3) 8 (6.6) 18 (3.8) 0.212 
WHO stage 4, n (%) 14 (6.5) 11 (5.1) 13 (6.1) 11 (9.1) 24 (5.1) 0.127 
Alcohol occasionally consumed, n (%) d 24 (11.7) 23 (11.0) 28 (13.7) 15 (12.8) 53 (11.6) 0.8769 
Alcohol frequently consumed, n (%) d 6 (2.9) 9 (4.3) 9 (4.4) 4 (3.4) 20 (4.4) 
Patients with CD4+ count <0.05 × 𝟏𝟎𝟗 cell/L n 
(%) 
37 (17.3) 35 (16.3) 41 (19.25) 42 (34.7) 61 (12.9) <.0001 
Median CD8+ count (IQR), × 𝟏𝟎𝟗 cell/L  0.697  
(0.417 - 1.030) 
0.660  





(0.336 – 0.877) 
0.690  
(0.482 – 1.021) 
0.0048 
Median log10 HIV RNA (IQR), copies/Ml  5.0 (0.9) 5.0 (0.9) 5.1 (0.7) 5.1(0.9) 5.0 (0.9) 0.277 
Median AST levels (IQR)  
 
29.0 
(22.0 to 41.0) 
29.0 
(22.0 to 42.0) 
29.0 
(22.0 to 42.0) 
   
Median ALT levels (IQR)  20.0 (13 - 33) 19.0 (13 - 29) 17.0 (12 - 28)    
Median Alkaline Phosphate (IQR)   
 
84.0 
(68.0 to 109.0) 
86.5 
(69.0 to 111.0) 
83.0 
(67.0 to 122.0) 
102.0 
 (74.0 to 149.0) 
82.0 
(68.0 to 105.0) 
<.0001 
Median Total bilirubin (IQR)  7.0 
(5.0 to 10.0) 
7.0 
(5.0 to 10.0) 
7.0 
(5.0 to 11.0) 
8.0 
(5.0 to 14.0) 
7.0 
(5.0 to 10.0) 
0.0019 









(264.0 to 376.0) 
240.0 
(210.0 to 281.0) 
<.0001 
HBsAg Positive n (%) e 15 (8.8) 15 (8.1) 13 (7.5) 12 (11.3) 30 (7.6) 0.2366 
SD = Standard Deviation BMI = Body Mass Index; IQR =Interquartile range; WHO = World Health Organization 
a p-value for the comparison of patients with liver enzyme abnormalities to those without.  
b Two patients in the late integrated arm and six patients in the sequential arm had missing baseline BMI data, which were not included in the percentage calculation.  
c Among these patients, none had tuberculosis of the liver. One patient in the late integrated arm, 2 patients in the sequential arm had missing extra pulmonary tuberculosis data, 
which were not included in the percentage calculation.  
d Eight patients in the early integrated arm, 4 patients in the late integrated arm and 6 patients in the sequential arm had missing alcohol records, which were not included in the 
percentage calculation.  




3.9.4. Fitting the Cox Model 
The candidate covariates to be included in the Cox model are age, sex, body mass index (BMI) 
strata, history of TB, extra pulmonary TB, World Health Organization (WHO) stage, alcohol 
consumed, CD4 count category, CD8 count, baseline log viral load, alkaline phosphate (ALK), 
total bilirubin (BILI), lactate dehydrogenase (LDH), hepatitis B surface antigen (HBsAg) and 
baseline LFTs.  
It is sensible to assess the association of baseline measurement with the occurrence of 
hepatotoxicity, as it is at baseline that the appropriate treatment regimen for a patient is 
determined and administered. Therefore, the analysis in this chapter will examine the baseline 
characteristics of a patient that are associated with the occurrence of hepatotoxicity, so as to 
inform clinicians on what precautionary measures to take when treating the patients with a high 
risk of developing hepaototoxicity. 
It is important to note the SAPiT is a randomised control trial, and therefore the abovementioned 
variables will be included in the model, with aim to quantify the association of these variables in 
relation to the occurrence of hepatotoxicity, and these variables are not included merely to adjust 
for confounding. 
The model build process will follow the backward elimination procedure as proposed by Jewell 
(2003). 
Univariate assessment 
A univariate Cox PH model is fitted per baseline exposure variable considered in the study. Table 











Table 3.2: Cox PH model Univariate assessment 
 Univariate assessment 








Early arm vs. Sequential arm (Reference) -0.082 0.184 0.921 0.6573 
Late arm vs. Sequential arm (Reference) 0.035 0.183 1.036 0.8488 
Age (years)  0.019 0.008 1.019 0.0215 
Sex = Male vs. Sex = Female (Reference) 0.306 0.150 1.358 0.0414 
BMI category < 18.5 kg/m2 vs. ≥18.5 kg/m2 
(Reference) 
-0.130 0.243 0.878 0.5929 
History of TB Yes vs. No (Reference) 0.026 0.160 1.026 0.8720 
Extra pulmonary TB Yes vs. No 
(Reference) 
-0.057 0.362 0.945 0.8748 
WHO stage 4 vs. 3 (Reference) -0.044 0.325 0.957 0.8921 
Alcohol = Consumer vs. Non-consumer 
(Reference) 
0.393 0.194 1.481 0.0424 
CD4Cat  ≥ 0.05 × 109 vs. CD4Cat <
0.05 × 109  (Reference) 
0.205 0.186 1.228 0.2707 
CD8 count × 109 cell/L 0.086 0.092 1.090 0.7032 
Log viral load    0.086 0.092 1.090 0.3512 
ALK 0.001 0.001 1.001 0.2753 
BILI -0.037 0.017 0.964 0.0299 
LDH -0.001 0.001 0.999 0.3079 
HBsAg = Positive status vs. HBsAg = 
Negative status (Reference) 
0.697 0.241 2.008 0.0038 
Baseline LFT= Abnormal vs. Normal 
(Reference) 
 
-0.117 0.193 0.890 0.5425 
Age, sex, alcohol, BILI and HBsAg status were all significant at 10% level significance in the 





First multivariable model 
A multivariable Cox PH model is fitted based on age, sex, alcohol, bilirubin and HBsAg status, 
model results are shown in the first four columns of Table 3.3. It is apparent that the sex variable 
is not significant in the multivariable model. Consequently, this variable will be omitted in the 
multivariable Cox PH model going forward. 
Table 3.3: Multivariable estimation of the preliminary effects model 





















0.0252 0.0097 1.026 0.0094 0.0261 0.0096 1.026 0.0063 
Sex = Male 
vs. Sex = 
Female 
(Reference) 






0.4448 0.2389 1.560 0.0626 0.4944 0.2195 1.640 0.0243 
BILI 








0.7167 0.2545 2.048 0.0049 0.7400 0.2470 2.096 0.0027 
-2 Log L 1579.086 1579.419 
 
Elimanating variable that are not significant in the first multivariable model 
Sex is excluded in the multivariable model (6th, 7th , 8th and 9th column of Table 3.3), the log 
likelihood ratio test statistic for excluding sex in the model is 1579.419 - 1579.086 = 0.333 with 1 
degrees of freedom, this is not statistically significant. Meaning that the inclusion of sex in the 





Re-considering risk factors that were eliminated in the univariable assessment 
The multivariable Cox PH model now consists of age, alcohol, BILI and HBsAg status variable. 
We will now assess the significance of the variables that were discarded at the univariable 
assessment stage. The significance of these variables will be examined by adding each variable 
one by one, into the current multivariable Cox PH model (that contains age, alcohol, BILI and 
HBsAg status). The p-values for this process are shown in Table 3.4. It is important to note that 
the p-value for the variables that are already in the model (age, alcohol consumed, BILI and 
HBsAg status) are not presented here, only the p-values for variables of interest are presented 
Table 3.4. 
Table 3.4: Re-considering risk factors that were eliminated in the univariable assessment 
Variable added to the model p-value* 
BMI < 18.5 kg/m2 vs. ≥18.5 kg/m2 (Reference) 0.7427 
History of TB Yes vs. No (Reference) 0.6260 
Extra pulmonary TB Yes vs. No (Reference) 0.7396 
WHO stage 4 vs. 3 (Reference) 0.7860 
CD4Cat  ≥ 0.05 × 109 vs. CD4Cat < 0.05 × 109  
(Reference) 
0.1708 
CD8 count cell/L 0.9874 
Baseline Log viral load 0.4809 
Baseline ALK 0.7024 
Baseline LDH 0.8112 
Baseline LFT= Abnormal vs. Normal 
(Reference) 
0.6124 
*p-value from a multivariable model containing age, alcohol, BILI and HBsAg 
status  
None of these variables had improved significance and thus none of these variables will be added 
to the model. Therefore, the model to be considered forward is unchanged and contains age, 
alcohol, BILI and HBsAg variable. Possible interactions will now be examined based on this 
model. 
Examining possible interactions effects in the model 
All possible interaction or mixed terms that can be formed between age, alcohol consumed, BILI 






Table 3.5: First review of the multivariable assessment of main and interaction effects  








Age (years) 0.020 0.018 1.020 0.2807 
Alcohol = Consumer vs. Non-consumer 
(Reference) 
-0.090 1.163 0.914 0.9385 
BILI -0.059 0.066 0.943 0.3697 
HBsAg = Positive status vs. HBsAg = Negative 
status (Reference) 
0.507 1.404 1.660 0.7179 
Age * Alcohol = Consumer vs. Non-consumer 
(Reference) 
0.013 0.029 1.013 0.6635 
Age * BILI 0.000 0.002 1.000 0.8308 
Age * (HBsAg = Positive status vs. HBsAg = 
Negative status (Reference)) 
0.039 0.034 1.040 0.2566 
Alcohol = Consumer vs. Non-consumer 
(Reference)* BILI 
0.002 0.043 1.002 0.9706 
Alcohol = Consumer vs. Non-consumer 
(Reference)* HBsAg = Positive status vs. HBsAg 
= Negative status (Reference) 
1.825 0.901 6.203 0.0427 
BILI * HBsAg = Positive status vs. HBsAg = 
Negative status (Reference)  
-0.171 0.081 0.843 0.0346 
-2 Log L 1571.886 
 
Interaction of alcohol with the HBsAg status and the interaction of BILI with the HBsAg status 
were significant at 10% level of significance. Subsequently, these terms were added to the model. 









Table 3.6: Second review of the multivariable assessment of main and interaction effects 








Age (years) 0.027 0.009 1.027 0.0042 
Alcohol = Consumer vs. Non-consumer 
(Reference) 
0.388 0.229 1.474 0.0906 
BILI -0.046 0.020 0.955 0.0237 
HBsAg = Positive status vs. HBsAg = Negative 
status (Reference) 
1.805 0.630 6.080 0.0042 
Alcohol = Consumer vs. Non-consumer 
(Reference)* HBsAg = Positive status vs. HBsAg 
= Negative status (Reference) 
1.719 0.925 5.579 0.0633 
BILI * HBsAg = Positive status vs. HBsAg = 
Negative status (Reference)  
-0.159 0.082 0.853 0.0538 
-2 Log L 1573.093 
The interaction terms included in the model are all significant Table 3.6. However, interaction term 
between alcohol and HBsAg status yielded a high standard error, indicating an overfit of the 
model. Therefore, this interaction term between alcohol and HBsAg will be excluded in the 
modelling process. 
Table 3.7: Third review of the multivariable assessment of main and interaction effects 









0.026 0.010 1.026 0.006 
Alcohol = Consumer vs. Non-consumer 
(Reference) 
0.513 0.220 1.670 0.0198 
BILI 
-0.047 0.020 0.954 0.0213 
HBsAg = Positive status vs. HBsAg = 
Negative status (Reference) 
1.430 0.604 4.179 0.0180 
BILI * HBsAg = Positive status vs. HBsAg = 
Negative status (Reference)  
-0.081 0.071 0.922 0.2536 
-2 Log L 1577.822 
The remaining mixed term between BILI and HBsAg status is now statistically not significant and 
will be excluded in the modeling process (Table 3.7). 
Final multivariable Cox PH model 
At this point all variables were included in model based on statistical significance and no variable 




treatment arm will be included in the final model since the aim of this project is to explain the 
association of treatment arm with the hazard of hepatotoxicity. Additionally, sex, CD4 count 
category and the baseline LFT variable will also be added in the model since these variables have 
commonly been predictive in literature. The final multivariable Cox model PH is as below 
𝜆( 𝑡, 𝑿(𝑡) ) = 𝜆0(𝑡) exp(𝛽𝐴𝑟𝑚1 × 𝐴𝑟𝑚1 +  𝛽𝐴𝑟𝑚2 × 𝐴𝑟𝑚2 +  𝛽𝑆𝑒𝑥 × 𝑆𝑒𝑥
+ 𝛽𝐴𝑔𝑒 × 𝐴𝑔𝑒 + 𝛽𝐴𝑙𝑐 × 𝐴𝑙𝑐 + 𝛽𝐶𝐷4𝑐𝑎𝑡 × 𝐶𝐷4𝑐𝑎𝑡  
+  𝛽𝐵𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛 × 𝐵𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛 + 𝛽𝐻𝐵𝑠𝐴𝑔𝑃𝑜𝑠 × 𝐻𝐵𝑠𝐴𝑔𝑃𝑜𝑠  
+ 𝛽𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐿𝐹𝑇𝐴𝑏𝑛 × 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐿𝐹𝑇𝐴𝑏𝑛). 
 
(3.20) 
The model results of the final multivariable Cox model are presented in Table 3.8 
Table 3.8: Final multivariable Cox PH model 








Early arm vs. Sequential arm (Reference) -0.047 0.212 0.954 0.8262 
Late arm vs. Sequential arm (Reference) 0.167 0.208 1.182 0.4214 
Age (years) 0.024 0.010 1.024 0.0146 
Sex = Male vs. Sex = Female (Reference) 0.066 0.193 1.068 0.7341 
Alcohol = Consumer vs. Non-consumer (Reference) 0.522 0.250 1.685 0.0372 





BILI -0.058 0.021 0.944 0.0051 





Baseline LFT= Abnormal vs. Normal (Reference) -0.212 0.229 0.809 0.3535 
-2 Log L 1575.451 
The next step is to assess the adequacy of the final multivariable Cox PH model. 
3.10 Model adequacy assessments 
Model adequacy assessment is crucial, because it helps us understand how well the estimated 
model fits the data, before proceeding to model interpretation. 
3.10.1. Assessment of the Cox Snell residuals 
The Cox Snell residuals for the final multivariable Cox PH model (Table 3.8) are displayed in 
Figure 3.1. The residuals (blue line) seem to map over the red line reasonably well for earlier 
events, however, towards the end of the study these lines vary. This suggests that the model fits 




towards the end of the study. This however is common is studies that have right censored 
observed survival times.  
 
Figure 3.1: Cox Snell residuals 
3.10.2. Assessment of the martingale and deviance residuals 
The martingale and deviance residual plots for each covariate fitted in the Cox multivariable model 
are presented in Figure 3.2. Graphical analysis of the martingale and deviance residuals for 
categorical variables is based on a box and whisker plot per categorical level and a smooth line 
is fitted on the residuals for continuous variables. 
The distribution of the residuals is the same in the early and late arm, and slightly different in the 
sequential arm (Figure 3.2 (a & b)). Marked in red are the outlier(s), and these are apparent in 
the sequential arm. Judging by the width size of the box and whisker plot for each treatment arm, 
there were more observations from the late arm used in the estimation of model parameters 
compared to the other arms. Recall that the number of observation for each arm was 195, 198, 
and 200 for the early arm, late arm and sequential arm respectively in Figure 2.2. However, there 
were observations that had a missing HBsAg status, 37 in the early arm, 22 in late arm and 33 in 




the modeling parameters. Essentially, a subject is deleted in the modeling sample if they have a 
missing record for any of the variables included in the model.  
The martingale and deviance residual distribution of the sex variable is same between females 
and males (Figure 3.2 (c & d)). Additionally, there were more male observations used in the model 
sample compared to females when comparing distribution of this variable as reported in Table 
3.1, for reasons mentioned above.  
The martingale residual distribution of age variable reveals that age is linearly related to the 
hazard of developing hepatotoxicity for ages less than 40 years old, from 40 to 50 years old the 
model underestimates occurrence of the hepatotoxicity event and beyond 50 years old the model 
overestimates the occurrence of the hepatotoxicity event (Figure 3.2 (e)). The deviance residual 
for age displays the same pattern as discussed above, however, the deviation of the smooth line 
is slightly more pronounced beyond 40 years old (Figure 3.2 (f)). 
The distribution of the martingale and deviance residuals is the same across the risk levels of the 
alcohol consumed and the CD4 count category (Figure 3.2 (g, h, i, & j)). Note that, unlike the other 
categorical variables, observations in each risk level of alcohol consumed and CD4 count 
category are not distorted by those observations that were discarded in the model estimation as 
a result of missing HBsAG status.  
The smooth line superimposed on the martingale and deviance residuals for BILI is roughly a 
straight line (Figure 3.2 (k & l)). This implies that BILI is linearly related to log hazard of 
hepatotoxicity. The number of observations used in the estimation of parameters per risk level of 
HBsAg, is different depending on the width size of the box whisker plot of HBsAg status (Figure 
3.2 (m & n)). However, the distribution of the martingale and deviance residuals is the same 
across the risk levels based on the mean.  Lastly, it can be seen that the model poorly fits the 
categories of the baseline LFT variable, and there is a large number of outliers, especially for the 

















































3.11 Proportional hazard assumption test 
In this section, the two methods to assess the validity of the proportional hazard assumption are 
used; namely time dependent covariates and the log-log survival curves method. 
3.11.1. Applying the time dependent covariates method 
Here the PH assumption is investigated by including interaction terms between the covariates 
and a function of time (𝑙𝑜𝑔 (𝑡)), to assess whether this function of time is making a significant 
contribution. The Cox model that includes time dependent covariate is as below:  
𝜆( 𝑡, 𝑿(𝑡) ) = 𝜆0(𝑡) exp(𝛽𝐴𝑟𝑚1 × 𝐴𝑟𝑚1 +  𝛽𝐴𝑟𝑚2 × 𝐴𝑟𝑚2 +   𝛽𝑆𝑒𝑥 × 𝑆𝑒𝑥
+ 𝛽𝐴𝑔𝑒 × 𝐴𝑔𝑒 + 𝛽𝐴𝑙𝑐 × 𝐴𝑙𝑐 + 𝛽𝐶𝐷4𝑐𝑎𝑡 × 𝐶𝐷4𝑐𝑎𝑡 
+ 𝛽𝐻𝐵𝑠𝐴𝑔𝑃𝑜𝑠 × 𝐻𝐵𝑠𝐴𝑔𝑃𝑜𝑠  +  𝛽𝐵𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛 × 𝐵𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛 
+ 𝛽𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐿𝐹𝑇𝐴𝑏𝑛 × 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐿𝐹𝑇𝐴𝑏𝑛 +  𝜑𝐴𝑟𝑚1 × 𝐴𝑟𝑚1 ×  𝑙𝑜𝑔 (𝑡)
+  𝜑𝐴𝑟𝑚2 × 𝐴𝑟𝑚2 ×  𝑙𝑜𝑔 (𝑡) + 𝜑𝑆𝑒𝑥 × 𝑆𝑒𝑥 ×  𝑙𝑜𝑔 (𝑡)
+ 𝜑𝐴𝑔𝑒 × 𝐴𝑔𝑒 ×  𝑙𝑜𝑔 (𝑡) +  𝜑𝐴𝑙𝑐 × 𝐴𝑙𝑐 ×  𝑙𝑜𝑔 (𝑡)
+ 𝜑𝐶𝐷4𝑐𝑎𝑡 × 𝐶𝐷4𝑐𝑎𝑡 ×  𝑙𝑜𝑔 (𝑡) +  𝜑𝐵𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛 × 𝐵𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛 ×  𝑙𝑜𝑔 (𝑡)
+ 𝜑𝐻𝐵𝑠𝐴𝑔𝑃𝑜𝑠 × 𝐻𝐵𝑠𝐴𝑔𝑃𝑜𝑠 ×  𝑙𝑜𝑔 (𝑡)   
+ 𝜑𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐿𝐹𝑇𝐴𝑏𝑛 × 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐿𝐹𝑇𝐴𝑏𝑛 ×  𝑙𝑜𝑔 (𝑡)). 
 
(3.21)   
In Table 3.9, the results for the estimated extended Cox model (3.21) are presented. The time 
dependent binary indicator based on Late arm (×  𝑙𝑜𝑔 (𝑡)) vs. Sequential arm (×  𝑙𝑜𝑔 (𝑡)) 
(Reference), and time dependent binary indicator based Alcohol = Consumer (×  𝑙𝑜𝑔 (𝑡)) vs. 
Alcohol = Non-consumer (×  𝑙𝑜𝑔 (𝑡)) (Reference), are significant with p-values of 0.0139 and 
0.0341, respectively. This indicates that the proportional hazard assumption might be violated by 









Table 3.9: Estimated Time dependent Cox model 











Early arm vs. Sequential arm 
(Reference) 
0.218 0.342 0.408 1.244 0.5232 
Late arm vs. Sequential arm 
(Reference) 
0.750 0.312 5.793 2.117 0.0161 
Age (years) 0.007 0.015 0.228 1.007 0.6331 
Sex = Male vs. Sex = Female 
(Reference) 
-0.148 0.306 0.233 0.862 0.6294 
Alcohol = Consumer vs. Non-
consumer (Reference) 
0.969 0.316 9.440 2.635 0.0021 
CD4Cat  ≥ 0.05 × 109 vs. CD4Cat <
0.05 × 109  (Reference) 
0.542 0.394 1.892 1.719 0.1690 
Bilirubin -0.111 0.044 6.362 0.895 0.0117 
HBsAgPos vs. HBsAgNeg 
(Reference) 
0.770 0.376 4.204 2.160 0.0403 
Baseline LFT= Abnormal vs. Normal 
(Reference) 
-0.460 0.423 1.183 0.631 0.2767 
Early arm (×  𝑙𝑜𝑔 (𝑡)) vs. Sequential 
arm (×  𝑙𝑜𝑔 (𝑡))   (Reference) 
-0.166 0.171 0.945 0.847 0.3309 
Late arm (×  𝑙𝑜𝑔 (𝑡)) vs. Sequential 
arm (× 𝑙𝑜𝑔 (𝑡)) (Reference) 
-0.402 0.164 6.047 0.669 0.0139 
Age (×  𝑙𝑜𝑔 (𝑡)) 0.149 0.155 0.927 1.161 0.3356 
Sex = Male (×  𝑙𝑜𝑔 (𝑡))  vs. Sex = 
Female (×  𝑙𝑜𝑔 (𝑡))  (Reference) 
0.011 0.008 2.018 1.011 0.1554 
Alcohol = Consumer (×  𝑙𝑜𝑔 (𝑡))   vs. 
Non-consumer (Reference) (×
 𝑙𝑜𝑔 (𝑡))  (Reference) 
-0.322 0.152 4.490 0.725 0.0341 
CD4Cat  ≥ 0.05 × 109 (×  𝑙𝑜𝑔 (𝑡))  vs. 
CD4Cat < 0.05 × 109 (×  𝑙𝑜𝑔 (𝑡))   
(Reference) 
-0.137 0.214 0.411 0.872 0.5217 
Bilirubin (×  𝑙𝑜𝑔 (𝑡)) 𝜗 0.032 0.020 2.467 1.033 0.1163 
HBsAgPos (×  𝑙𝑜𝑔 (𝑡))  vs. 
HBsAgNeg (×  𝑙𝑜𝑔 (𝑡))  (Reference) 
-0.044 0.186 0.056 0.957 0.8135 
Baseline LFT= Abnormal (×  𝑙𝑜𝑔 (𝑡))   
vs. Normal (×  𝑙𝑜𝑔 (𝑡)) (Reference)  
0.164 0.213 0.594 1.178 0.4410 
3.11.2. Graphical approach assessment of the PH assumption 
Recall that this method plots −𝑙𝑛(− 𝑙𝑛 ?̂?(𝑡)) for each category of a covariates against observed 
survival time 𝑡, if the curves intersect and or the curves show a lack of parallelism, then that implies 
that the covariate under investigation violates that proportional hazard assumption. The plots of 




























The negative log-log survival curves for each risk level of age, sex, alcohol and HBsAG status 
show reasonable level of parallelism (Figure 3.3 (b, c, d & g). In contrast, the negative log-log 
survival curves for each risk level of treatment arm, CD4 count category, BILI (risk levels based 
on a median of 7) and baseline LFT all show little parallelism (Figure 3.3 (a, e, f & h). The 
proportionality hazard assessment based on negative log-log survival curves for treatment arm, 
is agreeing with the results obtained in time dependent covariate approach. This suggests that 
the treatment arm is violating the proportional hazard assumption. Therefore, the treatment arm 
variable should be modelled as time dependent variable in the model going forward.  
There is conflicting evidence from the two approaches for alcohol, CD4 count category, BILI and 
Baseline LFT, therefore, there is not enough evidence to suggest that these covariates are 
violating the proportional hazards assumption.  
The graphical approach of assessing the proportional hazard assumption is quite subjective, 
because there is no specification of how parallel the curves should be to justify a violation of the 
proportional hazard assumption. 
3.12 The Cox model with non-proportional hazards 
3.12.1. Choosing the appropriate function of time 
Including the treatment arm variable as time dependent variable, requires the choice of a function 
of time. It can be seen from the negative log-log survival curves, that before 5 months, the late 
arm has the poorest survival rates compared to the other treatment arms. Beyond 5 months the 
survival rate in the late arm improves and then eventually matches the survival level of the other 
treatment arm.  
3.12.2. Defining the heavyside function  
Recall that the heavyside functions is a function that defines intervals so that the constant hazards 
can be estimated within each interval. A two sided heavyside functions will allow for estimation of 
different hazard in each interval defined by the heavyside function for the treatment arm variable. 
The heavyside function in equation (3.22) that will be used is as follows: 
                           𝑔1(𝑡) = {
 1     if 𝑡 ≤ 5 
0     if 𝑡 > 5






                                 𝑔2(𝑡) = {
1     if 𝑡 > 5
0     if 𝑡 ≤ 5
   
 
(3.23) 
where the 5th month is the chosen cut-off point to define two intervals in the study. Conceptually 
when the observed survival time is 5 months, or less (𝑡 ≤ 5), the heavyside function takes 
𝑔1(𝑡) = 1 and 𝑔2(𝑡) = 0. And when the observed survival time is greater than 5 months (𝑡 > 5), 
the heavyside function takes 𝑔1(𝑡) = 0 and 𝑔2(𝑡) = 1.   A different hazard will be estimable for 
the treatment arm in each interval 𝑡 ≤ 5 and when 𝑡 > 5.  
The choice of 5 months will facilitate the comparison of the hazard by treatment arm during the 
intensive phase of TB treatment through the function 𝑔1(𝑡). Moreover, the second function 𝑔2(𝑡) 
will facilitate comparison of the hazards during the continuation phase of the TB treatment and 
after completion of the TB treatment.   
3.12.3. Fitting the Cox model with non-proportional hazards 
A Cox model with non-proportional hazards, of the treatment arm variable, can be built by 
including interactions with the specified function of time. Therefore, the indicator variable 𝐴𝑟𝑚1 in 
equation expands to 𝐴𝑟𝑚1 × 𝑔1(𝑡)  or  𝐴𝑟𝑚1 × 𝑔2(𝑡) . Moreover, the indicator variable 𝐴𝑟𝑚2  
expands to 𝐴𝑟𝑚2 × 𝑔1(𝑡)  or 𝐴𝑟𝑚2 × 𝑔2(𝑡)  in the Cox regression model that was specified in 
equation (3.20). The Cox regression model with a time dependent effects takes the form: 
𝜆( 𝑡, 𝑿(𝑡) ) = 𝜆0(𝑡) exp(𝜑𝐴𝑟𝑚11 × 𝐴𝑟𝑚1 × 𝑔1(𝑡) +  𝜑𝐴𝑟𝑚12 × 𝐴𝑟𝑚1 × 𝑔2(𝑡)    
+ 𝜑𝐴𝑟𝑚21 × 𝐴𝑟𝑚2 × 𝑔1(𝑡) +   𝜑𝐴𝑟𝑚22 × 𝐴𝑟𝑚2 × 𝑔2(𝑡)
+   𝛽𝑆𝑒𝑥 × 𝑆𝑒𝑥 + 𝛽𝐴𝑔𝑒 × 𝐴𝑔𝑒 + 𝛽𝐴𝑙𝑐 × 𝐴𝑙𝑐 + 𝛽𝐶𝐷4𝑐𝑎𝑡 × 𝐶𝐷4𝑐𝑎𝑡 
+ 𝛽𝐶𝐷8 × 𝐶𝐷8 + 𝛽𝐻𝐵𝑠𝐴𝑔𝑀𝑖𝑠 × 𝐻𝐵𝑠𝐴𝑔𝑀𝑖𝑠  + 𝛽𝐵𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛 × 𝐵𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛 
+ 𝛽𝐻𝐵𝑠𝐴𝑔𝑃𝑜𝑠 × 𝐻𝐵𝑠𝐴𝑔𝑃𝑜𝑠  + 𝛽𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐿𝐹𝑇𝐴𝑏𝑛 × 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐿𝐹𝑇𝐴𝑏𝑛). 
(3.24) 
 







Table 3.10: Multivariable Cox PH and Cox model with non-proportional hazards  




p – value Hazard Ratio 
 (95% CI) 
p – value 
Early arm vs. Sequential arm 
(Reference) 




 (0.515; 1.839) 
0.9335 
Early arm vs. Sequential arm 
(Reference) 
(months > 5) 
0.933   
(0.534; 1.629) 
0.8074 
Late arm vs. Sequential arm 
(Reference) 
(0 ≤ months ≤ 5) 1.182 
(0.787; 1.775) 
0.4214 
1.648   
(0.923; 2.940) 
0.0912 
Late arm vs. Sequential arm 
(Reference) 
(months > 5) 







1.025   
(1.005; 1.045) 
0.0139 





1.061   
(0.724; 1.554) 
0.7618 





1.702   
(1.039; 2.789) 
0.0346 
CD4Cat  ≥ 0.05 × 109 vs. CD4Cat <











0.944   
(0.907; 0.983) 
0.0050 





2.097   
(1.262; 3.483) 
0.0042 









3.12.4. Model fit statistics  
Table 3.11 shows the model fit statistics, the Akaike Information Criterion (AIC) statistic is reduced 
in the Cox model with non-proportional hazards compared to the Cox PH model. This indicates 
that the Cox model with non-proportional hazards fits the data better when the treatment arm is 







Table 3.11: Model Fit Statistics  
Criterion Cox PH 
model 
Cox model with non-
proportional hazards 
AIC 1575.451 1572.245 
 
3.12.5. Interpreting the model Cox model with non-proportional hazards 
Within the first 5 months, patients in the early arm have 2.7% decreased hazard of developing 
hepatotoxicity, then patients in the sequential arm, the hazards ratio is (HR=0.973, 95%CI (0.515, 
1.839)), and this ratio is very close to unity and thus not statistically significant (p-value = 0.9335). 
However, within the same period, the adjusted hazard of developing hepatotoxicity is 1.6 times 
more for patients in late arm compared to patients in the sequential arm (HR=1.648, 95% CI 
(0.923, 2.940)) and a p-value of 0.0912. 
After 5 months, the hazard of developing hepatotoxicity is lower in both the early and late arm 
compared to the sequential arm. During this period patients in the early arm have a 6.7% 
decreased hazard of developing hepatotoxicity (HR=0.933, 95% CI (0.534, 1.629)) compared to 
patients in the sequential arm, however this not statistically significant. Also in the late arm, the 
hazard of developing hepatotoxicity is reduced by 13.9% compared to the hazard of developing 
hepatotoxicity in patients from the sequential arm (HR=0.861, 95% CI (0.494, 1.502)), this is not 
statistically significant (p-value = 0.5986).  
A year increase in the subjects age at baseline increases the hazard of developing hepatotoxicity 
by 2.5% (HR=1.025, 95% CI (1.005, 1.045)), statistically significant (p-value = 0.0139). The 
assessment of sex and CD4 count did not give compelling evidence that suggests that these 
variables affect the hazard of developing hepatotoxicity. 
Subjects who consumed alcohol are 1.7 times more likely to develop hepatotoxicity compared to 
subjects who never consume alcohol (HR=1.702, 95% CI (1.039, 2.789)) this is statistically 




An unit increase in the total bilirubin decreased the hazard of developing hepatotoxicity 5.6%, the 
95% confidence interval for the hazard ratio does not include unity (HR = 0.944, 95% CI (0.907, 
0.983)), and the confidence interval is narrow, this implies that the hazard ratio is statistically 
significant and precise. The hazard of developing hepatotoxicity for patients with a positive HBsAg 
was 2-fold the hazard of developing hepatotoxicity for patients with a negative HBsAg (HR=2.097, 
95% CI (1.262, 3.483)) this is statistically significant (p-value = 0.0042).  
The assessment of baseline LFT did not give statistical evidence that suggests that this variable 
affects the hazard of developing hepatotoxicity. 
3.13 Conclusion 
Upon fitting the Cox model based on the backward elimation procedure, the final model consisted 
of treatment arm, age, sex, alcohol consumed, CD4 count, BILI, HBsAg status and baseline LFT. 
Model adequacy evaluations were within expectactions, except for the baseline LFT variable, 
which had too many outliers under martingale and deviance residuals assesments. However, no 
modification was made to the model post model adequacy assessment. 
The outcome from assessing the validity of PH assumption indicated that the treatment arm 
variable violates the PH assumption. Some authors do not stress the importance of PH 
assumption, as they describe the resulting estimate as being the ‘average’ effect on the hazard 
(Allison, et al., 2010). However, in this project, since the main objective is to describe the 
relationship of treatment arm and the occurrence of hepatotoxicity, the intention was to estimate 
the most granular effect of treatment arm that the model could estimate. 
The treatment arm variable was then modified in the Cox model for non-proportional hazards. 
There is a choice of fitting a stratified Cox model to address the violated PH assumption, however, 
the shortfall of fitting a stratified Cox model is that effect of the treatment arm variable cannot be 
quantifed. Therefore, the effects of treatment arm were modeled as time varying, through the 
operation of a heavyside function that divides the observed time into two intervals, at a 5-month 
cut-off. 
The choice of the heavyside function was motivated by the pattern observed in the Kaplan-Meier 
(Figure 2.3) and the Cumulative incidence function (Figure 2.4). This highlight’s the importance 
of plotting the Kaplan-Meier and cumulative incidence function, as it has enhanced the resulting 




an AIC =1568.759, this is lower than the AIC of 1572.245 that was observed in the Cox model 
that modeled the effect of the treatment arm as fixed over time (Table 3.11). 
After considering the model modifications, the late arm appeared as the group with the highest 
risk of hepatotoxicity. In the first 5 months, patients in the late arm were 2 times more likely to 
develop hepatotoxicity, this statistic was marginally significant with p-value =0.0912. The 95% CI 
of this estimate is quite wide (0.923, 2.940), thus this statistic might be slightly imprecise. The risk 
of hepatotoxicity was similar between the treatment arms after 5 months of study randomization. 
Despite this, it is important to note that, the hazard ratios for treatment arm estimated for the 
period beyond 5 months, will not be comparable to hazard ratios estimated under a randomized 
cohort. Since after 5 months, high risk patients would have already experienced hepatotoxicity.   
Furthermore, age, alcohol, total bilirubin and HBsAg status remained strong predictors of the 
occurrence of first hepatotoxicity, under the univariate and multivariable analysis. The outcome 
of these variables is consistent with what has been observed in literature (Hoffmann, et al., 2007)). 
Sex, CD4 count category and baseline LFT variable were not statistically predictive in the model, 
contrary to what has been observed in the literature (Shu, et al., 2013).  
Through the Cox regression model risk factors associated with the first occurrence of 
hepatotoxicity have been identified. However, the Cox regression model as introduced in this 
chapter has failed to simultaneously identify factors associated with resolving hepatotoxicity, and 





Chapter 4  
 
Alternative models for recurrent 
hepatotoxicity events 
4.1 Introduction  
The Cox model introduced in Chapter 3, considers timing of the first hepatotoxicity event and 
determines the effect of the treatment arm and other associated risk factors on this timing. 
However, it is apparent in the data, that some patients experienced a recurrent episode of 
hepatotoxicity (Figure 2.2). The application of the Cox model thus far used information up to 
the first hepatotoxicity event, and discarded information that occurred at subsequent events.  
Recall that the purpose of the SAPiT trial was to effectively integrate TB treatment and ART, 
in patients co-infected with TB and HIV. The primary objective of integrating TB treatment and 
ART in the SAPiT trial, was to determine a treatment arm that reduces the rates of mortality 
(Abdool Karim, et al., 2010). The secondary objective of this trial was to evaluate the patient’s 
quality of life, more generally, by examining per treatment arm, how prone the patient is to 
opportunistic infections – like hepatotoxicity. If a patient experiences more than a single 
hepatotoxicity event, it is sensible therefore, to evaluate not only risk factors associated with 
the first event, but also risk factors associated with subsequent events to better understand 
the patient’s quality of life over time.  
The Cox PH Model has been generalized to analyze recurring events – by modifying four 
features of the Cox PH model (Ullah, et al., 2012): 
• The definition of a risk interval along the study period and as consequence whether a 
model is marginal or conditional. 
• The definition of a risk set at a certain point in time. 
• Whether the model will have an event specific or a common baseline hazard. 
• Incorporation of within subject correlation. 
In light of the above-mentioned features of recurrent events models, five models will be 




the Prentice-Williams-Petersen total time (PWP-TT) model, the Prentice-Williams-Petersen 
gap time (PWP-GP) model, and the transition and reverse transition models (recurrent and 
resolution models) as specified by Islam (1994). I will give a brief introduction of each model 
and the dynamics of each model in explaining the recurrent events.  
4.2 Islam’s multi-state models 
4.2.1. Description of the model 
The experience of a patient in a survival study may be modelled as a process with two states 
and one possible transition from an “alive” state to a “dead” state, this model is also called a 
two-state mortality model (Meira-Machado, et al., 2009). Multi-state survival models evolved 
from the two-state mortality model, where the intensity (hazard) function 𝜆(𝑡) is modeled by a 
Cox PH model introduced by Cox in 1972. Then shortly after Cox, Prentice et al. (1978), 
extended the theory of the Cox PH model to the analysis of failure times with competing 
causes of failure. They proved that the cause-specific hazard functions are estimable in the 
competing risk framework under a multi-state process. 
Kay (1982) extended the competing causes of failure model as formulated by Prentice et al. 
(1978), to a more general multi-state stochastic process allowing several transient states 
between entry and death. That is, if there is more than one transient state, subjects are open 
to transition from one state to another during a study follow up. Kay’s model was hierarchical 
in nature and the partial likelihood is identical to the partial likelihood presented by Cox in 
1972, except for the definitions of the risk sets (Islam, 1994). 
Islam (1994) developed a model framework, by extending Kay’s model for reverse and 
repeated transitions. Islam’s extension is suitable for the study of multi-state hepatotoxicity 
transitions as they occur in the SAPiT trial. Given that there is quite a significant rate of reverse 
and repeated transitions in the trial, Islam’s framework makes it convenient to explain the 
dynamics of the hepatotoxic event in the data in more dimensions. 
4.2.2. Model assumptions 
Figure 4.1 below is a graphical illustration of the hepatotoxicity states and transitions that are 
possible in the data, where H1 → H2 represents a transition (transition from a non-
hepatotoxicity state to a hepatotoxicity state); H2 → H1 represents a reverse transition 
(transition from a hepatotoxicity state to a resolved hepatotoxicity state); H1 → H2 represents 
a repeated transition, on condition that H1 → H2 has occurred at least once (transition from a 




indicate a transition from a hepatotoxicity state or resolved hepatotoxicity state to a censored 
state, which is a state reached if a patient dies or is lost to follow up during the study period. 
 
 
Figure 4.1:Transition dynamics of hepatotoxicity episodes 
Therefore, three models will be considered as defined below: 
• Model 1 – refers to the incidence of H1 → H2 this is identical to the Cox PH model 
discussed in Chapter 4. 
• Model 2 - refers to the incidence of H2 → H1, which will be called the resolution model 
hereafter. 
• Model 3 - refers to the repeat of H1 → H2 on condition that H1 → H2 has occurred, and 
this will be called the recurrent model hereafter.  
4.2.3. Risk interval and risk set  
In Table 4.1 the format of the data that will used to build the models in this section is presented. 
The following fields are included in Table 4.1; 
• participant id is a unique identifier for each subject, 
• tstart is the time at which the observation of the subject starts,  
• tstop is the time at which the subject developed hepatotoxicity.  
• Event is the event indicator 1 if the subject developed hepatotoxicity and 0 otherwise. 
• Resolved is 1 if a patient has resolved hepatotoxicity and 0 otherwise.  
• And the last column is called ‘ model number’ indicates the model number in which the 
specific observation will be used in. 
It is important to note that I will discard information where the patient has resolved their second 
hepatotoxicity event as there were too few of these observations. This is illustrated by a record 
H1 H2 H1 H2 




from participant_id = 121002 in Table 4.1 where the model number for this record is indicated 
by N/A, indicating that this record will not considered in any of the models. 
Table 4.1: Islam’s model framework data structure 
Participant 
ID 
Tstart Tstop Time Event  Resolved Arm Model 
number 
121002 01/Jan/2007 31/Mar/2007 3 1 . Late Arm 1 
121002 31/Mar/2007 10/Jun/2007 2 0 1 Late Arm 2 
121002 10/Jun/2007 30/Sep/2007 4 1 0 Late Arm 3 
121002 30/Sep/2007 18/Nov/2007 2 0 1 Late Arm N/A 
121002 18/Nov/2007 01/Jan/2008 1 0 0 Late Arm 3 
121139 01/Jan/2007 30/Sep/2007 9 1 . Late Arm 1 
121139 30/Sep/2007 01/Nov/2007 1 0 1 Late Arm 2 
121139 01/Nov/2007 01/Mar/2008 4 0 0 Late Arm 3 
121170 01/Jan/2007 31/Jan/2007 1 1 . Sequential Arm  1 
121170 31/Jan/2007 17/Jun/2007 4 0 1 Sequential Arm  2 
121170 17/Jun/2007 01/Apr/2008 9 0 0 Sequential Arm  3 
121178 01/Jan/2007 31/Jan/2008 13 1 . Late Arm 1 
121178 17/Jun/2007 07/Jun/2008 12 0 1 Late Arm 2 
121178 07/Jun/2008 30/Sep/2008 4 0 0 Late Arm 3 
121179 01/Jan/2007 01/Jan/2009 24 1 . Early Arm 1 
121179 01/Jan/2009 12/Feb/2009 1 0 1 Early Arm 2 
121179 12/Feb/2009 01/Apr/2009 2 0 0 Early Arm 3 
 
4.2.4. Model form  
Notation used here will be as employed by (Islam, 1994). Let 𝑓 (𝑓 = 1, 2. . ) be the state of 
origin and 𝑔 (𝑔 = 1, 2. . . ) the state of destination. The general hazard function model is written 
as: 
 
𝜆𝑓𝑔𝑖 =  𝜆0𝑓𝑔(𝑡) exp(𝜷𝑓𝑔




• 𝜆𝑓𝑔𝑖 is the hazard function for moving from state 𝑓 to state 𝑔, 
• 𝜆0𝑓𝑔(𝑡) denotes the baseline hazard function specific for sequential move from state 
𝑓 to state 𝑔, 
• 𝒙𝑓𝑔𝑖  represents covariates for 𝑖
𝑡ℎ subject in respect of moving from state 𝑓 to state 𝑔, 
• 𝜷𝑓𝑔 represents the corresponding regression coefficients.  
4.2.5. Likelihood function 














where 𝑅(𝑡𝑓𝑔𝑠, 𝑓) denotes the risk set of patients who are in state 𝑓,  thus are at risk of making 
a transition to state 𝑔. 
4.3 Andersen Gill model 
4.3.1. Description of the model 
 
Andersen & Gill (1982) proposed the Andersen-Gill (AG) counting process model, which 
models timing of recurrent events. This model, extends the Cox PH model by using more 
information about the subject. This is, subjects not only contribute the survival time of the first 
event into the model, but also survival times related to subsequent events.  
This model simplifies the approach of examining the overall treatment effect, when events are 
likely to occur recurrently. There is also minimal effort of transitioning from a commonly applied 
Cox PH model to the AG model. Moreover, this model is a building block to more sophisticated 
recurring events model - to be discussed in proceeding sections. It thus, plays a role in 
explaining the intermediate step that is found between applying the Cox PH to applying a more 
sophisticated recurrent events model.  
4.3.2. Model assumptions 
The AG model assumes that the multiple event times from the same subject are independent. 
Suppose that a subject develops their first event, this model assumes that, this does not 
change the subject’s likelihood of experiencing successive events. Hence, a common baseline 
hazard function for each possible event is assumed and a global parameter is estimated for 
the factor of interest (Amorim & Cai, 2014). 
If there is correlation between events from the same subject, and it is ignored or unknown, 
then the confidence intervals for the estimated rates could be artificially narrow, and the null 
hypothesis is rejected more often than it should (Amorim & Cai, 2014). This issue could be 
averted in one of two ways, first by assuming that the correlation between events is measured 
by a covariate, thus the dependence is captured by specifying a time-varying covariate, such 
as the number of previous events, or some function of previous events (Sagara, et al., 2014). 
Secondly, Lin & Wei (1989) proposed a sandwich robust standard error: this is a variance-




inflation of Type I error, due to multiple observation per subject which do not require 
specification of a correlation matrix (Sagara, et al., 2014). 
4.3.3. Risk interval and risk set  
An example in Table 4.2 to illustrate the data structure, by specifically defining  the risk interval 
and risk set construct of the AG model. 
Table 4.2: AG model data structure 
Participant ID Tstart Tstop Event Arm 
121002 01/Jan/2007 31/Mar/2007 1 Late Arm 
121002 10/Jun/2007 30/Sep/2007 1 Late Arm 
121002 18/Nov/2007 01/Jan/2008 0 Late Arm 
121139 01/Jan/2007 30/Sep/2007 1 Late Arm 
121139 01/Nov/2007 01/Mar/2008 0 Late Arm 
121170 01/Jan/2007 31/Jan/2007 1 Sequential Arm  
121170 17/Jun/2007 01/Apr/2008 0 Sequential Arm  
121178 01/Jan/2007 31/Jan/2008 1 Late Arm 
121178 07/Jun/2008 30/Sep/2008 0 Late Arm 
121179 23/Nov/2008 01/Jan/2009 1 Early Arm 
121179 12/Feb/2009 01/Apr/2009 0 Early Arm 
The risk set of a Cox PH model comprises of the observations that are in bold, whereas the 
risk set of the AG model comprises of all the observations that have been recorded in the 
longitudinal data for each subject – i.e. every record in Table 4.2.   
The survival time (risk interval) variable is discontinuous in nature (Gisolf, et al., 2000). This 
means that the time in which the subject sustains hepatotoxicity is excluded, since the subject 
is not at risk of hepatotoxicity at that point. For example, in Table 4.2 subject 121139 
developed the first hepatotoxicity event on the 30th of September 2007, and this hepatotoxicity 
episode was not resolved until 1st of November 2007. The time between 30th of September 
2007 and 1st of November 2007 is not included in the analysis, since the subject already has 
hepatotoxicity in this time and therefore not at a risk of developing hepatotoxicity.  
The notation that is used to describe the models from now onwards is as adopted by Sagara, 
et al., (2014). 
4.3.4. Model form  
 




 𝜆𝑖𝑘 = 𝑌𝑖𝑘𝜆0(𝑡)exp(𝜷
′𝒙𝑖𝑘). (4.3) 
Here: 
• 𝜆𝑖𝑘 represents the hazard of the 𝑘
𝑡ℎ event for the 𝑖𝑡ℎ subject. 
• 𝜆0(𝑡) represents the common baseline hazard function over time. 
• 𝒙𝑖𝑘 is the vector of explanatory variables for subject 𝑖 relevant to the 𝑘
𝑡ℎ event. 
• 𝜷 represents a vector of global regression coefficients.  
• 𝑌𝑖𝑘 represents a predictable process taking value [0,1] indicating when a subject is 
under observation. 
The model in equation (4.3) is identical to a standard Cox PH model in equation (3.2). The 
difference lies in the definition of 𝑌𝑖𝑘. In the Cox PH model, once the individual experiences 
an event, 𝑌𝑖𝑘 goes from one to zero. Whereas for the AG model 𝑌𝑖𝑘 remains one as the events 
occur (Therneau & Grambsch, 2000).  
4.3.5. Likelihood function 
 
To estimate the regression coefficients let 𝑡1, … , 𝑡𝑛 be 𝑛 ordered possible survival times, 
corresponding to vectors of explanatory variables 𝒙1, … , 𝒙𝑛. The partial likelihood to estimate 
the regression coefficients is as below: 
 










where 𝑌𝑖𝑘 takes on 1 if the subject is at risk of event  𝑘 and 0 otherwise (Therneau & Grambsch, 
2000) and 𝛿𝑖𝑘 represents the censoring variable for the 𝑘
𝑡ℎ event and subject 𝑖 (Amorim & 
Cai, 2015). 




4.4 Shared frailty model 
4.4.1. Model background 
 
Although the AG model claims that survival times are independent, it does happen however, 
that subjects present survival times that are not independent. This typically occurs when the 
subjects in the study share some common risk. For instance, suppose the study is conducted 
in multiple clinics, and so subjects that attend the same clinic may have different survival times, 
compared to subjects that attend a different clinic. This may be due to different clinical practice 
standards that are followed by treating physicians per clinic (Collet, 2003).  
Let’s suppose a trial is conducted across 20 different clinics. To adjust for this clinic variable 
in the model, a design variable containing 19 factors is included in the model, clearly, analyzing 
this model might a bit cumbersome. Consequently, a random effect component that is realized 
by a probability distribution function that has a zero mean, and a variance equal to 𝜃 is included 
in a survival model (Ullah, et al., 2012). This then reduces the number of estimated coefficients 
related to the clinic variable from 19 to a single parameter 𝜃. More generally, when there are 
numerous clinical sites that need to be considered in the survival analysis, including a random 
effect in a Cox PH model is a more efficient way of modeling timing of the event than 
considering modeling for each level of the clinical site in Cox PH model.  
Under the current study of recurring events, some subjects present more than a single survival 
time in the study, and thus the survival times within a subject may not be independent. It 
follows then from the clinic analogy, that a subject-specific random effect can be included in 
the model, to explain the dependent survival times that arise in within the same subject. More 
generally, a random effect is included in the AG model – to reflect a suitable model for recurring 
events.  
4.4.2. Description of the model 
The random effect is a continuous variable that describes excess risk for distinct categories 
such as individuals, clinic sites or innate groups like families – the term ‘excess risk’ is known 
as frailty in the survival analysis context (Collet, 2003).  
The interpretation of this model is that individuals have different frailties, and that those that 
are more frail experience the event earlier than others (Therneau & Grambsch, 2000). 
Accordingly, the frail term captures unobserved heterogeneity/covariates that is not captured 
by the observed covariates (Therneau & Grambsch, 2000). If individuals in a group share the 




(1995). In the context of recurrent event models, given that an individual contributes more than 
a single observation in the study, a frailty term/random effect is then modeled for each 
individual to capture within subject heterogeneity. 
4.4.3. Model assumptions 
The shared frailty model assumes that all observations included in the model are independent, 
and the dependence structure is explained by the random effect. It also assumes a common 
baseline hazard function for all 𝑘 events. 
It is important to realize that the AG and shared frailty model share the same assumptions 
except that the dependence structure in the shared frailty model is captured by the random 
effect, this is in addition to using a robust variance estimator that accounts for possible 
correlation in the AG model. Therefore, the difference in the estimated coefficients between 
the AG and shared frailty model depend largely on how significant the random effect is in the 
model (Sagara, et al., 2014).  
The random covariate can have a Gamma, a Gaussian or any other distribution. However, the 
Gamma distribution is widely preferred over other distributions because of its tractability 
(Sagara, et al., 2014).  
4.4.4. Risk interval and risk set  
The data structure used for the shared frailty model is the same as specified for the AG model 
in Table 4.2, since the only additional variable that will considered in the model is the 
participant ID and this is already included in Table 4.2. 
4.4.5. Model form  
 
The model notation employed here is as adopted by Therneau & Grambsch, (2000). Suppose 
that there are 𝑛 total number of subject observations in the study and 𝑞 subjects considered 
in the model, then the proportional hazard function for the subjects’ 𝑖𝑡ℎ observation (𝑖 =




                   = 𝑌𝑖𝑘𝜆0(𝑡)exp (𝜷
′𝒙𝑖𝑘 + 𝒖𝑗
′𝒛𝑗).   
(4.5) 
Here:  
• 𝜆𝑖𝑗𝑘 represents the hazard of event 𝑘 for the subjects’ 𝑖





• 𝜆0(𝑡) the baseline hazard function which is the same for all events in the study.  
• 𝒙𝑖𝑘 represents the vector of explanatory variables for the subjects’ 𝑖
𝑡ℎ observation and 
event 𝑘 
• 𝜷 is a vector of regression coefficients. 
• 𝒖𝑗 is a vector of unknown random effects. 
• 𝒛𝑗 is the design vector that is 1 if the observation belongs to 𝑗
𝑡ℎ subject, and 0 
otherwise.  
• 𝑌𝑖𝑘 represents a predictable process taking value [0,1] indicating when a subject is 
under observation. 
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, where Γ is the Gamma function, and 𝜃 is the tuning parameter. 
4.4.6. Likelihood function 
The partial likelihood function that estimates the regression coefficient 𝜷 is as follows 
 












where 𝑌𝑖𝑘 takes on 1 if the subject is at risk of event 𝑘 and 0 otherwise (Therneau & Grambsch, 
2000) and 𝛿𝑖𝑘 represents the censoring variable for the 𝑘
𝑡ℎ event and subject 𝑖. 
4.5 Prentice, Williams and Peterson (PWP) model 
4.5.1. Description of the model 
 
When choosing a model for the timing to recurrent event, the analyst should consider the 
underlying dynamics of the recurring event within a subject. For instance, if the interest of the 
study is to model timing of recurrent infections, it is possible that after experiencing the first 
infection the risk of the next infection may increase per subject. This could happen if each 
infection permanently compromised the ability of the subjects’ immune system to respond to 
subsequent infections (Therneau & Grambsch, 2000). Therefore, it of interest to evaluate 
whether the recurring events weakens the subjects’ immune system, as result, the subject is 




immunity in response to the recurring events, as a result, will experience fewer events in the 
foreseeable future.  
Prentice, et al., (1981) proposed a conditional model which is widely known as the Prentice, 
Williams  and Peterson (PWP) model, this conditional model analyses ordered recurring 
events by a way of stratification, based on the prior number of events during the study follow-
up (Sagara, et al., 2014). In general, a subject cannot be at risk for the 𝑘𝑡ℎ event, if they haven’t 
terminated the (𝑘 − 1)𝑡ℎ event. This model analyses event specific effects and overall effects 
per covariate (Sagara, et al., 2014).  
4.5.2. Model assumptions 
This model preserves the sequence of event occurrence implying that the event dependence 
is accounted for in the model (Olawumi, et al., 2014). This model considerers the time scale 
of events in one of two ways: 
• Total time (TT) – which is the time since study entry, also known as calendar time. The 
same time scale for all events is referenced to a fixed point in time, but does not allow 
an overlap of the risk periods for a given subject (Ullah, et al., 2012).  
• Gap time (GT) – which is the time since previous event and is not relative to the actual 
time scale (Ullah, et al., 2012). When using gap or waiting time scale the time index is 
reset to zero after each recurrence of event with an assumption of a renewal process. 
Gaps between events are often useful for infrequent events this is when a renewal 
occurs after an event, or when the interest lies in the prediction of the next event 
(Amorim & Cai, 2014). 
Hence, there are two types of PWP models based on the above-mentioned time scales: first 
of which is the PWP TT model, which evaluates the effect of the covariate for time since entry 
into the study. And secondly there is the PWP GT model, which evaluates the effect of 
covariate on the 𝑘𝑡ℎ event since time from the previous event (Amorim & Cai, 2014).  The use 
of a time-dependent strata means that the underlying baseline hazard function varies from 
event-to-event, unlike the AG model that assumes that all events are identical (Therneau & 
Grambsch, 2000).  
Moreover, unlike the AG model the effects of a covariate may vary from event to event in the 
stratified model. Therefore, the PWP model may be preferred over the AG model when the 
effects are different in subsequent events, which is likely to be the case for diseases such as 
viral infections because of immunity, or weakened immune system due to severe disease 




4.5.3. Risk interval and risk set  
The data structure of the PWP models is the same as that of the AG and shared frailty model 
Table 4.2. However, there are two added fields that show the event number – which will be 
used as the stratification variable in the models and a field called ‘time’ which is the value of 
the gap time between successive events (time suggests time is duration to event not gap time 
between events or start of the next interval), this field will be used in the PWP GT model only. 
Table 4.3: PWP model data structure 
Participant ID Tstart Tstop Time Event Arm Event 
number 
121002 01/Jan/2007 31/Mar/2007 3 1 Late Arm 1 
121002 10/Jun/2007 30/Sep/2007 4 1 Late Arm 2 
121002 18/Nov/2007 01/Jan/2008 1 0 Late Arm 3 
121139 01/Jan/2007 30/Sep/2007 9 1 Late Arm 1 
121139 01/Nov/2007 01/Mar/2008 4 0 Late Arm 2 
121170 01/Jan/2007 31/Jan/2007 1 1 Sequential Arm  1 
121170 17/Jun/2007 01/Apr/2008 9 0 Sequential Arm  2 
121178 01/Jan/2007 31/Jan/2008 13 1 Late Arm 1 
121178 07/Jun/2008 30/Sep/2008 4 0 Late Arm 2 
121179 01/Jan/2007 01/Jan/2009 24 1 Early Arm 1 
121179 12/Feb/2009 01/Apr/2009 2 0 Early Arm 2 
 
4.5.4. Model form  
 
The PWP TT hazard function for 𝑖𝑡ℎ subject (𝑖 = 1, … , 𝑛) for event 𝑘 (𝑘 = 1, … , 𝑙𝑖) is written 
as: 
 𝜆𝑖𝑘 = 𝑌𝑖𝑘𝜆0𝑘(𝑡) exp(𝜷𝑘
′ 𝒙𝑖𝑘). (4.7) 
The PWP GT hazard function for 𝑖𝑡ℎ subject (𝑖 = 1, … , 𝑛) for event 𝑘 (𝑘 = 1, … , 𝑙𝑖) is written 
as: 
 𝜆𝑖𝑘 = 𝑌𝑖𝑘𝜆0𝑘(𝑡𝑘 − 𝑡𝑘−1) exp(𝜷𝑘
′ 𝒙𝑖𝑘).    (4.8) 
Here: 
• 𝜆𝑖𝑘 represents the hazard of the 𝑘
𝑡ℎ event for the 𝑖𝑡ℎ subject. 
• 𝜆0𝑘(𝑡) represents the event specific baseline hazard function of event 𝑘 
• 𝒙𝑖𝑘 is the vector of explanatory variables for subject 𝑖. 




• 𝑡𝑘 − 𝑡𝑘−1 represents survival times for the PWP GT model, this is the difference 
between the time when the 𝑘𝑡ℎ event occurred (𝑡𝑘), and the time when the event 
before the 𝑘𝑡ℎ event occurred (𝑡𝑘−1). 
•  𝑌𝑖𝑘 represents a predictable process taking value [0,1] indicating when a subject is 
under observation 
4.5.5. Likelihood function 
The regression coefficients are estimable with a partial likelihood function that is specified by 
(Labarga, et al., 2007). Let 𝑡𝑘𝑖 < ⋯ <  𝑡𝑘𝑑𝑘 denotes the ordered distinct survival times in 
stratum 𝑘, where 𝑑𝑘 is the number of distinct events in stratum 𝑘. Suppose subject 𝑖 
experiences an event in stratum 𝑘 at time 𝑡𝑘𝑖 and let 𝒙𝑘𝑖(𝑡𝑘𝑖) denote this subject’s covariate 
vector at 𝑡𝑘𝑖. Let  𝑁(𝑡) = {𝑛(𝑢): 𝑢 ≤ 𝑡}, where 𝑛(𝑢), is the number of events of a subject in 
study prior to time 𝑢. 
The partial likelihood to estimate 𝜷𝑘 in the PWP TT is: 
 












Here 𝑅(𝑡, 𝑘) denotes the set of subjects in stratum 𝑘 just prior to time 𝑡. The partial likelihood 
is valid for the PWP TT model provided that the stratification is restricted to be 𝑘 = 𝑛(𝑡) + 1 
so that a subject can contribute at most a single survival time in a specific stratum (Labarga 
et al., 2007). 
Furthermore, let 𝑢𝑘𝑖 < ⋯ <  𝑢𝑘𝑑𝑘, denote the distinct gap times from immediately preceding 
failure on the same subject, for the 𝑑𝑘 events occurring in stratum 𝑘. Suppose subject 𝑖 gives 
rise to the failure with gap time  𝑢𝑘𝑖 at time 𝑡𝑘𝑖, and let 𝒙𝑘𝑖(𝑡𝑘𝑖) denote this subject’s 
corresponding covariate value.  
The partial likelihood to estimate 𝜷𝑘 in the PWP GP is: 
 











Here ?̃?(𝑢, 𝑘) denotes the set of subjects at risk in stratum 𝑘 at gap time 𝑢 −
0, 𝑢 𝜖 [𝑢𝑘,𝑖−1, 𝑢𝑘𝑖) (𝑖 = 1, … , 𝑑𝑘 + 1) where 𝑢𝑘0 = 0 and 𝑢𝑘,𝑑𝑘+1 = ∞. 𝜏𝑚 is the last event 
time on subject 𝑚 prior to entry into stratum 𝑘, 𝜏𝑚 = 0 means that there are no further event 




4.6 Model building approach 
Each of the models will potentially include many covariates and hence we need a strategy for 
variable selection. The below steps will be followed to obtain a final multivariable model: 
• Univariate analysis - the first step in building the models is to perform a univariate 
analysis on each covariate considered per model. If a covariate is statistically 
significant at 10% level of significance under the univariate analysis then this covariate 
will be fitted in the preliminary multivariable model (note that treatment arm will not be 
included included at this stage). 
• Preliminary multivariable model - all covariates that are significant at 10% level of 
significance at this stage are noted and included in all the models that have been 
discussed in this section. Suppose for instance that covariate X is a significant 
predictor for preliminary multivariable Model A and covariate X is not significant in 
preliminary multivariable Model B stage, covariate X will be included in the final 
multivariable analysis for Model A and Model B, regardless of lack significance that 
covariate X achieved under Model B. This is to make comparison of the models easier. 
Results for the preliminary multivariable models will not be presented, as this is an 
interim step, which is not of interest, with regards to interpretting the models. 
• Final multivariable model – All models fitted will contain the same covariates that 
proved to be statistically significant in any of the preliminary multivariable models that 
were fitted in the previous step, and the treatment arm variable, and other clinical 
important variables will be added into the final model regardless of statistical 
significance results obtained in the univariate and preliminary multivariable analysis. 
4.7 Model adequacy assessment 
The main goal here is to determine how accurately each of the models predict the survival 
probability. This is done by plotting estimated survival probability from each model with the 
plot of Kaplan-Meier estimates (estimate for observed survival function ) estimating probability 




The Cox regression model has been fitted in Chapter 3, and the final model that was obtained 




Antigen and Baseline LFT results. The best Cox regression model obtained assumed that 
there is a time-varying coefficient that explains the association of treatment arm and timing of 
hepatotoxicity. This information is carried through in building models in this section. 
4.8.2. Univariate analysis 
The potential covariates to be included in the models and that therefore will be assessed in 
the univariate analysis, are the treatment arm, age, sex, body mass index (BMI) strata, history 
of TB, extra pulmonary TB, World Health Organization (WHO) stage, alcohol consumed, CD4 
count category, CD8 count, baseline: log viral load, alkaline phosphatase (ALK), total bilirubin 
(BILI), lactate dehydrogenase (LDH), hepatitis B surface antigen (HBsAg) and Baseline LFT. 
Results from the univariate analysis are presented in Figure 4.2 to Figure 4.4 for each model, 
the hazard ratio and the 95% CI are depicted in a graph, where the dots represent the hazard 
ratio, color coded red if the hazard ratio is significant at 5% level of significance and color is 
yellow if the hazard ratio is significant at 10% level of significance in the model, otherwise the 






Figure 4.2: Univariate Cox model analysis 
 











Figure 4.5: Univariate AG model analysis 
 
 







Figure 4.7: Univariate PWP TT model 
 
 
Figure 4.8: Univariate PWP GT model 
 
 
A summary of variables that are statistically significant on the univariate analysis level (shown 




BILI, HBsAg status and baseline LFT were significant enough to be considered in the 
preliminary multivariable models. However, the level of significance for each variable per 
model output varied, for instance age is statistically significance at 5% level of significance as 
a predictor of occurrence of hepatotoxicity according to the Cox and AG model, whereas, it is 
only statistically significant at 10% level of the significance as a predictor of occurrence of 
hepatotoxicity for shared frailty model, PWP TT, PWP GT and the recurrent model. 
The male sex has an increased risk of developing hepatotoxicity compared to females, the 
sex variable is statistically significant at 5% level for significance as a predictor of 
hepatotoxicity occurrence based on the Cox model, whereas, it is only statistically significant 
at 10% level of significance as a predictor of occurrence of hepatotoxicity for the AG, Shared 
frailty, PWP TT, and PWP GT model. Alcohol is statistically significant at 5% level for 
significance as a predictor of occurrence of hepatotoxicity based on the Cox model, whereas, 
it is only statistically significant at 10% level of the significance as a predictor of occurrence of 
hepatotoxicity for the AG model. 
CD4 category and ALK are statistically significant at 10% level of the significance as a 
predictor of resolution and occurrence of hepatotoxicity respectively based for the Resolution 
and Shared frailty univariable model assessment respectively. BILI and HBsAg are statistically 
significance at 5% level for significance based the Cox, AG, Shared frailty, PWP TT and PWP 
GT. And lastly, baseline LFT variable is statistically significant at 10% level of the significance 
based on the recurrent univariate assessment. 
Therefore, for each model considered, treatment arm will be included since this is a factor of 
interest, and it will be included with an assumption that it has time-varying coefficient, since 
this has been proved in the previous section, where treatment arm fits the model better if it the 
effect is assumed to be time-varying. The proportional hazards assumption test will be not re-
performed for each of the recurrent event models, the results from the proportional hazards 
assumption from the Cox Model will be assumed for the recurrent event models, this is to 
faciliatate the comparability of the models. 
Secondly, variable: age, sex, alcohol consumed, CD4 category, BILI, HBsAg status and 
Baseline LFT will be included in the final multivariable models since these variables were 
significant for at least one of the preliminary multivariable models that were fitted after the 
univariate analysis. It is important to note that ALK was not significant in the shared fraily 







Table 4.4: Summary of statistically significant variables from the univariable analysis by 
significance levels and respective model 





• Shared frailty 
• PWP TT 
• PWP GT 
• Recurrent 
Sex • Cox 
• AG 
• Shared frailty 
• PWP TT 
• PWP GT 
Alcohol • Cox • AG 
CD4 category  • Resolution 




• Shared frailty 
• PWP TT 





• Shared frailty 
• PWP TT 
• PWP GT 
 
Baseline LFT  • Recurrent 
 
4.8.3. Multivariable models 
The multivariable models were considered and compared based on two views, the first view 
is in Figure 4.9 considers the multistate model as depicted in Figure 4.1, i.e. the Cox, resolution 
and recurrent model is considered and examined, note that these are the models presented 
in Islam’s recurrent model framework (Islam, 1994). The second part presented in Figure 4.10 
is the multivariable analysis that considers the Cox model and compares it to the AG, shared 
frailty, PWP TT and the PWP GT model. Note that in each figure the hazard ratios are depicted 
by a dot that is color code red if the variable is statistically significant at 5% level of significance, 
yellow if it is statistically significant at 10% level of significance and black otherwise, the 95% 
CI is indicated by lines extending from the dot. And on the right of each figure the covariate 
that has been assessed is shown, as well as the value of hazard ratio, 95% CI, p-value and 




4.8.4. Multivariable models output for Islam’s multistate models  
Treatment arm in the first 5 months 
Cox model  
• Patients in the early arm had a 3% decreased relative hazard of developing first 
hepatotoxicity compared to patients in the sequential arm (HR=0.97, 95% CI (0.52, 1.84)). 
• In the late arm patients were 1.65 times more likely to develop the first episode of 
hepatotoxicity compared to patients in the sequential arm (HR=1.65, 95% CI (0.92, 2.94)) 
with p-value = 0.0912. 
Resolution model  
• In the early arm patients had a 22% decreased chance of resolving hepatotoxicity 
compared to patients in the sequential arm  (HR=0.78, 95% CI (0.46, 1.32)). 
• Patients in late arm had a 32% decreased chance of resolving hepatotoxicity compared to 
patients in the sequential arm  (HR=0.68, 95% CI (0.41, 1.14)). 
Recurrent model  
• In the early arm patients were 3.49 times more likely to develop the second episode of 
hepatotoxicity compared to patients in the sequential arm (HR=3.49, 95% CI (0.33, 36.70)) 
and the standard error for this estimate is 1.2013. 
• Patients in the late arm were 2.66 times more likely to develop the second episode of 
hepatotoxicity compared to patients in the sequential arm (HR=2.66, 95% CI (0.27, 26.12)) 
and the standard error for this estimate is 1.1663. 
Treatment arm post 5 months 
Cox model  
• Patients in the early arm had a 7% decreased hazard of developing first hepatotoxicity 
compared to patients in the sequential arm  (HR=0.93, 95% CI (0.53, 1.63)). 
• In the late arm patients has 14% decreased hazard of developing first hepaptotoxicity 
compared to patients in the sequential arm (HR=0.86, 95% CI (0.49, 1.50)). 
Resolution model  
• Patients in the early arm had a 18% decreased chance of resolving hepatotoxicity 




• Patients in the late arm were 1.79 times more likely to resolve hepatotoxicity compared to 
patients in the sequential arm  (HR=1.79, 95% CI (0.65, 4.95)). 
Recurrent model  
• In the early arm patients had a 16% reduced hazard of developing the second 
hepatotoxicity episode compared to patients in the sequential arm  (HR=0.84, 95% CI 
(0.24, 2.88)). 
• In the late arm patients had a 70% reduced chance of developing the second episode of 
hepatotoxicity compared to patients in the sequential arm (HR=0.3, 95% CI (0.10, 0.90)) 
with p-value = 0.0322. 
Age is significant predictor for two of the multistate models, for every year increase in the 
baseline age, the hazard for developing the first hepatotoxicity increased by 3% according to 
the Cox model (HR=1.03, 95% CI (1.01, 1.05)) with a small p-value = 0.0139. In contrast, for 
every year increase in the baseline age the hazard for developing recurring hepatotoxicity 
decreases by 8% according to the recurrent model (HR=0.92, 95% CI (0.86, 1.00)) with a p-
value = 0.0422. Age is not predictive in the resolution model. 
Alcohol is a significant factor in the Cox model, where subjects who consume alcohol are 1.7 
times more likely to develop hepatotoxicity compared to patients who never consume alcohol 
(HR=1.7, 95% CI (1.04, 2.79)) with a small p-value = 0.0349. According to the resolution 
model, patients who consume alcohol have a 44% reduced chance of resolving hepatotoxicity, 
compared to patients who never consume alcohol (HR=0.56, 95% CI (0.33, 0.97)) with a small 
p-value = 0.0399. Alcohol was not a predictive factor for the recurrent model. 
Total bilirubin and HBsAg status are predictive factors for the Cox model only. An unit increase 
of the total bilirubin reduces the hazard of developing hepatotoxicity by 6% (HR=0.94, 95% CI 
(0.91, 0.98)) with p-value = 0.0399, and patients with a positive HBsAg status are 2.1 time 
more likely to develop first hepatotoxicity compared to patients with a positive HBsAg status 
at baseline (HR=2.1, 95% CI (1.26, 3.48)) with p-value = 0.0042. 
Baseline LFT is a signicant factor for the resolution model, patients with abnormal baseline 
LFTs are 1.57 times more likely to resolve their first hepatotoxicity (HR=1.57, 95% CI (1.02, 
2.43)) with p-value = 0.0042. 




4.8.5. Multivariable models for Cox’s generalized recurrent models -  AG, Shared 
fraily, PWP TT and PWP GT  
Treatment arm in the first 5 months 
Cox model  
• Patients in the early arm had a 3% decreased hazard of developing first hepatotoxicity 
compared to patients in the sequential arm  (HR=0.97, 95% CI (0.52, 1.84)). 
• Patients in the late arm are 1.65 times more likely to develop first hepatotoxicity compared 
to patients in the sequential arm (HR=1.65, 95% CI (0.92, 2.94)) with p-value = 0.0912. 
Recurrent models  
• In contrast to the Cox model output, all recurrent models indicated subjects in the early 
arm have increased hazard of developing hepatotoxicity compared to patients in the 
sequential arm. AG model - (HR=2.16, 95% CI (0.74, 6.27)), Shared frailty model - 
(HR=2.21, 95% CI (0.74, 6.56)), PWP TT model - (HR=2.17, 95% CI (0.74, 6.34)), and  
PWP GT model - (HR=1.69, 95% CI (0.68, 4.21)), none of these estimates were 
statistically significant. The lowest to highest standard error observed per model is in this 
order, Cox model (SE= 0.3245), PWP GT model (SE= 0.4661), PWP TT model (SE= 
0.5475), AG model (SE= 0.5450) and the shared frailty model (SE= 0.5555).  
• Concurrent to the Cox model, all recurrent models indicated patients in the late arm have 
an increased hazard of developing hepatotoxicity compared to patients in the sequential 
arm. AG model - (HR=5.70, 95% CI (2.19, 14.83)), Shared frailty model - (HR=6.06, 95% 
CI (2.28, 16.10)), PWP TT model - (HR=5.70, 95% CI (2.19, 14.83)), and  PWP GT model 
- (HR=3.17, 95% CI (1.44, 6.99)), all estimates were statistically significant across the 
models. The lowest to highest standard error observed per model is ranked as, AG model 
(SE= 0.2394), Cox model (SE= 0.2956), PWP GT model (SE= 0.4035), PWP TT model 
(SE= 0.4874), and the shared frailty model (SE= 0.4984). 
Treatment arm post 5 months 
Cox model  
• In the early arm patients had a 7% decreased hazard of developing first hepatotoxicity 
compared to patients in the sequential arm  (HR=0.93, 95% CI (0.53, 1.63)). 
• Patients in the late arm had a 14% decreased hazard of developing first hepatotoxicity 




Recurrent models  
• Concurrent to the Cox model output, all recurrent models indicated subjects in the early 
arm have decreased hazard of developing hepatotoxicity compared to patients in the 
sequential arm. AG model - (HR=0.78, 95% CI (0.49, 1.25)), Shared frailty model - 
(HR=0.79, 95% CI (0.48, 1.29)), PWP TT model - (HR=0.80, 95% CI (0.50, 1.28)), and  
PWP GT model - (HR=0.84, 95% CI (0.53, 1.33)), none of these estimates were 
statistically significant. The lowest to highest standard error observed per model is in this 
order, PWP GT model (SE= 0.2328), PWP TT model (SE= 0.2398), AG model (SE= 
0.2394), shared frailty model (SE= 0.2510) and Cox model (SE= 0.2845).  
• Concurrent to the Cox model, all recurrent models indicated subjects in the late arm have 
decreased hazard of developing hepatotoxicity compared to patients in the sequential arm. 
AG model - (HR=0.65, 95% CI (0.40, 1.04)), Shared frailty model - (HR=0.64, 95% CI 
(0.39, 1.07)), PWP TT model - (HR=0.68, 95% CI (0.42, 1.08)), and  PWP GT model - 
(HR=0.67, 95% CI (0.43, 1.05)), the AG, shared frailty and PWP GT model had estimates 
that were marginally significant. The lowest to highest standard error observed per model 
is in this order, PWP GT model (SE= 0.2317), PWP TT model (SE= 0.2408), AG model 
(SE= 0.2420), shared frailty model (SE= 0.2600) and Cox model (SE= 0.2838). 
Age and alcohol are significant predictors of hepatotoxicity for the Cox model and all the 
recurrent models except the PWP GT model. The hazard ratio, the 95% confidence interval 
and the SE is similar for the Cox model and all the recurrent models, as well as the PWP GT 
model, despite the lack of significance for this estimate under this model. 
CD4 count is not a significant predictor of hepatotoxicity for the Cox model and the PWP GT 
model and it is a marginal significant predictor for AG, shared frailty and the PWP TT model. 
The hazard ratio, the 95% confidence interval and the SE are similar for the Cox model and 
all the recurrent models. The PWP GT had the least SE and the Cox model the highest SE. 
Total bilirubin and HBsAG status are significant predictors of hepatotoxicity for the Cox model 
and all the recurrent models. The hazard ratio, the 95% confidence interval and the SE are for 
the Cox model and all the recurrent models. 



















4.8.6. Model validation 
In Figure 4.11 to Figure 4.18 the Kaplan- Meier curves are plotted with the estimated survival 
functions based on covariates that are contained in the final models. The estimated survival 
function depicts the survival distribution for a patient that is in the sequential arm, with an average 
age, who is female that never consumes alcohol, had a baseline CD4 + count < 50 cells/mm3, 
with an average BILI, negative HBsAg status and had normal LFTs at baseline . In Figure 4.11 
and Figure 4.12, an estimated survival function derived from the Cox regression model is shown, 
and it is compared to the observed Kaplan-Meier curve based on the realization of the first 
hepatotoxicity in - Figure 4.11, and it is compared to the observed Kaplan-Meier curve that is 
based on the realization of recurring hepatotoxicity in  Figure 4.12. In Figure 4.11 the Cox 
regression model is not convincing that it fits the data well. Coincidentally, in Figure 4.12, the Cox 
regression model fits the data fairly well.  
In Figure 4.13 and Figure 4.14, both the resolution model and the recurrent model fit the data 
well. The figure in Figure 4.14 displays some volatility, when comparing the KM curve and survival 
function for recurrent model, this is due to the thinning out of data for this model. 
In Figure 4.15 and Figure 4.16, the AG model and the shared frailty model fit is assessed, a good 
fit of both these models is questionable. In Figure 4.17 and Figure 4.18, observed Kaplan-Meier 
curve is stratified by the event number, and compared with estimated survival curves produced 
by the PWP TT and the PWP GT model respectively.  The PWP TT models seems to have a 
better fit for the stratified observed survival time. The fit of the PWP GT model is questionable. It 
important note that the time function in each Kaplan-Meier plotted in Figure 4.18 is based on a 
Gap time for the PWP GT model and based on calendar time for the PWP TT model, hence the 




Figure 4.11: Observed Kaplan-Meier based plot on first hepatotoxicity 
event versus Cox regression output of estimated survival function 
 
 
Figure 4.12: Observed Kaplan-Meier plot based on recurring hepatotoxicity event 
versus Cox regression model’s estimated survival function 
 
Figure 4.13: Observed Kaplan-Meier plot based on the first resolution of 
hepatotoxicity versus the resolution model’s estimated survival function 
 
 
Figure 4.14: Observed Kaplan-Meier plot based on the occurrence of the second 






Figure 4.15: Observed Kaplan-Meier plot based on recurring hepatotoxicity 
event versus AG model’s estimated survival function 
 
 
Figure 4.16: Observed Kaplan-Meier plot based on recurring hepatotoxicity event 
versus shared frailty model’s estimated survival function 
 
Figure 4.17: Observed Kaplan-Meier plot based on recurring hepatotoxicity 
event versus PWP TT model’s estimated survival function 
 
Figure 4.18: Observed Kaplan-Meier plot based on recurring 





4.8.7. Model fit statisitcs 
The PWP TT model has the lowest AIC statistic amongst Cox’s generalized recurrent model. This 
implies that the PWP TT model fit the recurrent data better, than the other models. 
Table 4.5: Akaike information criterion 
4.9 Conclusion 
If Islam’s multistate models are considered in combination (Cox, resolution and recurrent model) 
a chronological view of the evolution of hepatotoxicity is examined throughout the study duration. 
Through these multistate models, it can be assessed, how patients in the SAPiT trial transition 
from study randomization to the first hepatotoxicity (Cox model), and then transition from the first 
hepatotoxicity to resolving hepatotoxicity (resolution model) and evaluate how patients transition 
from the first resolution of hepatotoxicity to the second development of hepatotoxicity (recurrent 
model).  
The Cox model and the recurrent model (second hepatotoxicity) are attempting to model the same 
risk, this is the risk of developing hepatotoxicity in the study. The difference between these two 
models is the time when this risk is estimated and the risk set used in the model. It is important to 
note that the risk set considered in the recurrent model are patients who have developed 
hepatotoxicity at least once in their lifetime, therefore patients in this model may be vulnerable or 
immune to hepatotoxicity depending on the biological impact hepatotoxicity has on the body of 
the patient. This suggests that results from this model cannot be generalized to patients who do 
not have a history of hepatotoxicity, as results from the recurrent model are biased by the history 
that the patient has with hepatotoxicity.  
The estimated hazard ratio per covariate when comparing the Cox model and the recurrent model 
differs in magnitude for some covariates in the models, in a sense that the hazard ratio output can 
be below 1 for one model and above 1 for another model. This fundamentaly changes how the 
association of that factor with the development of hepatotoxicity is interpreted. In general if the 
Cox generalised recurrent models  AIC 
AG model  1581.644 
Shared Frailty model  1580.603 
PWP TT 1557.512 




hazard ratio is below 1 for a continuous covariate, for every unit increase in that covariate 
decreases the hazard of hepatotoxicity, and if the hazard ratio is above 1, then for every unit 
increase of the continuous covariate increases the hazard of development of hepatotoxicity. For 
a categorical variable if a hazard ratio is below 1 then the reference category of that covariate has 
an increased hazard of developing hepatotoixicty compared to the category at hand, if the hazard 
ratio is above 1 for a categorical variable then the reference category has an decreased hazard 
of developing hepatotoxicity then the category in question. 
For instance the Cox model, indicated that patients in sequential arm (reference category) are 
more likely to develop first hepatotoxicity compared to patients in the early arm (category in 
question)  in the first 5 months. In contrast, within the same period the recurrent model suggested 
that patients in the sequential arm have a much lower chance of developing second hepatotoxicity 
compared to patients in the early arm. This suggests that the risk profile of a patient is not the 
same when modelling first hepatotoxicity compared to when modelling second hepatotoxicity.  
Likewise for variables: age, alcohol consumed and total bilirubin indicate that the risk profile for a 
patient who develops first hepatotoxicity is different to risk profile of patient who develops second 
hepatotoxicity. Whereas sex, CD4 count, HBsAg status and the baseline LFT are inconclusive of 
how the risk changes from the first hepatotoxicity to the second hepatotoxicity. 
Considering the resolution model in comparison to the Cox model and recurrent model  is akin 
comparing apples with oranges, since the resolution model assesses timing of resolving 
hepatotoxicity compared to timing of development of hepatotoxicity (either first or second) 
hepatotoxicity. Information that is gathered from analyzing the Cox model, the recurrent model 
alongside a resolution model indicate that, for instance, although increase of a continuous variable 
X  increases the hazard of developing hepatotoxicity it does not automatically mean that the 
decrease of variable X increases the chance of resolving hepatotoxicity. The same applies if 
variable X is categorical variable, if category A increases the hazard of developing hepatotoxicity 
compared to category B of X, that does not always mean that category A decreases the chance 
of resolving hepatotoxicity compared to category B of X.  
However, it is worthwhile to investigate protective factors of resolving hepatotoxicity, since at 
times it is difficult to prevent hepatotoxicity from occurring, therefore clinicians can refer to the 
protective factors from the resolution model to determine if the patient has high chance of 




during integrated TB-HIV treatment: results of the SAPiT trial’, and the outcome from this study 
was that only 3 patients changed their treatment regimen because of elevated transaminases 
(liver function test) and hyperlactatemia. Consequentially, it could be recommended that clinicians 
refrain from interrupting optimal TB treatment or ART, and rather allow time to pass and maybe 
hepatotoxicity will resolve by itself without treatment interuption, like the majority of hepatotoxicity 
cases that occurred during the study period. 
All of Islam’s multistate model can be designated as a piecewise Cox models, since the model 
form for all three models is the same as that of Cox model, the data is considered ‘piece by piece’ 
depending on whether a participant is eligible to make the risk set or not. The Cox model has the 
largest risk set, the resolution model has the next largest risk set, and the recurrent model has 
the smallest risk set of the three models. The impact of size of each risk set is apparent when 
comparing the standard errors. The recurrent model has the highest standard error compared to 
the Cox model and the resolution model. This translates to a wider confidence interval output from 
the recurrent model compared to the Cox and the resolution model. Suggesting that estimates 
from the recurrent model are not very precise. And the results can not really be generalized to 
another population.  
However, modeling the recurrent model alongside the Cox model gives an indication of whether 
there is event dependence when considering recurring hepatotoxicity or not. As mentioned above 
assessment of the Cox model and the recurrent model as Islam suggested indicated that risk 
profile of the patient changes from the first hepatotoxicity to the second hepatotoxicity, this implied 
that there is some level event dependence. 
The AG model and shared frailty models intended to model the overall effect of the risk factors on 
the occurrence of an event, and this is accomplished through an application of a common baseline 
hazard, rather than an event specific baseline hazard. And a single coefficient is estimated per 
risk factor included in the model, rather than estimating event specific coefficient for each risk 
factor in the model. The difference between the two models is that a random effect is modelled in 
the shared frailty model to account for heterogeneity (or participant specific excess risk) that 
comes with each subject in the data set.  
On the other hand the PWP TT and PWP GT assumes an event specific baseline hazard and 
models an event specific coefficient for each covariate in the model, this is, the parameter 
esimates are allowed to vary from event to event. Based on the description of the models in 




dependence is evident when modelling the occurrence of second hepatotoxicity, suggesting that 
the PWP TT and PWP GT models are the more appropriate to models for recurring hepatotoxicity 
in the SAPiT data compared to the AG and the shared frailty model, since event dependence is 
accounted for explicitly in the former models. 
The model estimates are often closely comparable for the AG, shared fraily and the PWP TT, 
while parameter estimates for the PWP GT is slightly different to the rest, and the standard error 
for the PWP GT is lower than other models. It can be deduced that the estimates are similar for 
for the three models AG, shared frailty and PWP TT because risk interval for each of the models 
is the same, it is based on calendar time, this is time since study entry, whereas the risk interval 
for the PWP GT model is based on time since last event. 
The parameter estimates that quantifies the hazard ratio for the treatment arm variable are quite 
wide for the AG, shared frailty, PWP TT, PWP GT as well as the Islam’s recurrent model 
specifically in the first 5 months of study randomization. This may be because, although they may 
be reasonable enough first hepatotoxicity events occurring with the first 5 months, there are not 
many recurring events that happen in that period, the sparse occurrence of the second, third and 
fourth events causes the standard errors to be high, as a result the confidence intervals are wide, 
suggesting that the resulting parameter estimates are not precise. 
As mentioned above, the two models contending for the best model for recurring hepatotoxicity 
is between PWP TT and PWP GT, since these models address event dependence directly in its 
formulae. However, PWP TT has the lowest AIC compared to the PWP GT model, suggesting 




Chapter 5  
Discussion 
 
This project used data from the ‘Starting Antiretroviral therapy at three Points in Tuberculosis’ 
(SAPiT) trial that was conducted in sub-Saharan Africa. The SAPiT trial was intended to identify 
an optimal timing of ART initiation in patients who are on TB-treatment. Patients were randomized 
into three treatment arms, the first arm initiated ART during the intensive phase of TB treatment 
(early arm), the second arm initiated ART during the continuation phase of TB treatment (late 
arm) and the third arm initiated ART after the completion of the continuation phase of TB treatment 
(sequential arm). Reduced mortality rates were observed in the early and late arm compared 
patients in sequential arm were noted (Abdool Karim, et al., 2010). Modelling hepatotoxicity in 
this trial is of secondary importance, despite this, a thorough assessment of hepatotoxicity is 
important, since occurrence of hepatotoxicity may lead to treatment cessation, or treatment 
regime interruption which may result in a sub-optimial treatment outcome.  
In this study, 30% (179/593) of the patients in the trial developed the first occurrence of 
hepatotoxicity (Grade >= 1). Severe hepatotoxicity was not common, with only just 2% (13/593) 
occurring in the study. Of the patients who developed the first occurrence of hepatotoxicity 76% 
(136/179) resolved their first hepatotoxicity. Thereafter, of the patients who resolved 
hepatotoxicity, 24% (32/136) of them developed a second event of hepatotoxicity. Incidence rate 
comparison were similar across the treatment arms, when assessing the occurrence of first 
hepatotoxicity, severe hepatotoxicity, resolved hepatotoxicity and recurring hepatoxicity (Table 
2.2). 
The occurrence of first hepatotoxicity is in line with other studies conducted in the sub-Saharan 
Africa, like the Ethopian study which revealed that 24% of patients that were been treated for HIV 
and TB, developed hepatotoxicity (Yimer, et al., 2014). In contrast to the current study, the same 
study revealed that 16% of the population developed severe hepatotoxicity. This could be due to 
misaligned hepatotoxicity classification. For instance, the upper limit of normal (ULN) used for 
ALT in the Ethopian study was lower compared to the current study, and the grading threshold 




similar to this study was a study conducted in South Africa which revealed that 4.6% of the 
population developed severe hepatotoxicity (Hoffmann, et al., 2007). 
The lack of a unanimous definition for hepatotoxicity has been an obstacle when studying 
hepatotoxicity in the past; most studies relied on their country specific national health policies to 
dictate the definition of hepatotoxicity. As a result the hepatotoxicity definitions from different 
countries were not comparable, this hindered precise comparisons of the incidence and factors 
associated with hepatotoxicity across regions. Aithal, et al  (2011) propose a uniform definition of 
hepatotoxicity to facilitate ease of comparison of study results. Additionally, a common name for 
‘hepatotoxicity’ is now ‘drug induced liver injury’ (DILI) (Yimer, et al., 2014; Naidoo, et al., 2019; 
Aithal, et al., 2011; Naidoo, et al., 2015). 
The manner in which hepatotoxicity is defined in this project was not progressive since this project 
still relied on the guidance from clinicians that worked on the SAPiT trial to advise on the definition 
of hepatotoxicity. As noted in earlier chapters the definition was based on the DAIDS tables (U.S. 
Department of Health and Human Services, National Institutes of Health, National Institute of 
Allergy and Infectious Diseases, Division of AIDS, 2004), while other studies like Hoffmann, et al 
(2007) cited that they used definitions as specified in the ‘AIDS Clinical Trials Network definitions’ 
and Yimer, et al (2014) cited that they have used definitions as specified by Aithal, et al  (2011).  
The incidence rate of first hepatotoxicity in patients who had an abnormal liver function at baseline 
in this study was 39.1 and 38.2 per 100 py in the late arm and the sequential arm respectively, 
this was much higher than 14.1 incidence rates per 100 py observed in the early arm. Suggesting 
that if a patient presents themselves with an abnormal liver function before TB-treatment/ART 
initiation, then initiating ART during the intensive phase of TB might curb their chance of 
developing hepatotoxicity.  
Patients with baseline CD4 count greater than 50 cells per mm3 had an increased likelihood of 
developing hepatotoxicity post ART initiation in the early arm 28.4 incidence cases per 100 py, 
this was higher than 16.4 and 13.1 incidence cases of first hepatotoxicity that occurred in the late 
and sequential arm respectively. This difference is partly because patients in the early arm did 
not have much time to experience hepatotoxixity prior ART initiation, hence the higher incidence 
cases post ART initiation compared to the other treatment arm. However, despite the lack of 
strong evidence, ART initiation could be delayed until the continuation phase of TB treatment for 
patients with baseline CD4 count greater than 50 cells per mm3 as this decreases the chance of 




since mortality rate in the early and late arm were similar (Abdool Karim, et al., 2010), an added 
advantage is that the chance of the Immune Reconstitution Inflammatory Syndrome (IRIS) after 
ART initiation is reduced in the late arm compared to the early arm  (Naidoo, et al., 2012). 
Furthermore, the Cox regression multivariable model demonstrated that the chance of developing 
first hepatotoxicity is increased for a patient who is older, consumes alcohol, has low baseline 
total bilirubin, has a positive baseline Hepatitus B surface antigen status and or if the patient is in 
the late arm instead of the sequential arm (this risk is favorable for the sequential arm - only in 
the first 5 months of study randomization).  
In line with the current study, the following factors associated with the occurrence of hepatotoxicity 
were identified in other studies: Hepatitus B surface antigen status (Hoffmann, et al., 2007), Age 
(Naidoo, Evans, Jong, Mellet, & Berhanu, 2015) and alcohol (Pukenyte, et al., 2007). High ‘direct’ 
bilirubin has been identified as a risk factor (Yimer, et al., 2014) as opposed to the low ‘total’ 
bilirubin that has been identified in this study. 
Shortfall of this study on a clinical perspective, is that herbal and traditional remedies were not 
considered in this study and some of these are known hepatotoxins (Mills, et al., 2005), and are 
commonly used among ART patients in Africa (Babb, et al., 2007). 
The sequential arm is no longer a recommended treatment regimen for patients co-infected with 
HIV and TB according to the clinical guidelines in South Africa, given that patients in the early and 
late arm have reduced mortality rates compared to the sequential arm (Abdool Karim, et al., 2010). 
However, there were parts of this project that indicated that patients in the early and especially 
late arm have a higher risk of developing hepatoxicity compared to patients in the sequential arm. 
Moreover, the late arm had a high chance of developing severe hepatotoxicity than the sequential 
arm. Therefore, close monitoring of the early arm is required post ART initiation as incidence 
cases of hepatotoxicity were high in this arm compared to the sequential arm. And close 
monitoring is recommend for the late arm, particulary in the first 5 month of TB treatment as the 
risk of hepatotoxicity was high for this arm compared the sequential arm.  
Patients who do not consume alcohol and or had an abnormal baseline LFT have an increased 
chance of resolving their first hepatotoxicity. To the best of my knowledge, no study has gone to 
the extent of  analyzing resolution of hepatotoxicity beyond quantifying just the number of patients 
that resolved hepatotoxicity by the end of the study. And this is an important topic, since through 




is mild with a high resolution rate (76%). Therefore, the study of occurence hepatotoxicity should 
be coupled with the study of resolving hepatotoxicity, to inform clinicians or treating phyisicians of 
factors associated with resolving hepatotoxicity so that they can relay these to the patients who 
have developed hepatotoxicity and this might prevent uneccessary treatment interruptions.  
The risk of developing second hepatotoxicity is increased in patients who are younger and are in 
the sequential arm instead of the late arm (this risk is sustained after 5 months of study 
randomization). Moreover, the assessment of the overall effects on recurring hepatotoxicity were 
determined through the AG model and shared fraily model, where in both models, the applied 
time scale is based on a calendar time interval (time since study entry) and event dependence is 
addressed by a robust variance estimator. The former model assumes that each of the patient’s 
observations are homogenous and the latter model assumes that each of the patient’s 
observations are heterogenous and therefore accounted for accordingly through a random effect 
(or frailty term). Both models demonstrated indistinguishable results; patients have an increased 
hazard of developing recurrent hepatotoxicity if a patient is older, consumes alcohol, has a 
baseline: CD4 count that is greater than 50 cells per mm3, low total bilirubin, and positive Hepatitus 
B surface antigen status, if the patient is in the late arm rather than the sequential arm particulary 
in the first 5 months of study randomization, and if the patient is in the sequential arm rather than 
the late arm after 5 months of study randomization. The similar model output from the AG and 
shared frailty model suggests that the heterogeneity within the subjects’ observations is minimal. 
The assessment of the overall effects on recurring hepatotoxicity was performed yet again 
through the PWP TT and the PWP GT model and the time scale applied was based on calendar 
time interval for the former and based on gap time (time since last event) for the latter model. 
Assuming that each of the patient’s observations are homogenous, however, event dependence 
was accounted for via stratrification instead of variance correction, and the overall effects were 
obtained through averaging effect for each event per covariate. The PWP TT model demonstrated 
that patients have an increased hazard of developing recurrent hepatotoxicity: if the patient is 
older, consumes alcohol, baseline CD4 count is greater than 50 cell per mm3, have a low a 
baseline total bilirubin, the Hepatitus B surface antigen is positive and if the patient is in the late 
arm rather than the sequential arm particulary in the first 5 months of study randomization. Lastly, 
the PWP GT model, demonstrated that patients have an increased hazard of developing recurring 
hepatotoxicity: if they have a low baseline total bilirubin, the Hepatitus B surface antigen is 




months of study randomization, and if the patient is in the sequential arm rather than the late arm 
after 5 months of study randomization. 
The study of recurring events has been studied for recurrent sports injuries (Ullah, et al., 2012) 
and studied for infectious diseases like malaria (Sagara, et al., 2014). To my knowledge recurring 
events of hepatotoxicity have not been studied in literature to the extent that has been done in 
this project. And as such, studies are needed given that ART is for the longterm and that there is 
high prevalence of a common risk factor which is chronic hepatitis B in sub-Saharan Africa (Yimer, 
et al., 2014), therefore patients in sub-Saharan Africa are continually at risk of developing 
hepatotoxicity. In addition, the distribution of factors associated with hepatotoxicity may differ from 
those observed during the first year of therapy, and this has been observed through modelling 
timing of the second hepatotoxicity event. 
Recurrent events model use more information about the subject than a traditional Cox model, 
which improves the power of these models relative to the Cox model. Although power for each 
model was not quantified in this study, other studies have reported increased power for recurrent 
models compared to the Cox model (Ullah, et al., 2012). However, it seems as though recurrent 
event models produce higher standard errors compared to the traditional Cox model,  this reduces 
the precision of the estimates produced by these models.  In addition, the AG, shared frailty and 
the PWP TT model identified CD4 category as marginal predictive factor for hepatotoxicity, this 
factor was not identified by Cox model in the current study, however, it has been identified in other 
studies related to hepatotoxicity (Pukenyte, et al., 2007), indicating that considering the recurring 
event gives additional information about the significant risk factors associated with hepatotoxicity. 
Risk factors associated with the development of hepatotoxicity were not the same for the Cox 
model compared to the recurrent model that modelled second hepatotoxicity. Suggesting that 
there is a event dependence in the biological mechanism of recurring hepatotoxicity. This 
narrowed down the appropriate models for recurring hepatotoxicity to two models, PWP TT and 
PWP GT. The PWP TT had lower AIC compared to the PWP GT, consequentially, it can be 
deduced that the best model to model hepatotoxicity is the PWP TT. 
A method weakness to be noted is regarding the use of the heavyside function to account for non-
proportional hazards. It is important to note that the estimate of the hazard ratio after 5 months is 
not comparable to estimates from a randomised cohort. Given that, the population at risk used to 
estimate the hazard ratio will already exclude all high risk patients that have experienced 




It is important to note that, there was a high volume of censored patients in this study due to loss 
to follow up and death as shown in Figure 2.2. And it seems as though the former and latter group 
were mainly comprised of patients who did not initiate ART. The main purpose of this study was 
to investigate hepatotoxicity in patients who initiated ART during TB treatment, given this, the high 
volume of censored patients that did not intiate ART may have influenced the results in this study. 
Therefore, the assumption of non-informative censoring may have been violated. In this regard, 
further research of modelling hepatotoxicity under a competing risk framework is proposed. This 
is possible under Islam’s multi-state models (Islam, 1994). 
In conclusion, although there is an high rate of hepatotoxicity occurrence in the current study it 
was usually transient or mild and did not necessisate treatment interruption. However, close 
monitoring of patients especially in the first 5 months of TB-treatment is recommended. It is also 
recommended that patients with an abnormal liver function at baseline, and have CD4 count less 
than 50 cell/L mm3 should be started on ART during the intensive phase as opposed to delaying 
their ART initiation to the continuation phase. In contrast patients who are healthier (baseline CD4 
count greater than 50 cell/L mm3), should rather initiate ART during the continuation phase of TB 
treatment, so as to avoid high rates of hepatotoxicity.  
Understanding the biological mechanism of an infection makes it clear which reccurent event 
model to apply, if there is minimal knowledge of the infection like the case of hepatotoxicity in this 
study, it is worthwhile to consider multistate models recommended by Islam (1994) to help choose 
the recurrent event model that explains the data. The PWP TT model seemed to be the best 
model for modelling recurring hepatotoxicity, however more research is still required to support 









SAS code used 
 
Kaplan Meier Curves  
proc lifetest data=mss.y2 plots=(s lls)   ; 
time &mon*hepa(0);/* the zero is a censor*/ 
symbol v=none; 
strata Group ; 
/*where base_res = 0 ;*/ 
run; 
  
 data failtemp; set est; 
  lagsurv=lag(failure); 
  do i=1 to 100; if failure eq . then failure=lagsurv; 
lagsurv=lag(failure); end; 
  if censor eq 0 then failure2=failure; 
  surv=1-lagsurv; 
 run; 
 goptions reset=all gunit=pct  cback=white           
ftitle=times ftext=times htitle=3 htext=3 noborder; 
axis1 label=(a=90 h=3 'Probabilty of any Hepatotoxicity') 
order = (0 to 1 by 0.20)  value=(h=3)  width=2 minor=none; 
axis2 label=(h=3 'Months after randomization') order= (0 to 24 by 3) 
value=(h=3)  width=2 minor=none; 
legend label=none value=('Early arm' 'Late arm' 'Sequential arm') 
MODE = PROTECT position=(outside); 
/*ods rtf file='D:\Users\F4733061\Desktop\KM3.rtf';*/ 
proc gplot data=Failtemp; 
plot surv*&mon =group /haxis=axis2 vaxis=axis1 /*nolegend;*/ 
legend=legend1; 
symbol1 i=stepjoin color=red v=none width=1 line=1; 
symbol2 i=stepjoin color=blue  width=1 v=none line=2; 
symbol3 i=stepjoin color=black width=3 v=none line=20 ; 




Cumulative incidence  
 
Data mss.cause_of_death_v2; 













create table Y7 
as select a.*,b._1a_Date_Of_Death as Date_Of_Death 
from mss.y2 as a 
left join death_list as b 
On a.participant_id = b.participant_id; 





 set Y7; 
 
 if hepa= 0 and Date_Of_Death ne "" then 
  do; 
   Days = Date_Of_Death - FSPECIMEN; 
 
   if Days ne . then 
    do; 
     Hepa = 2; 
     Event =2; 
     Months = Days/30.5; 
     Monthz = Months; 
     Years = Months/12; 
     Yearz= Years; 
    end; 




create table Y8 
as select a.*,b._1a_Date_Of_Death as Date_Of_Death 
from mss.y3_2ndpos as a 
left join death_list as b 
On a.participant_id = b.participant_id; 





 set Y8; 
 
 if hepa= 0 and Date_Of_Death ne "" then 




   Days = Date_Of_Death - FSPECIMEN; 
 
   if Days ne . then 
    do; 
     Hepa = 2; 
     Event =2; 
     Months = Days/30.5; 
     Monthz = Months; 
     Years = Months/12; 
     Yearz= Years; 
    end; 
  end; 
RUN; 
 











ods graphics on; 
proc lifetest data=mss.y2_death plots=cif(test) outcif= cif 
/*timelist=0.5 1.0 1.5 2.0 4.0 6.0*/; 
time Monthz*Event(0)/eventcode=1; 
strata Group / order=internal; 
/*format Disease diseaseLabel. Gender genderLabel.;*/ 
run; 
 
 goptions reset=all gunit=pct  cback=white           
ftitle=times ftext=times htitle=3 htext=3 noborder; 
axis1 label=(a=90 h=3 'Cumulative Incidence Function') 
order = (0 to 0.5 by 0.1)  value=(h=3)  width=2 minor=none; 
axis2 label=(h=3 'Months after randomization') order= (0 to 24 by 3) 
value=(h=3)  width=2 minor=none; 
legend label=none value=('Early arm' 'Late arm' 'Sequential arm') 
MODE = PROTECT position=(outside); 
/*ods rtf file='D:\Users\F4733061\Desktop\KM3.rtf';*/ 
proc gplot data=cif; 
plot cif*monthz = group /haxis=axis2 vaxis=axis1 /*nolegend;*/ 
legend=legend1; 
symbol1 i=stepjoin color=red v=none width=1 line=1; 
symbol2 i=stepjoin color=blue  width=1 v=none line=2; 
symbol3 i=stepjoin color=black width=3 v=none line=20 ; 








/*First and recurring event*/ 
 
 
proc lifetest data=first_second plots=cif(test) outcif= cif 
/*timelist=0.5 1.0 1.5 2.0 4.0 6.0*/; 
time Monthz*Event(0)/eventcode=1; 
strata Group / order=internal; 
/*format Disease diseaseLabel. Gender genderLabel.;*/ 
run; 
 
 goptions reset=all gunit=pct  cback=white           
ftitle=times ftext=times htitle=3 htext=3 noborder; 
axis1 label=(a=90 h=3 'Cumulative Incidence Function') 
order = (0 to 0.5 by 0.1)  value=(h=3)  width=2 minor=none; 
axis2 label=(h=3 'Months after randomization') order= (0 to 24 by 3) 
value=(h=3)  width=2 minor=none; 
legend label=none value=('Early arm' 'Late arm' 'Sequential arm') 
MODE = PROTECT position=(outside); 
/*ods rtf file='D:\Users\F4733061\Desktop\KM3.rtf';*/ 
proc gplot data=cif; 
plot cif*monthz = group /haxis=axis2 vaxis=axis1 /*nolegend;*/ 
legend=legend1; 
symbol1 i=stepjoin color=red v=none width=1 line=1; 
symbol2 i=stepjoin color=blue  width=1 v=none line=2; 
symbol3 i=stepjoin color=black width=3 v=none line=20 ; 




Cox proportional hazard model 
 
 
/*Does not outputs Hazard ratios*/ 
 
Proc PHREG data=MSS.NEW_STACKHEPA covm covs /*Plot(overlay) = 
cumhaz*/; 
 class  
 Group (ref= 'Sequential Arm')  
    gender(ref='0')  
 alcohol2(ref='Not a consumer') 
 cd4cat (ref='0') 
 hbv (ref='0')  




 model Months*Hepa(0) =  




 age  
    gender  
 Alcohol2 
    cd4cat  
 bil  





 / risklimits ties=efron; 
 /*GRage = age_C*months;*/ 
 Baseline  out=_null_; 
/* strata res ;*/ 
run; 
 
/*Outputs Hazard ratios*/ 
 
DATA cox_stack2; 
 SET mss.new_stackhepa; 
 Format groupy1 1. groupy2 1.; 
 
 if group = "Early Arm" then 
  groupy1 = "1"; 
 else groupy1 = "0"; 
 
 if group = "Late Arm" then 
  groupy2 = "1"; 
 else groupy2 = "0"; 
 
 Format alc1 1. alc2 1.; 
 
 if alcohol2 = 'Not a consumer' then 
  alc2 = "0"; 
 else alc2 = "1"; 
 
 format months 30.; 
     
 tstop =months; 
 if tstop < =5 then 
  gt1 = 1; 
 else gt1 = 0; 
 
 if tstop > 5 then 
  gt2 = 1; 
 else gt2 = 0; 
 
 if bil < =8.43 then 
  bilcat = 1; 






Proc PHREG data=cox_stack2 covm covs /*Plot(overlay) = cumhaz*/; 
 class  
 Group (ref= 'Sequential Arm')  
    gender(ref='0')  
 alcohol2(ref='Not a consumer') 
 cd4cat (ref='0') 
 hbv (ref='0')  




 model Months*Hepa(0) =  
 Group   
 age  
    gender  
 Alcohol2 
    cd4cat  
 bil  





 / risklimits ties=efron; 
/* Alc_hbv = Alc2*hbv;*/ 
/* Bil_hbv = bil*hbv;*/ 
 Baseline  out=_null_; 




Proc PHREG data=MSS.NEW_STACKHEPA covm covs /*Plot(overlay) = 
cumhaz*/; 
 class  
 Group (ref= 'Sequential Arm')  
    gender(ref='0')  
 alcohol2(ref='Not a consumer') 
 cd4cat (ref='0') 
 hbv (ref='0')  




 model Months*Hepa(0) =  
 Group   
 age  
    gender  
 Alcohol2 




 bil  
 hbv  
 res 
/* Alcohol2*hbv*/ 
/* bil*hbv */ 
  /alpha=0.05 risklimits ties=efron; 
 ID participant_id; 
/* where tstart < tstop;*/ 
  output out = figure11_1  
LOGSURV = h  
/method = ch;   




  set figure11_1; 
  h = -h; 
  cons = 1; 
run; 
/* Creating gradient 1 */ 
proc phreg data = figure11_1a ; 
  model  h*hepa(0) = cons; 
  output out = figure11_1b logsurv = ls /method = ch; 
run; 
data figure11_1c; 
  set figure11_1b; 
    haz = - ls; 
run; 
proc sort data = figure11_1c; 
 by h; 
run; 
title "Cox Snell Residual"; 
axis1 order = (0 to 3 by .5) minor = none; 
axis2 order = (0 to 3 by .5) minor = none label = ( a=90); 
symbol1 i = stepjl c= blue; 
symbol2 i = join c = red l = 3; 
proc gplot data = figure11_1c; 
  plot haz*h =1 h*h =2 /overlay haxis=axis1 vaxis= axis2; 
  label haz = "Estimated Cumulative Hazard Rates"; 







proc phreg data = COX_STACK1; 
 class  




/* age1(ref="(<=34.5)") */ 
 gender1(ref="Female") 
 CD4_category(ref="CD4<0.05x10^9")  
 hbv1(ref="Negative")  
 alcohol (ref ='Not a consumer') 
    Baseline_LFT (ref ="Normal") 
; 
model months*hepa(0)= 
    Treatment_Arm  
 age  
 gender1 




    Baseline_LFT 
    alcohol*hbv1 
 hbv1*bil 
    
  /alpha=0.05 risklimits ties=efron; 
 ID participant_id; 
/* where tstart < tstop;*/ 
output out=resid resmart=mart resdev=dev; 
run; 
proc gplot data=resid; 
/*title "Schoenfeld Residuals for Treatment arm ";*/ 
plot (mart)*Treatment_arm 
/ CFRAME=white OVERLAY VAXIS=axis1 HAXIS=axis2 FRAME VREF=0 VMINOR=0 
HMINOR=0 
CAXIS = blue NAME='plot3'; 
symbol value=dot i=sm60s h=0.5 w=3; 
axis1 label =(a=90 r=0 f='Arial''Schoenfeld Residuals') 
value=(f='Arial' ); 









ods graphics on; 
ods graphics off; 
options nogstyle; 
title ' Treatment Arm'; 
   proc boxplot data=a; 
/*   by group;*/ 
   id Participant_ID; 
      plot mart*group  
/ 




         boxstyle      = schematic 
         boxwidthscale = 1 
/*         bwslegend*/ 
   cboxfill=white 
   cboxes=blue 
   font='Arial' 
   CLABEL=black 
   BOXWIDTH=10 
   
   HEIGHT= 4.5 
   CLIPSYMBOL=Red 
/*   haxis=axis2*/ 
   idcolor=red 
   idsymbol=diamond 
; 
symbol1 /*color=blue*/ w=2.5 h=2.5 height=2 value=dot; 
 label group = 'Treatment Arm'; 
 
   run; 
 
   options gstyle; 
goptions reset=symbol ; 
 
/*Gender*/ 




/*title ' Treatment Arm';*/ 
   proc boxplot data=ab; 
/*   by group;*/ 
   id Participant_ID; 
      plot mart*gender1  
/ 
/*          nohlabel*/ 
         boxstyle      = schematic 
         boxwidthscale = 1 
/*         bwslegend*/ 
   cboxfill=white 
   cboxes=blue 
   font='Arial' 
   CLABEL=black 
   BOXWIDTH=10 
   HEIGHT= 5 
   CLIPSYMBOL=Red 
/*   haxis=axis2*/ 
   idcolor=red 
   idsymbol=diamond 
; 
symbol1 /*color=blue*/ w=2.5 h=2.5 height=2 value=dot; 





   run; 
 
   options gstyle; 
goptions reset=symbol ; 
 
proc gplot data=resid; 
/*title "Schoenfeld Residuals for Treatment arm ";*/ 
plot (mart)*age 
/ CFRAME=white OVERLAY VAXIS=axis1 HAXIS=axis2 FRAME VREF=0 VMINOR=0 
HMINOR=0 
CAXIS = blue NAME='plot3' ; 
symbol1 color=black interpol= value=dot i=sm60s h=0.5 w=3; 
/*symbol2 color=red value=line i=sm60s h=0.5 w=3;*/ 
axis1 label =(a=90 r=0 f='Arial''Martingale Residuals') 
value=(f='Arial' ); 







proc phreg data = COX_STACK1; 
 class  
    Treatment_Arm (ref='Sequential Arm') 
/* age1(ref="(<=34.5)") */ 
 gender1(ref="Female") 
 CD4_category(ref="CD4<0.05x10^9")  
 hbv1(ref="Negative")  
 alcohol (ref ='Not a consumer') 
    Baseline_LFT (ref ="Normal") 
; 
model months*hepa(0)= 
    Treatment_Arm  
 age  
 gender1 




    Baseline_LFT 
    alcohol*hbv1 
 hbv1*bil 
    
  /alpha=0.05 risklimits ties=efron; 
 ID participant_id; 
/* where tstart < tstop;*/ 






proc gplot data=resid; 
/*title "Schoenfeld Residuals for Treatment arm ";*/ 
plot (mart)*Treatment_arm 
/ CFRAME=white OVERLAY VAXIS=axis1 HAXIS=axis2 FRAME VREF=0 VMINOR=0 
HMINOR=0 
CAXIS = blue NAME='plot3'; 
symbol value=dot i=sm60s h=0.5 w=3; 
axis1 label =(a=90 r=0 f='Arial''Schoenfeld Residuals') 
value=(f='Arial' ); 









ods graphics on; 
ods graphics off; 
options nogstyle; 
title ' Treatment Arm'; 
   proc boxplot data=a; 
/*   by group;*/ 
   id Participant_ID; 
      plot dev*group  
/ 
/*          nohlabel*/ 
         boxstyle      = schematic 
         boxwidthscale = 1 
/*         bwslegend*/ 
   cboxfill=white 
   cboxes=blue 
   font='Arial' 
   CLABEL=black 
   BOXWIDTH=10 
   
   HEIGHT= 4.5 
   CLIPSYMBOL=Red 
/*   haxis=axis2*/ 
   idcolor=red 
   idsymbol=diamond 
; 
symbol1 /*color=blue*/ w=2.5 h=2.5 height=2 value=dot; 
 label group = 'Treatment Arm'; 
 
   run; 
 
   options gstyle; 










/*title ' Treatment Arm';*/ 
   proc boxplot data=ab; 
/*   by group;*/ 
   id Participant_ID; 
      plot dev*gender1  
/ 
/*          nohlabel*/ 
         boxstyle      = schematic 
         boxwidthscale = 1 
/*         bwslegend*/ 
   cboxfill=white 
   cboxes=blue 
   font='Arial' 
   CLABEL=black 
   BOXWIDTH=10 
   HEIGHT= 5 
   CLIPSYMBOL=Red 
/*   haxis=axis2*/ 
   idcolor=red 
   idsymbol=diamond 
; 
symbol1 /*color=blue*/ w=2.5 h=2.5 height=2 value=dot; 
 label gender1 = 'Sex'; 
 
   run; 
 
   options gstyle; 
goptions reset=symbol ; 
 
proc gplot data=resid; 
/*title "Schoenfeld Residuals for Treatment arm ";*/ 
plot (dev)*age 
/ CFRAME=white OVERLAY VAXIS=axis1 HAXIS=axis2 FRAME VREF=0 VMINOR=0 
HMINOR=0 
CAXIS = blue NAME='plot3' ; 
symbol1 color=black interpol= value=dot i=sm60s h=0.5 w=3; 
/*symbol2 color=red value=line i=sm60s h=0.5 w=3;*/ 
axis1 label =(a=90 r=0 f='Arial''Martingale Residuals') 
value=(f='Arial' ); 




Testing for non proportional hazard 
 





 class  
 Group (ref= 'Sequential Arm')  
 gender(ref='0')  
    alcohol2(ref='Not a consumer') 
 cd4cat (ref='0') 
 hbv (ref='0') 
 res ( ref='0') 
 ; 
 model Months*Hepa(0) =  
 Group   
 age  
 gender   
 Alcohol2 
 cd4cat  
 bil  
 hbv   













 /*  a b*/ 
 / risklimits ties=efron; 
 /*GRage = age_C*months;*/ 
 Baseline  out=_null_; 
 where months not in (0 .); 
 fun=log(months); 
 
 /*      a=   group*fun;*/ 
 /*  b=gender*fun;*/ 
 /*  age*fun*/ 
 /*  alcohol1*fun*/ 
 /*  cd4cat*fun*/ 
 /*  bil*fun*/ 
 /*  hbv*fun*/ 
 /*  hazardratio 'Group' Group /cl=both;*/ 
 /*     hazardratio 'Gender' Gender / cl=both;*/ 









/*proc summary data=cox_stack nway missing;*/ 
/*var viral_load baseast basealt alk bil ldh  ;*/ 





 set mss.new_stackhepa; 
 Format Treatment_Arm $20.; 
 
    Treatment_Arm = group; 
 
 
 Format age1 $15.; 
 
 
    if age > 34.5 then age1 = "Age >34.5"; 
    else age1 = "Age <=34.5"; 
 
 
 Format CD4_category  $30.; 
 
 if cd4cat = "1" then 
  CD4_category = "CD4<0.05x10^9"; 
 else if cd4cat = "0" then 
  CD4_category = "CD4>=0.05x10^9"; 
 Format hbv1 $30.; 
 
if hbv = "1" then 
  hbv1 = "Positive"; 
 else if hbv = "0" then  hbv1 = "Negative"; 
 Format Baseline_Bilirubin $30.; 
 
 
 if bil < 7 then 
  Baseline_Bilirubin = "Bilirubin <7"; 
 else Baseline_Bilirubin = "Bilirubin >=7"; 
 
 
 drop age gender    HBV   bil ; 
 Rename age1 =Age gender1 =Sex  alcohol2 =alcohol 
  hbv1= HBV  months= time  ; 
      
     
 format Baseline_LFT $15.; 
 
 if res = 1 then Baseline_LFT = "Abnormal"; 









ods graphics on; 
/*%let var = Treatment_arm;*/ 
proc lifetest data=cox_stack1 method=km OUTSURV=CURVES&VAR. ; 
time Time*HEPA(0); 
STRATA &VAR.  ; 








/* if Treatment_Arm = "Early arm" then lls_early = neg_lls;*/ 
/* else lls_early = .;*/ 
/* if  Treatment_Arm = "Late arm" then lls_late = neg_lls;*/ 
/* else lls_late = .;*/ 
/* if  Treatment_Arm = "Sequential arm" then lls_seq = neg_lls;*/ 
/* else lls_seq = .;*/ 






symbol color=black  width=2 v=none line=1  ; 
symbol2 color=blue  width=2 v=none line=1; 
symbol3 color=red width=2 v=none line=1 ; 
 
proc gplot data=CAT&VAR.; 
plot Neg_LLS*time=&VAR. 
/ CFRAME=white OVERLAY VAXIS=axis1 HAXIS=axis2 FRAME VREF=0 VMINOR=0 
HMINOR=0 
CAXIS = black NAME='plot3'    ; 
symbol color=black  width=2 v=none line=1  ; 
symbol2 color=blue  width=2 v=none line=1; 
symbol3 color=red width=2 v=none line=1 ; 
axis1 label =(a=90 r=0 f='Arial''Schoenfeld Residuals') 
value=(f='Arial' ); 
/*axis2 label=( f='Arial' 'Age')value=(f='Arial') ;*/ 
; 















 SET mss.new_stackhepa; 
 Format groupy1 1. groupy2 1.; 
 
 if group = "Early Arm" then 
  groupy1 = "1"; 
 else groupy1 = "0"; 
 
 if group = "Late Arm" then 
  groupy2 = "1"; 
 else groupy2 = "0"; 
 
 Format alc1 1. alc2 1.; 
 
 if alcohol1 = "Occasionally" then 
  alc1 = "1"; 
 else alc1 = "0"; 
 
 if alcohol1 = "Frequently" then 
  alc2 = "1"; 
 else alc2 = "0"; 
 
 
 format months 30.; 
     
 tstop =months; 
 if tstop < =5 then 
  gt1 = 1; 
 else gt1 = 0; 
 
 if tstop > 5 then 
  gt2 = 1; 
 else gt2 = 0; 
 
 if bil < =8.43 then 
  bilcat = 1; 
 else bilcat = 0; 
RUN; 
 
%let mon = 4; 
proc phreg data = cox_stack2 covm covs(aggregate); 
 class  
  gender(ref='0') 




  alcohol2 (ref='Not a consumer') 
/*  cd8(ref='0') */ 
  hbv(ref='0') 
        res (ref='0')  
 ; 
 model Months*hepa(0)= 
 
  groupy11  
  groupy12  
  groupy21  
  groupy22  
  age  
  gender 
  alcohol2 
  cd4cat 
  bil 
  hbv  




  /alpha=0.05 risklimits ties=efron; 
 
 if Months <= &mon. then 
  groupy11 = groupy1; 
 else groupy11 = 0; 
 
 if Months > &mon. then 
  groupy12 = groupy1; 
 else groupy12 = 0; 
 
 if Months <= &mon. then 
  groupy21 = groupy2; 
 else groupy21 = 0; 
 
 if Months > &mon. then 
  groupy22 = groupy2; 
 else groupy22 = 0; 
 
 where months>0; 
 
 id participant_id; 
run; 
 
Resolution multivariable model 
 
%let mon = 5; 
proc phreg data = cox_stack2_res covm covs(aggregate); 




  gender(ref='0') 
  cd4cat(ref='0') 
  alcohol1 (ref="Never") 
/*  cd8(ref='0') */ 
  hbv(ref='0')  
 ; 
 model Months*reso(0)= 
 
  groupy11  
  groupy12  
  groupy21  
  groupy22  
  age  
  gender 
  alcohol1 
  cd4cat 
  bil 




  /alpha=0.05 risklimits ties=efron; 
 
 if Months <= &mon. then 
  groupy11 = groupy1; 
 else groupy11 = 0; 
 
 if Months > &mon. then 
  groupy12 = groupy1; 
 else groupy12 = 0; 
 
 if Months <= &mon. then 
  groupy21 = groupy2; 
 else groupy21 = 0; 
 
 if Months > &mon. then 
  groupy22 = groupy2; 
 else groupy22 = 0; 
 
 where months>0; 
 
 id participant_id; 
run; 
 
Recurrent multivariable model 
%let mon = 5; 
proc phreg data = cox_stack2_r covm covs(aggregate); 
 class  




  cd4cat(ref='0') 
  alcohol1 (ref="Never") 
/*  cd8(ref='0') */ 
  hbv(ref='0')  
 ; 
 model Months*hepar(0)= 
 
  groupy11  
  groupy12  
  groupy21  
  groupy22  
  age  
  gender 
  alcohol1 
  cd4cat 
  bil 




  /alpha=0.05 risklimits ties=efron; 
 
 if Months <= &mon. then 
  groupy11 = groupy1; 
 else groupy11 = 0; 
 
 if Months > &mon. then 
  groupy12 = groupy1; 
 else groupy12 = 0; 
 
 if Months <= &mon. then 
  groupy21 = groupy2; 
 else groupy21 = 0; 
 
 if Months > &mon. then 
  groupy22 = groupy2; 
 else groupy22 = 0; 
 
 where months>0; 
 
 id participant_id; 
run; 
Andersen Gill model 
 
DATA mss.ag_stack2; 
 SET mss.ag_stack; 
 Format groupy1 1. groupy2 1.; 
 




  groupy1 = "1"; 
 else groupy1 = "0"; 
 
 if group = "Late Arm" then 
  groupy2 = "1"; 





 format months 30.; 
     
 tstop =months; 
 if tstop < =5 then 
  gt1 = 1; 
 else gt1 = 0; 
 
 if tstop > 5 then 
  gt2 = 1; 
 else gt2 = 0; 
 
 if bil < =8.43 then 
  bilcat = 1; 




proc phreg data = mss.ag_stack2 covm covs(aggregate); 
 class  
  gender(ref='0') 
        alcohol1 (ref = 'Never') 
  cd4cat(ref='0') 
  hbv(ref='0')  
 ; 
 model (tstart, tstop)*hepa(0)= 
 
  groupy11  
  groupy12  
  groupy21  
  groupy22  
  age  
  gender 
        alcohol1 
  cd4cat 
  bil 
  hbv  
  interval 
 
  /alpha=0.05 risklimits; 
 
 if time <= 5  then 




 else groupy11 = 0; 
 
 if time > 5 then 
  groupy12 = groupy1; 
 else groupy12 = 0; 
 
 if time <= 5 then 
  groupy21 = groupy2; 
 else groupy21 = 0; 
 
 if time > 5 then 
  groupy22 = groupy2; 
 else groupy22 = 0; 
 id participant_id; 
run; 
 
Shared frailty model 
 
%let mon = 5; 
 
proc phreg data = mss.ag_stack2   covm  covs(aggregate); 
 class  
     Participant_ID 
  gender(ref='0') 
  cd4cat(ref='0') 
  alcohol1 (ref="Never") 
  hbv(ref='0')  
 ; 
 model (tstart, tstop)*hepa(0)= 
 
  groupy11  
  groupy12  
  groupy21  
  groupy22  
  age  
  gender 
  alcohol1 
  cd4cat 
  bil 




  /alpha=0.05 risklimits ties=efron; 
 
 if tstop <= &mon. then 
  groupy11 = groupy1; 





 if tstop > &mon. then 
  groupy12 = groupy1; 
 else groupy12 = 0; 
 
 if tstop <= &mon. then 
  groupy21 = groupy2; 
 else groupy21 = 0; 
 
 if tstop > &mon. then 
  groupy22 = groupy2; 
 else groupy22 = 0; 
 
 id participant_id; 
 random participant_id; 
 where tstart < tstop or time ne 0;; 
run; 
PWP TT  
 
%let mon = 5; 
 
proc phreg data = mss.ag_stack2  covs(aggregate); 
 class  
  gender(ref='0') 
  cd4cat(ref='0') 
  alcohol1 (ref="Never") 
  hbv(ref='0')  
 ; 
 model (tstart, tstop)*hepa(0)= 
 
  groupy11  
  groupy12  
  groupy21  
  groupy22  
  age  
  gender 
  alcohol1 
  cd4cat 
  bil 




  /alpha=0.05 risklimits ties=efron; 
 
 if tstop <= &mon. then 
  groupy11 = groupy1; 





 if tstop > &mon. then 
  groupy12 = groupy1; 
 else groupy12 = 0; 
 
 if tstop <= &mon. then 
  groupy21 = groupy2; 
 else groupy21 = 0; 
 
 if tstop > &mon. then 
  groupy22 = groupy2; 
 else groupy22 = 0; 
 
 id participant_id; 
 where tstart < tstop or time ne 0; 




%let mon = 5; 
 
proc phreg data = mss.ag_stack2  covs(aggregate); 
 class  
  gender(ref='0') 
  cd4cat(ref='0') 
  alcohol1 (ref="Never") 
  hbv(ref='0')  
 ; 
 model time*hepa(0)= 
 
  groupy11  
  groupy12  
  groupy21  
  groupy22  
  age  
  gender 
  alcohol1 
  cd4cat 
  bil 




  /alpha=0.05 risklimits ties=efron; 
 
 if time <= &mon. then 
  groupy11 = groupy1; 
 else groupy11 = 0; 
 




  groupy12 = groupy1; 
 else groupy12 = 0; 
 
 if time <= &mon. then 
  groupy21 = groupy2; 
 else groupy21 = 0; 
 
 if time > &mon. then 
  groupy22 = groupy2; 
 else groupy22 = 0; 
 
 id participant_id; 
 where tstart < tstop or time ne 0; 
 strata interval; 
run; 
 






/*"|| "(" || put(l) || ", " ||put(h) ||")";*/ 
 
/*--Leading blanks in the "Baseline Exposure Variable"n variable must 
be non--blank spaces  --*/ 
/*--Use character value 'A0', or copy from Windows System Character 
Map--*/ 
/*--Regular leading blanks will be stripped, losing the indentation    
--*/ 
data forest; 
 input index Indent "Baseline Exposure Variable"n $6-47 "p-value"n 
Hazard  Low  High; 
 format "p-value"n 7.4 ; 
 datalines; 
 
10 0 Early arm vs Sequential arm (months <=5)......... . . . . 
11 2 ..Cox ................................... 0.9335 0.973 0.515 
1.839 
12 2 ..AG .................................... 0.1590 2.155 0.740 
6.271 
13 2 ..Frailty................................. 0.1535 2.210 0.744 
6.564 
14 2 ..PWP TT.................................. 0.1574 2.169 0.742 
6.341 
15 2 ..PWP GT.................................. 0.2618 1.687 0.677 
4.206 




17 0 Early arm vs Sequential arm (months >5).......... . . . . 
18 2 ..Cox ................................... 0.8074 0.933 0.534 
1.629 
19 2 ..AG .................................... 0.3104 0.784 0.491 
1.254 
20 2 ..Frailty................................. 0.3405 0.787 0.481 
1.287 
21 2 ..PWP TT.................................. 0.3489 0.799 0.499 
1.278 
22 2 ..PWP GT.................................. 0.4606 0.842 0.534 
1.329 
23 0 .......................................... . . . . 
24 0 Late arm vs Sequential arm (months <=5).......... . . . . 
25 2 ..Cox ................................... 0.0912 1.648 0.923 
2.940 
26 2 ..AG .................................... 0.0004 5.699 2.191 
14.828 
27 2 ..Frailty................................. 0.0003 6.062 2.282 
16.101 
28 2 ..PWP TT.................................. 0.0004 5.703 2.194 
14.825 
29 2 ..PWP GT.................................. 0.0042 3.170 1.437 
6.991 
30 0 .......................................... . . . . 
31 0 Late arm vs Sequential arm (months >5)........... . . . . 
32 2 ..Cox ................................... 0.5986 0.861 0.494 
1.502 
33 2 ..AG .................................... 0.0725 0.648 0.403 
1.041 
34 2 ..Frailty................................. 0.0898 0.643 0.387 
1.071 
35 2 ..PWP TT.................................. 0.1043 0.676 0.422 
1.084 
36 2 ..PWP GT.................................. 0.0834 0.670 0.425 
1.054 
37 0 .......................................... . . . . 
38 0 Age...................................... . . . . 
39 2 ..Cox ................................... 0.0139 1.025 1.005 
1.045 
40 2 ..AG .................................... 0.0233 1.023 1.003 
1.043 
41 2 ..Frailty................................. 0.0419 1.023 1.001 
1.046 
42 2 ..PWP TT.................................. 0.0277 1.023 1.002 
1.043 
43 2 ..PWP GT.................................. 0.1008 1.016 0.997 
1.035 
44 0 .......................................... . . . . 
45 0 Sex...................................... . . . . 





47 2 ..AG .................................... 0.6087 1.102 0.761 
1.596 
48 2 ..Frailty................................. 0.6241 1.107 0.738 
1.660 
49 2 ..PWP TT.................................. 0.6681 1.085 0.746 
1.579 
50 2 ..PWP GT.................................. 0.6145 1.092 0.774 
1.541 
51 0 .......................................... . . . . 
52 0 Alcohol................................... . . . . 
53 2 ..Cox ................................... 0.0346 1.702 1.039 
2.789 
54 2 ..AG .................................... 0.0220 1.801 1.088 
2.979 
55 2 ..Frailty................................. 0.0103 1.908 1.164 
3.126 
56 2 ..PWP TT.................................. 0.0181 1.812 1.107 
2.965 
57 2 ..PWP GT.................................. 0.1315 1.388 0.906 
2.126 
58 0 .......................................... . . . . 
59 0 CD4 category.............................. . . . . 
60 2 ..Cox ................................... 0.1397 1.417 0.892 
2.251 
61 2 ..AG .................................... 0.0761 1.543 0.955 
2.491 
62 2 ..Frailty................................. 0.0666 1.597 0.969 
2.633 
63 2 ..PWP TT.................................. 0.0670 1.555 0.970 
2.494 
64 2 ..PWP GT.................................. 0.1538 1.373 0.888 
2.122 
65 0 .......................................... . . . . 
66 0 BILI..................................... . . . . 
67 2 ..Cox ................................... 0.0050 0.944 0.907 
0.983 
68 2 ..AG .................................... 0.0039 0.943 0.907 
0.981 
69 2 ..Frailty................................. 0.0036 0.940 0.901 
0.980 
70 2 ..PWP TT.................................. 0.0035 0.941 0.904 
0.980 
71 2 ..PWP GT.................................. 0.0162 0.954 0.917 
0.991 
72 0 .......................................... . . . . 
73 0 HBsAg status.............................. . . . . 
74 2 ..Cox ................................... 0.0042 2.097 1.262 
3.483 
75 2 ..AG .................................... 0.0087 1.883 1.174 
3.021 





77 2 ..PWP TT.................................. 0.0066 2.003 1.213 
3.306 
78 2 ..PWP GT.................................. 0.0203 1.678 1.084 
2.599 
79 0 .......................................... . . . . 
80 0 Baseline LFT.............................. . . . . 
81 2 ..Cox ................................... 0.3499 0.807 0.515 
1.265 
82 2 ..AG .................................... 0.2394 0.764 0.488 
1.196 
83 2 ..Frailty................................. 0.2370 0.748 0.462 
1.211 
84 2 ..PWP TT.................................. 0.2134 0.728 0.442 
1.200 
85 2 ..PWP GT.................................. 0.2647 0.763 0.475 
1.227 







/*--Replace '.' in "Baseline Exposure Variable"n with blank--*/ 
data forest2; 
  set forest; 
  format h $5. lo $5. hi $5. ; 




 "Hazard Ratio (95% CI)"n= put(h, $5.) ||" " || "(" || put(lo,$5.) 
|| ", " ||put(hi,$5.) ||")"; 
 if hazard =. then "Hazard Ratio (95% CI)"n = ""; 
 
  "Baseline Exposure Variable"n=translate("Baseline Exposure 
Variable"n, ' ', '.'); 
/*  val=mod(_N_-1, 6);*/ 
/*  indent=ifn(indent eq 2, 1, 0);*/ 
/*  if val eq 1 or val eq 2 or val eq 3 then ref="Baseline Exposure 
Variable"n;*/ 
  run; 
 
/*--Create font with smaller fonts for axis label, value and data--*/ 
/*--Define templage for Forest Plot--*/ 
/*--Template uses a Layout Lattice of 6 columns--*/ 
%let title =Forest plot of the univariable Cox Model Hazard Ratios 
(95% CI) ; 
 
proc template; 
 define statgraph Forest; 





  /*  STYLE  DATA /*/ 
  /*     FONT_FACE = "Arial, Helvetica, 
sans-serif"*/ 
  /*     FONT_SIZE = 5*/ 
  /*     FONT_WEIGHT = bold*/ 
  /*     FONT_STYLE = italic*/ 
  /*     FOREGROUND = cx002288*/ 
  /*     BACKGROUND = cxe0e0e0;*/ 
  begingraph; 
 
   /*   entrytitle 'Univariable Cox Model';*/ 
   discreteattrmap name='text'; 
   value '0' / textattrs=(weight=bold size=14); 
   value other; 
   enddiscreteattrmap; 
   discreteattrvar attrvar=type var=indent 
attrmap='text'; 
   rangeattrmap name="ResponseRange"; 
   range min-0.05   / rangeAltColor=RED;   /* or use the 
OVER or UNDER keyword */ 
   range 0.05-0.1 / rangeAltColor=Orange;    /* color for 
missing values */ 
   range other / rangeAltColor=black;    /* color for 
missing values */ 
   endrangeattrmap; 
   rangeattrvar var="p-value"n                          
/* specify response variable in data set */ 
   attrmap="ResponseRange"        /* specify custom color 
ramp */ 
   attrvar=RangeVar;              /* alias for this 
variable/ramp combination */ 
   layout lattice / columns=4 columnweights=( 0.45 0.4 
0.17 0.09 ); 
 
    /*--Column headers--*/ 
    /*      sidebar / align=top;*/ 
    /*        layout lattice / rows=2 columns=4 
columnweights=(0.2 0.25 0.25 0.3);*/ 
    /*          entry textattrs=(size=8) halign=left 
""Baseline Exposure Variable"n";*/ 
    /*          entry textattrs=(size=8) halign=left 
" No.of Patients (%)";*/ 
    /*          entry textattrs=(size=8) halign=left 
"Hazard Ratio";*/ 
    /*          entry halign=center 
textattrs=(size=8) "4-Yr Cumulative Event Rate" ;*/ 
    /*          entry " "; */ 
    /*          entry " "; */ 
    /*          entry " "; */ 
    /*          entry halign=center 




    /*        endlayout;*/ 
    /*      endsidebar;*/ 
    /*--First "Baseline Exposure Variable"n column, 
shows only the Y2 axis--*/ 
/*    layout overlay / walldisplay=none 
xaxisopts=(display=none) */ 
/*     yaxisopts=(reverse=true display=none */ 
/*     tickvalueattrs=(weight=bold));*/ 
/*     referenceline y=index / 
lineattrs=(thickness=_thk color=_color);*/ 
/*     axistable y=index value=index*/ 
/*      / /*indentweight=indent 
textgroup=type*/*/ 
/*     valueattrs= (family='arial' size = 10)*/ 
/*      labelALIGN =left labelATTRS = 
(weight=bold);*/ 
/*    endlayout;*/ 
; 
    /*--First "Baseline Exposure Variable"n column, 
shows only the Y2 axis--*/ 
    layout overlay / walldisplay=none 
xaxisopts=(display=none)  
     yaxisopts=(reverse=true display=none  
     tickvalueattrs=(weight=bold)); 
     referenceline y=index/ 
lineattrs=(thickness=_thk color=_color); 
     axistable y=index value="Baseline Exposure 
Variable"n  
      / indentweight=indent 
/*textgroup=type*/ 
     valueattrs= (family='arial' size = 10) 
      labelALIGN =left labelATTRS = 
(weight=bold); 
    endlayout; 
 
    /*--Third column showing odds ratio graph--*/ 
    layout overlay / xaxisopts =(label='Hazard Ratio 
(95% CI) plot per exposure variable'  
     linearopts=(tickvaluepriority=true  
     tickvaluelist=(0.0 0.5 1.0 1.5 2.0 2.5 3.0 
6.0 9.0 12.0 15.0 18.0)) tickvalueattrs=(size=8 family='arial')) 
     yaxisopts=(reverse=true display=none) 
walldisplay=none; 
     referenceline y=index / 
lineattrs=(thickness=_thk color=_color); 
     scatterplot y=index x=hazard /  
xerrorlower=low xerrorupper=high  errorbarattrs=(color=blr) 
      markerattrs=(symbol=circlefilled 
color=blr) markercolorgradient=RangeVar; 
     referenceline x=1; 





    /*--Second column showing Count and percent--*/ 
    layout overlay / xaxisopts=(display=none)  
     yaxisopts=(reverse=true display=none) 
walldisplay=none; 
     referenceline y=index / 
lineattrs=(thickness=_thk color=_color); 
     axistable y=index value="Hazard Ratio (95% 
CI)"n / 
      valueattrs= (family='arial' size = 10) 
      labelALIGN =left labelATTRS = 
(weight=bold); 
    endlayout; 
 
    /*--Sixth column showing P-Values--*/ 
    layout overlay / x2axisopts=(display=(tickvalues) 
offsetmin=0.25 offsetmax=0.25)  
     yaxisopts=(reverse=true display=none) 
walldisplay=none; 
     referenceline y=index / 
lineattrs=(thickness=_thk color=_color); 
     axistable y=index value="p-value"n /  
      display=(label) labelposition=min 
valueattrs= (family='arial' size = 10) 
      labelALIGN =left labelATTRS = 
(weight=bold); 
    endlayout; 
 
    /*--Fourth column showing PCIGroup--*/ 
    /*       layout overlay / 
x2axisopts=(display=(tickvalues) offsetmin=0.25 offsetmax=0.25) */ 
    /*            yaxisopts=(reverse=true 
display=none) walldisplay=none;*/ 
    /*         referenceline y=ref / 
lineattrs=(thickness=_thk color=_color);*/ 
    /*         axistable y="Baseline Exposure 
Variable"n value=PCIGroup / display=(label) labelposition=max;*/ 
    /*       endlayout;*/ 
    /*--Fifth column showing Group--*/ 
    /*       layout overlay / 
x2axisopts=(display=(tickvalues) offsetmin=0.25 offsetmax=0.25) */ 
    /*            yaxisopts=(reverse=true 
display=none) walldisplay=none;*/ 
    /*         referenceline y=ref / 
lineattrs=(thickness=_thk color=_color);*/ 
    /*         axistable y="Baseline Exposure 
Variable"n value=group / display=(label) labelposition=max;*/ 
    /*       endlayout;*/ 
   endlayout; 
 





   /*    'The p-value is from the test 
statistic for testing the interaction between the '*/ 
   /*    'treatment and any "Baseline 
Exposure Variable"n variable';*/ 
   /*     entryfootnote halign=left 'This graph uses the 
new AXISTABLE plot to display the textual columns';*/ 
  endgraph; 
 end; 
run;/*--Need format to show missing as blank--*/ 
 
proc format; 
  value misblank 




ods listing style=htmlblue gpath=&graphs image_dpi=&dpi sge=on; 
ods graphics / reset noscale width=&w height=&h 
imagename='GTL_ForestPlot'; 
proc sgrender data=Forest2 template=Forest; 
format "p-value"n misblank7.2; 
dynamic _color='white' _thk=16 ; 
run; 
 
ods listing sge=off; 
 
Model validation for shared frailty model 
 
%macro coxtvc1(data = , y = , x = , tvvar = , nontvvar = , covs = , 
ests = , 
    modopts = , procopts = , addstmts = , out = SurvEsts); 
 
    
**********************************************************************
**** 
    * Fit the model, if applicable; 
    %if (&ESTS = ) %then %do; 
        *Run model and output estimates; 
        proc phreg data = &DATA &PROCOPTS outest = _ests_; 
            &ADDSTMTS.; 
            model &Y = &X / &MODOPTS.; 
 
            *Add time-varying variables in case not previously 
defined; 
            %VARDEFN; 
 id participant_id; 
 random participant_id; 





        %local ESTS; 
        %let ESTS = _ests_; 




    
**********************************************************************
**** 
    * Create COVS dataset 
    *   1. Variables of type (B) and (C) will have the values 
specified by the 
    *        user in COVS, if applicable. 
    *   2. If not specified, variables of type (B) and (C) will take 
on their 
    *        mean or reference value, if applicable. This is done 
using 
    *        PHREG to get the same effect as BASELINE statement. To 
get 
    *        correct averages, we use one-record-per-patient. In 
addition, as 
    *        this procedure is only being used to obtain averages, the 
time- 
    *        varying variables are not needed in the model at this 
point. They 
    *        will be included in the actual modeling. ; 
 
    *Determine minimum value of start time; 
    proc means data = &DATA noprint; 
        var %scan(&Y, 1, "()*,"); 
        output out = _means_ min = min; 
        run; 
 
    %local TMMIN; 
    data _null_; 
        set _means_; 
        call symput("TMMIN", trim(left(min))); 
        run; 
 
    *Obtain correct value for time-varying covariates when not 
specified; 
    proc phreg data = &DATA noprint; 
        *only considering one-record-per-patient ensures correct 
averages; 
        where %scan(&Y, 1, "()*,") = &TMMIN; 
        &ADDSTMTS.; 
        model &Y = &TVVAR &NONTVVAR; 
 
        *obtain correct values; 
   id participant_id; 
 random participant_id; 




        run; 
 
    *Remove death-time from dataset and keep only one record; 
    data _means_; 
        set _means_; 
        keep &TVVAR &NONTVVAR; 
        if (_n_ = 1); 
        run; 
 
    *If COVS pre-specified, set all missing variables to default 
values 
    *  obtained from PHREG above; 
    %if (&COVS ^= ) %then %do; 
        data &COVS.; 
            if(_n_ = 1) then set _means_; 
            set &COVS; 
            run; 
        %end; 
 
    *If COVS not pre-specified, set all variables to default value; 
    %if (&COVS = ) %then %do; 
        %let COVS = _means_; 
        %end; 
 
    *Add time-varying variables to COVS dataset; 
    %local I NTVVAR; 
    data _temp_covs_; 
        %let I = 1; 
        %do %while(%scan(&X, &I, %str( )) ^= ); 
            %scan(&X, &I, %str( )) = 0; 
            %let I = %eval(&I + 1); 
            %end; 
 
        %let I = 1; 
        %do %while(%scan(&TVVAR, &I, %str( )) ^= ); 
            %scan(&TVVAR, &I, %str( )) = 0; 
            %let NTVVAR = %eval(&I); 
            %let I = %eval(&I + 1); 
            %end; 
        run; 
 
    data &COVS; 
        *Set only variables accounting for time-varying coefficients; 
        if (_n_ = 1) then set _temp_covs_(drop = &TVVAR &NONTVVAR); 
        set &COVS; 










    * Create dataset that contains the unique records of TVVAR 
variables; 
 
    *Obtain unique records; 
    proc sort data = &COVS (keep = &TVVAR) out = _unique_ nodupkey; 
        by &TVVAR; 
        run; 
 
    *Determine the number of unique records; 
    %local NUNIQUE; 
    data _null_; 
        set _unique_; 
        call symput("NUNIQUE", trim(left(_n_))); 
        run; 
 
    *Sort COVS dataset for later use; 
    proc sort data = &COVS out = &COVS; 
        by &TVVAR; 




    
**********************************************************************
**** 
    * Iterate through unique records; 
 
    *Define macros to hold value of interest; 
    %do I = 1 %to &NTVVAR; 
        %local XTV&I; 
        %end; 
 
    %local J; 
    %do I = 1 %to &NUNIQUE; 
        *Assign to macro variables the unique values for this record; 
        data _null_; 
            _point_ = &I; 
            *grab only record of interest; 
            set _unique_ point = _point_; 
 
            %do J = 1 %to &NTVVAR; 
                call symput("XTV&J", trim(left(%scan(&TVVAR, &J, %str( 
))))); 
                %end; 
            stop; 
            run; 
 
        *Restructure time-varying variables to perform integration; 
        data &DATA._temp; 
            set &DATA.; 
 




            %do J = 1 %to &NTVVAR; 
                %scan(&TVVAR, &J, %str( )) = 
                  %scan(&TVVAR, &J, %str( )) - &&XTV&J; 
                %end; 
 
            %VARDEFN; 
            run; 
 
        *Put other variables back to normal; 
        data &DATA._temp; 
            set &DATA._temp; 
            set &DATA.(keep = &TVVAR); 
            run; 
 
        *Get only relevant records from COVS dataset; 
        data &COVS._temp; 
            set &COVS.; 
            by &TVVAR; 
 
            retain _point_ 0; 
            _any_first_ = 0; 
            %do J = 1 %to &NTVVAR; 
                _any_first_ = 
                  max(_any_first_, first.%scan(&TVVAR, &J, %str( ))); 
                %end; 
 
            if (_any_first_ = 1) then _point_ = _point_ + 1; 
 
            *keep only relevant records; 
            if(_point_ = &I) then output; 
 
            *only keep variables in the model; 
            keep &X; 
            run; 
 
        *Get survival estimates; 
        proc phreg data = &DATA._temp inest = &ESTS. noprint; 
            &ADDSTMTS.; 
            model &Y. = &X / maxiter = 0; 
       id participant_id; 
 random participant_id; 
            baseline out = &OUT._temp covariates = &COVS._temp 
              survival = Shat / method = emp; 
            run; 
 
        *Update output dataset; 
        %if (&I = 1) %then %do; 
            data &OUT; 
                set &OUT._temp; 
                run; 





        %if (&I ^= 1) %then %do; 
            data &OUT; 
                set &OUT 
                    &OUT._temp; 
                run; 
            %end; 
        %end; 
 
    %exit: 





/**Creating counting process data */ 
%let SURV= cox_stack2; 
%Let time = tstop; 
%cpdata(data = &SURV., time = tstop, event = Hepa(0), outdata = 
SURV2); 





 age  = 34.018711019; 
 bil  = 8.70; 
 gender2 =0; 
 cd4cat1 =0; 
 alcohol =0; 
 hbv1=0; 
 res1=0; 






 if tstop1 <= &mon. then 
  groupy11 = groupy1; 
 else groupy11 = 0; 
 
 if tstop1 > &mon. then 
  groupy12 = groupy1; 
 else groupy12 = 0; 
 
 if tstop1 <= &mon. then 
  groupy21 = groupy2; 
 else groupy21 = 0; 
 
 if tstop1 > &mon. then 
  groupy22 = groupy2; 











%coxtvc1(data = SURV2,  
    y = (tstop0, tstop1)*hepa(0), 
    x =  
   groupy11 groupy12 groupy21 groupy22 
/*gr1_lt5 gr1_ge5 gr2_lt5 gr2_ge5*/ 
 
   age gender2 alcohol cd4cat1 bil hbv1 res1, 
    tvvar = gr ,  
    nontvvar = age gender2 alcohol cd4cat1 bil hbv1 res1 ,  
    covs = covs, 








/*%let mon = months ;*/ 
ods output ProductLimitEstimates=est; 
proc lifetest data=mss.ag_stack plots=(s lls)   ; 
time tstop*hepa(0);/* the zero is a censor*/ 
symbol v=none; 
/*strata Group ;*/ 
/*where base_res = 0 ;*/ 
run; 
  
 data failtemp; set est; 
  lagsurv=lag(failure); 
  do i=1 to 100; if failure eq . then failure=lagsurv; 
lagsurv=lag(failure); end; 
  if censor eq 0 then failure2=failure; 









proc sort data= Failtemp1 out= Failtemp2 (Keep=surv Monthz) nodupkey; 

















format Model $30.; 
 
If a then Model = "Shared Frailty Model"; 




Proc sort data= Mss.Surv_Frailty; 
by Model tstop1; 
run; 
 
title "Kaplan Meier and Predicted surival plots"; 
axis1 order = (0 to 24 by 3) minor = none; 
axis2 order = (0 to 1 by 0.2) minor = none label = ( a=90); 
symbol1 i=stepjoin color=red v=none width=1 line=1; 
symbol2 i=stepjoin color=blue  width=1 v=none line=2; 
legend label=none /*value=('Early arm' 'Late arm' 'Sequential arm')*/ 
MODE = PROTECT position=(Top right inside); 
 
 
proc gplot data= Mss.Surv_Frailty; 
 plot (Shat)*tstop1 = Model / overlay haxis=axis1 vaxis= axis2 
legend=legend1 
 ; 
 label Shat = "Probability of remaining hepatotoxicty free"; 
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